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Summary 
 
G protein-coupled receptors (GPCRs) play regulatory roles in many different 
physiological processes and they represent one of the most important class of drug 
targets. However, due to the lack of three-dimensional structures, structure based drug 
design has not been possible. The major bottleneck in getting three-dimensional crystal 
structure of GPCRs is to obtain milligram quantities of pure, homogenous and stable 
protein. Therefore, during my Ph.D. thesis, I focused on expression, characterization and 
isolation of three GPCRs namely human bradykinin receptor subtype 2 (B2R), human 
angiotensin II receptor subtype 1 (AT1aR), and human neuromedin U receptor subtype 2 
(NmU2R). These receptors were heterologously produced in three different expression 
systems (i.e. Pichia pastoris, insect cells and mammalian cells), biochemically 
characterized and subsequently solubilized and purified for structural studies 
The human bradykinin receptor subtype 2 (B2R) is constitutively expressed in a 
variety of cells, including endothelial cells, vascular smooth muscle cells and 
cardiomyocytes. Activation of B2R is important in pathogenesis of inflammation, pain, 
tissue injury and cardioprotective mechanisms. During this study, recombinant B2R was 
produced in methylotrophic yeast Pichia pastoris (3.5 pmol/mg), insect cells (10 
pmol/mg) and mammalian cells (60 pmol/mg). The recombinant receptor was 
characterized in terms of [
3H] bradykinin binding, G protein coupling, localization, and 
glycosylation. Subsequently, it was solubilized and purified using affinity 
chromatography. Homogeneity and stability of purified B2R was monitored by gel 
filtration analysis. Milligram amounts of pure and stable receptor were obtained from 
BHK cells and Sf9 cells, which were used for three-dimensional crystallization attempts.  
The second receptor, which I worked on, is human angiotensin II receptor subtype 
1 (AT1aR). AT1aR is distributed in smooth muscle cells, liver, kidney, heart, lung and 
testis. Activation of AT1aR is implicated in the regulation of blood pressure, hypertension 
and cardiovascular diseases. Recombinant AT1aR was produced at high levels in Pichia 
pastoris (167 pmol/mg), while at moderate levels in insect cells (29 pmol/mg) and 
mammalian cells (32 pmol/mg). The recombinant receptor was characterized in terms of 
[
3H] angiotensin II binding, localization, and glycosylation. Subsequently, the receptor   - 2 -
was solubilized and purified using affinity chromatography. Homogeneity and stability of 
purified AT1aR was monitored by gel filtration analysis. Milligram amounts of pure and 
stable receptor were obtained from Pichia pastoris, which were used for three-
dimensional crystallization attempts.  
In addition to B2R and AT1aR, I also attempted to produce and isolate the human 
neuromedin U receptor subtype 2 (NmU2R), which was deorphanized recently. It is found 
in highest abundance in the central nervous system, particularly the medulla oblongata, 
spinal
 cord and thalamus. The distribution of this receptor suggests its regulatory role in 
sensory transmission and modulation. During this study, recombinant NmU2R was 
produced in Pichia pastoris (6 pmol/mg) and BHK cells (9 pmol/mg). Recombinant 
receptor was characterized with regard to [
125I] NmU binding, localization and 
glycosylation. Subsequently, the receptor was solubilized and purified using affinity 
chromatography. Due to its low expression level, further expression optimization is 
required in order to obtain milligram amounts for structural studies. 
The long-term goal of this study was to obtain three-dimensional crystal structure 
of recombinant GPCRs. However, 3-dimensional crystallization of human recombinant 
membrane proteins still remains a difficult task. On the other hand, recent advances in the 
solid-state NMR spectroscopy offer ample opportunities to study receptor-ligand systems, 
provided milligram quantities of purified receptor are available. Therefore, in parallel to 
3-dimensional crystallization trials, purified B2R was also used for solid-state NMR 
analysis in order to investigate the receptor bound conformation of bradykinin. 
Preliminary results are promising and indicate significant structural changes in 
bradykinin upon binding to B2R. Further experiments are ongoing and will hopefully 
result in the structure of receptor bound bradykinin.             
One of the challenges in GPCR crystallization is the small hydrophilic surface 
area that is available to make crystal contacts. One possibility to overcome this problem 
can be the reconstitution of a GPCR complex with an interacting protein for 
cocrystallization. For this purpose, I coexpressed B2R and AT1aR, which form a stable 
heterodimer complex, in BHK cells. I could successfully isolate the heterodimer complex 
by using two-step affinity purification. Unfortunately, this complex was not stable over 
time and disassociates within three days of purification. However, during coexpression of   - 3 -
B2R and AT1aR in BHK cells, I observed that B2R was localized in the plasma membrane 
in coexpressing cells while it was retained intracellularly when expressed alone. This 
coexpression of AT1aR with B2R resulted in a four-fold increase in [
3H] bradykinin 
binding sites on the cell surface. In addition, these two receptors were cointernalized in 
response to their individual specific ligands. Interestingly, colocalization of B2R and 
AT1aR was also found in human foreskin fibroblasts (which endogenously express both 
receptors), in line with the possibility that heterodimerization may be required for surface 
localization of B2R in native tissues as well. This is the first report where surface 
localization of a peptide GPCR is triggered by a distantly related peptide GPCR. These
 
data support the hypothesis that heterodimerization may be a prerequisite for cell surface 
localization
 of some GPCRs.  
A second approach that I followed to stabilize the purified B2R was to reconstitute 
the B2R-β-arrestin complex. β-arrestin is a cytosolic protein that participates in agonist 
mediated desensitization of GPCRs and therefore dampens the cellular responses initiated 
by the activation of GPCRs. I tried to reconstitute B2R-β-arrestin complex in vitro by 
mixing purified B2R and purified β-arrestin. But, no interaction of these two proteins was 
observed in the pull-down assays. However, a C-terminal mutant of B2R (where a part of 
the C-terminus of the B2R is exchanged with that of the vasopressin receptor) was found 
to interact with β-arrestin in vitro as revealed by pull-down assays. 
In conclusion, this work establishes the production, characterization and isolation 
of three recombinant human GPCRs. Recombinant receptors were produced in milligram 
amounts and therefore, pave the way for structural analysis. The heterodimer complex of 
B2R-AT1aR and B2R-β-arrestin complex can be of great help during crystallization. In 
addition, it was also found for the first time that the surface localization of a peptide 
GPCR can be triggered by heterodimerization with a distantly related peptide GPCR. 
   4
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1: Introduction 
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1.1 G protein-coupled receptors 
 
G protein-coupled receptors (GPCRs) constitute the largest family of cell surface 
receptors involved in signalling across biological membranes. Approximately, 1-5% of 
the vertebrate genomes encode for GPCRs. In human genome, there are 800-1000 genes, 
which encode for receptors of this superfamily (Takeda et al., 2002). GPCRs modulate a 
wide range of physiological processes and represent the largest class of therapeutic 
targets (reviewed in Wise et al., 2002). Despite large variations in their stimuli, all 
GPCRs share a common seven α-helix transmembrane architecture and presumably 
perform signal transduction by a common mechanism via heterotrimeric guanyl 
nucleotide-binding proteins (G proteins) (reviewed in Okada et al., 2001). 
 
  
 
 
Fig. 1.1 All GPCRs contain a central common core of seven transmembrane helices. 
These helices are connected by three intracellular (i1, i2, i3) and three extracellular (e1, e2, 
e3) loops (from Bockaert et al., 1999).   
   6
1.2 GPCR classification 
 
Based on the amino acid sequence comparison, GPCRs can be classified in five main 
families (Fig. 1.2). No significant sequence similarity is observed among the receptors 
from different families, representing a remarkable example of molecular convergence 
(Bockaert et al., 1999). 
 
 
        
 
  
        
 
 
 
 
 
 
 
Family 1 
Class A Rhodopsin like 
 
 
 
 
 
 
 
 
 
 
 
 
 
Family2 
Class B Secretin like 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   7
        
 
Fungal pheromone A-Factor like (STE2, 
STE3), fungal pheromone B like (BAR, 
BBR, RCB, PRA), fungal pheromone M- 
and P-Factor receptors 
 
Frizzled and Smoothened receptors 
 
 
Dictyostelium discoideum receptors 
 
 
Fig. 1.2 Classification of GPCRs based on the amino acid sequence comparison 
(modified from Bockaert et al., 1999). 
 
 
1.3 GPCR activation (G protein cycle) 
 
Agonist activation of receptors leads to conformational changes, which are not well 
understood. These changes probably involve rearrangements of transmembrane helices 3 
and 6 (Ballesteros et al., 2001). The activated receptor interacts with the heterotrimeric G 
protein (α, β and γ subunits) and serves as a guanine nucleotide exchange factor (GEF) to 
promote GDP dissociation and GTP binding. It has been proposed that the critical event 
in agonist activation of GPCR is the stabilization of the ternary complex of 
agonist/receptor/G protein. The activated G protein heterotrimer (i.e. GTP bound form) 
dissociates into α subunit and a βγ dimer, both of which can regulate separate effectors. 
 
 
Family 3 
Class C Metabotropic 
glutamate / pheromone 
 
 
 
 
 
 
Family 4 
Class D Fungal pheromone 
 
 
 
Family 5 
Frizzled/Smoothened family 
 
 
cAMP Family 
Class E cAMP receptors    8
Afterwards, hydrolysis of GTP to GDP occurs by the enzymatic activity of Gα subunit 
itself (known as GTPase activity of Gα). This leads to reassociation of the G protein 
heterotrimer and termination of the activation cycle (Fig.1.3). 
 
    
Fig. 1.3 Schematic representation of GPCR activation (G protein cycle). 
 
It has also been found that the process of GTP hydrolysis is regulated by RGS proteins 
(regulator of G protein signalling) (De Vries et al., 2000 & Ross et al., 2000). More 
importantly, many GPCRs exhibit agonist independent coupling to G proteins, which is 
termed as constitutive activity of GPCRs. 
The repertoire of heterotrimeric G Proteins consists of 21 different Gα subunits, 5 
β subunits and 11 different γ subunits in humans (Helper et al., 1992). The α subunit is a 
GTPase and functions as a molecular switch that can flip between two states i.e. active, 
when GTP is bound and inactive, when GDP is bound. β and γ subunits are associated in   9
a tightly linked βγ complex (Gilman et al., 1987). Both, the α subunit and the βγ dimmer, 
signal through the activation or inhibition of a broad range of effectors (Fig. 1.4).  
 
 
 
 
Fig. 1.4. Examples of some effectors, which are activated or inhibited by G proteins 
(from Lefkowitz et al., 2002). 
 
The combinatorial complexity of αβγ heterotrimers is enormous and relatively 
little is known about the specificity of subunit composition involved in specific pathways. 
M o s t  G P C R s  c a n  c o u p l e  t o  m o r e  t h a n  o n e  type of G protein and therefore, several 
intracellular signalling pathways can be activated by the stimulation of just one particular   10
receptor. In addition, as the numbers of effectors, which are regulated by GPCRs, are 
relatively smaller in comparison to the large number of GPCRs, cross-regulation of the 
signalling pathways has also been observed.  
In addition to G proteins, a number of other cellular proteins also interact with 
GPCRs (reviewed in Brady et al., 2002). These proteins include GPCRs themselves as 
homo or heterodimers (described in detail in the section 1.5), molecular chaperones (e.g. 
Calnexin, Nina A etc.), receptor activity modifying proteins (RAMPs), PDZ domain 
containing proteins (e.g. Spinophilin, Homer etc.), arrestins, calmodulin and G protein-
coupled receptor kinases (GRKs). Interaction of these accessory proteins with GPCRs has 
implications in ligand recognition, signalling specificity and receptor trafficking.  
 
1.4 Receptor desensitization and internalization 
 
In order to protect the cells from receptor overstimulation, many mechanisms have 
evolved, which are crucial for fine-tuning and regulating receptor signalling. Such 
mechanisms operate at the level of receptors as well as at the level of downstream 
effectors. Receptor desensitization is one of these mechanisms, which downregulates 
signalling, even in the presence of continuing agonist stimulation (reviewed in Ferguson 
et al., 2001). Rapid desensitization of receptors is generally controlled by G protein-
coupled receptor kinases (GRKs), which selectively phosphorylate agonist activated 
receptor. Subsequently, β-arrestin (a cytosolic protein) binds to the phosphorylated 
receptor. Binding of β-arrestin uncouples the receptor from the G protein and the receptor 
is targeted for endocytosis and subsequent degradation or recycling. Desensitization 
process at the level of downstream effectors is mediated by second messenger kinases 
such as protein kinase A and protein kinase C (Lawler et al., 2001).  
 
1.5 Dimerization of GPCRs  
 
In the classical view of GPCR signalling, a single receptor is activated by the agonist. 
This activated receptor can activate many G proteins but one at a time. However, recent    11
 
 
Fig. 1.5 Trafficking of GPCRs during downregulation process (from Lefkowitz et al., 
2002) 
 
studies have established that many GPCRs,
 like other membrane receptors, can form both 
homo
 and heterodimers (reviewed in Bouvier et al., 2001 & George et al., 2002). Various 
functions have been attributed
 to the dimerization between different receptor subtypes. 
For
 example, heterodimerization has been proposed to promote the
 formation of receptors 
with unique pharmacological properties, which
  contributes to the pharmacological 
diversity of GPCRs (Jordan et al., 1999, Jordan et al., 2001 & Levac et al., 2002). In 
addition, changes in the G protein coupling specificity (George et al., 2000) and altered
 
receptor endocytosis (Terillon et al., 2004) have also been reported to occur upon 
receptor heterodimerization. For the metabotropic
 GABAb receptor, heterodimerization 
between two subtypes (GABAb-R1 and GABAb-R2)
 is an obligatory step for cell surface 
expression of a functional
 receptor (White et al., 1998 & Ng et al., 1999). This surface 
translocation results from the masking
 of an endoplasmic reticulum (ER) retention signal 
present in the
 C-terminus of GABAb-R1, through the formation of a coiled-coil domain 
between the C-termini of the two receptor
 subtypes (Margeta-Mitrovic et al., 2000). Until 
recently, effect of heterodimerization on cell surface trafficking was considered to be   12
confined to the GABAb receptor. However, a recent study suggests that the 
heterodimerization
  between the α-adrenergic-1D and α-adrenergic-1B receptors is a 
prerequisite for the cell
 surface localization of the α-1D receptor (Hague et al., 2004).
 It 
has also been published that the cell surface trafficking of mouse olfactory receptor is 
promoted by heterodimerization with β2-adrenergic receptor (Hague et al., 2005). 
Recently, a heterodimer selective ligand has been identified (Waldhoer et al., 2005) that 
has the unique property of selectively activating opioid receptor heterodimers but not 
monomers. These results firmly establish the physiological significance of GPCR 
heterodimerization. 
  On the other hand, the evidence for biological significance of GPCR 
homodimerization remains circumstantial despite numerous examples of receptor 
homodimerization reported in the literature (Angers et al., 2002 & Terillon et al., 2004). 
This is probably due to the technical limitations in differentiating the properties of a 
homodimer from that of a monomer.
  Several reports suggest constitutive 
homodimerization of GPCRs in the endoplasmic reticulum (ER) and indicate a role of 
homodimerization in quality control
 and ER export of these receptors (Ayoub et al., 2002, 
Issafras et al., 2002 & Terrillon et al., 2003). Experimental support for this hypothesis is 
provided by a report describing homodimerization of β-2 adrenergic receptor as a 
prerequisite for its surface trafficking (Salahpour et al., 2004).  
 
1.6 Structural studies on GPCRs 
 
Despite their importance as drug targets, little is known about the structure of GPCRs. 
The only GPCR structure currently available is that of bovine rhodopsin (Palczewski et 
al., 2000). Although a number of different techniques have been applied to GPCR 
research, the GPCR activation mechanism still remains poorly understood.  
 
1.6.1 Biophysical approaches 
 
Electron paramagnetic resonance (EPR) spectroscopy and cys-crosslinking experiments 
have been used to study the orientation of helices and light induced conformational   13
changes in rhodopsin (Altenbach et al., 1999 and reviewed in Columbus et al., 2002). 
Zinc (II) binding sites were introduced in the neurokinin and κ-opioid receptors, which 
have provided some insight into the distance and orientation of different transmembrane 
helices (Elling et al., 1996 and Thirstrup et al., 1996).  
 
1.6.2 Nuclear Magnetic Resonance (NMR) studies on GPCRs 
 
Solution-state NMR spectroscopy has now been established as a promising method for 
the structure determination of polytopic membrane proteins (MacKenzie et al., 1997, 
Girvin et al., 1998 and Arora et al., 2001). However, the feasibility of this approach 
remains unclear for GPCRs. Until now, solution-state NMR has been mainly used for 
studying GPCR fragments (Demene et al., 2003, Grace et al., 2004), isolated 
extramembrane domains (Estephan et al., 2005) and  dynamics of rhodopsin (Klein-
Seetharaman et al., 2002 and Klein-Seetharaman et al., 2004). Only recently, attempts 
have been made to study a uniformly isotopically labeled full length GPCR (Tian et al., 
2005).  
 
1.6.2.1 Solid-state NMR to study receptor-ligand interaction 
 
High resolution solid-state NMR (ss-NMR) based on rapid rotation of sample at magic 
angle spinning (MAS) under ultrahigh magnetic field provides a unique opportunity to 
study receptor-ligand systems (reviwed in Luca et al., 2005). In order to investigate 
GPCR-ligand system by ss-NMR, isotopic labeling of ligand is required. This is to detect 
the ligand signal in a highly sensitive and specific way while the background signals are 
suppressed.  Although the natural abundance of the NMR active nucleus 
13C is only 1%, 
in detergent purified GPCR samples, the background is much higher due to high 
concentration of detergents and lipids. To circumvent this problem, two-dimensional 
double-quantum filtering techniques (Bax et al., 1980) are used. In the resulting spectra, 
only those NMR active nuclei give rise to the overall signal, which are in the direct 
neighbourhood of another NMR active nucleus. This approach has already been   14
successfully used to investigate the structural changes in neurotensin upon binding to its 
cognate GPCR, the neurotensin receptor (Luca et al., 2003). 
               
 
 
 
Fig. 1.6 ss-NMR set up to study molecular dynamics and structure (from Luca et al., 
2005).   15
1.6.3 Three-dimensional crystallization 
 
The only GPCR structure currently available is that of the bovine rhodopsin (Palczewski 
et al., 2000) (Fig. 1.7). Rhodopsin is unique among GPCRs for having its ligand 11-cis-
retinal covalently attached to it. It can be isolated in large quantities directly from cow 
retina. On the contrary, most other GPCRs are present in tiny amounts in native tissues. 
Therefore, a lot of efforts have been put into developing different expression systems for 
GPCRs in the last decade. As a result, a number of recombinant GPCRs can now be 
produced using different heterologous expression systems (reviewed in Lundstrom  et al., 
2005). As a next step, the major emphasis is on large-scale production and isolation of 
functional, homogenous and stable GPCR samples for three-dimensional crystallization 
attempts. 
 
                      
 
Fig. 1.7 Three-dimensional structure of bovine rhodopsin (parallel to the plane of the 
membrane) (from Palczewski et al., 2000).   16
 1.7 Renin-angiotensin-kinin system 
 
The renin-angiotensin-kinin system (Fig. 1.8) is a hormone system that plays a crucial 
role in the long term regulation of blood pressure and blood volume in the body. This 
system is activated in the case of loss of blood volume or decrease in blood pressure. The 
pathways of the renin-angiotensin-kinin systems are active in a wide range of tissues, 
kidney being the most important site of renin release. Due to the direct involvement of 
these pathways in a number of physiological processes, this system represents an 
important target for therapeutic manipulation. Angiotensin converting enzyme (ACE) 
inhibitors and angiotensin II receptor blockers are widely used in the treatment of 
hypertension, heart failure and kidney disorders. B2R and AT1aR are two important 
signalling receptors involved in this system. Understanding the structure and function of 
these two GPCRs may help in designing potent and specific drugs that can be used in the 
treatment of cardiovascular diseases.  
 
1.7.1 Kinins and their receptors 
 
Kinins are small peptides that are present in blood plasma and affect smooth muscle 
contraction, blood pressure, blood flow throughout the body and permeability of small 
capillaries. Kinins are generated from kininogens by the action of plasma kallikrein. Two 
receptor subtypes (B1R and B2R) for kinins have been identified and characterized. These 
receptors belong to the rhodopsin family of G protein-coupled receptors (Regoli et al., 
1977). Bradykinin (BK) and lysyl-bradykinin (lys-BK) are the first set of bioactive kinins 
that are derived from kininogen in response to tissues injury. The action of BK and lys-
BK are mediated by the activation of B2R. Through the actions of carboxypeptidases
 on 
BK and lys-BK respectively, new set of kinin peptides (des-Arg
9-BK and Lys-des-Arg
9-
BK) are derived and they activate B1R (Blaukat et al., 2003).  
The genes of B1R and B2R are located on chromosome 14q32.1-q32.2. The B2R 
gene is proximal to the
  B1R receptor gene. These two genes are separated by an   17
intergenic region of only
 12 kb (Cayla et al., 2002). The close proximity of these two 
genes suggests
 that they evolved from a common ancestor by a gene duplication
 event. 
 
Fig. 1.8 Components and pathways involved in renin-angiotensin-kinin system. 
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1.7.2 Bradykinin B2 receptor (B2R) 
 
B2R is distributed in endothelial cells, vascular smooth muscle cells and cardiomyocytes. 
It mediates many physiological functions such as vasodilation, increased vascular 
permeability and cardiovascular protective mechanisms. 
 
1.7.2.1 Ligand binding region of B2R 
 
Based on site-directed
 mutagenesis, ligand receptor
 cross-linking experiments and using 
antipeptide antibodies against
 extracellular receptor domains, several residues
 have been 
identified that appear to be important for the binding of agonist and antagonist to the B2R.   
These residues are depicted in Table 1. 
 
Domain                        Agonist                           Antagonist 
 BK  FR190997  NPC/Icatib  LF16–0335  FR173657 
N-terminus Cys
20       
TM2   Trp
86      
TM3 Ser
111 Ile
110 Ser
111 Ile
110 Ile
110 
TM4 Lys
172       
TM6 Phe
259,Thr
263 Phe
259   Trp
256  
EC3 Cys
277, Asp
266, Asp
284       
TM7 Gln
288      G l n
288, Tyr
295 
 
 
Table 1. Amino acids of B2R, which are important for ligand binding (Leeb-Lundberg et 
al., 2005). 
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1.7.2.2 Post-translational modifications of B2R 
 
Post-translational modifications of B2R include glycosylation, disulfide bridge formation
 
in the extracellular domains, palmitoylation and phosphorylation.
  
 
1.7.2.2.1 Glycosylation 
 
B2R has three potential
 N-linked glycosylation sites. These are N
3 and N
12 at the N-
terminus of the receptor and N
180 in the second extracellular
 loop. A previous study has 
shown that all three asparagines are glycosylated when the recombinant receptor was 
expressed in mammalian cells (Michineau et al., 2004). However, the glycosylation is not 
required for receptor function.  
 
1.7.2.2.2. Disulfide bridging 
 
There are four cysteines in the extracellular loops
 of B2R. These include C
20 (in the N-
terminus), C
103 (in extracellular loop 1), C
184  (in extracellular loop 2), and C
277 (in 
extracellular loop 3). Most members of GPCR superfamily have conserved cysteines in 
the extracellular loop 1 and 2. The crystal structure of rhodopsin revealed that these 
conserved cysteines are involved in a disulfide bridge formation. Although, there is 
indirect evidence of a disulfide bond between Cys
103 and Cys
184 in B2R (Leeb-Lundberg 
et al., 1995), reducing agents e.g. DTT, do not affect the
 binding of bradykinin to the 
B2R. 
 
1.7.2.2.3. Palmitoylation 
 
The C-terminus of B2R contains
 two potential sites for acylation (C
324 and C
329). A 
previous study has shown that both sites are palmitoylated (Pizard et al., 2001). Mutation   20
of these sites has a negative effect on agonist induced receptor internalization but it does 
not affect ligand binding properties of the receptor. 
 
1.7.2.2.4. Phosphorylation 
 
Metabolic 
32P labeling experiments and phosphopeptide sequencing has identified three 
serine residues (Ser
339, Ser
346, and Ser
348) at the C-terminus of B2R which are major 
phosphorylation sites (Blaukat et al., 2001). Ser
348 shows constitutive
 phosphorylation 
while Ser
339 and Ser
346 are phosphorylated upon agonist stimulation. In addition, Thr
342 
and Thr
345 have also been identified as minor phosphorylation sites. Agonist induced 
phosphorylation of B2R plays a role in receptor sequestration. 
 
1.7.2.3 B2R interactome 
 
B2R interacts with a number of proteins in vivo (Table 2). In addition to these proteins, 
B2R is also known to form agonist induced homodimers (Abdalla et al., 1999). 
 
Interacting partner  Physiological significance  Reference   
B1R  - Increased constitutive and agonist stimulated
 receptor 
signalling. 
- Proteolytic degradation of B2R 
Kang et al., 2004 
AT1aR  - Enhanced G protein activation and altered receptor 
sequestration 
Abdalla et al., 2000 
SHP2  - Antiproliferative effect  Duchene et al., 2002 
G(q/11) alpha  - G protein signalling  Kang et al., 2000 
Nitric oxide synthase 1 & 3  - Inhibition of receptor activation  Ju et al., 1998 
 
Table 2. Interacting partners of B2R and physiological significance of their interactions.   21
1.7.3 Angiotensin II and its receptors 
 
Angiotensin II is a potent vasoconstrictor. Its physiological functions include regulation 
of blood pressure, increased secretion of vasopressin and aldosterone, increased sodium 
resorption at the proximal tubules and cardiac muscle hypertrophy. Angiotensin II exerts 
its physiological effects mainly via two G protein-coupled receptors, AT1R and AT2R. 
The AT1R and AT2R are only ~30-35% homologous in the amino acid sequence but they 
have similar affinity for their endogenous ligand, angiotensin II. AT1R has two distinct 
subtypes termed as AT1aR and
 AT1bR. These two receptor subtypes are ~95% identical in 
their amino acid sequences (Gou et al., 1994). Although they have similar ligand binding
 
and activation properties, they differ in their tissue distribution,
  chromosomal 
localization, genomic structure and transcriptional
 regulation. 
 
1.7.4 Angiotensin II type 1 receptor (AT1aR) 
 
The human AT1aR contains 359 amino acids and the gene is located on the q22 band of 
chromosome 3 (Tissir et al., 1995).  AT1aR is expressed in a variety of cells including 
endometrial blood vessels, placenta, components of the renin-angiotensin system, 
vascular endothelial cells, renal vasculature and glomeruli. Activation of AT1aR regulates 
smooth muscle contraction, aldosterone
 secretion, neuronal activation, neurosecretion, 
ion transport
 and cell growth. 
 
1.7.4.1 Ligand binding region of AT1aR 
 
Based on site-directed mutagenesis and other biochemical experiments, a number of 
residues have been found to play important role in agonist and antagonist binding of 
AT1aR (Fig. 1.9). 
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Fig. 1.9 Amino acids (shown in black) which contribute to the agonist binding site (top) 
and antagonist binding site of AT1aR (bottom) (from De Gasparo et al., 2000).   23
1.7.4.2 Post-translational modifications of AT1aR 
 
Post-translational modifications of AT1aR include glycosylation, disulfide bond formation 
and phosphorylation. 
 
1.7.4.2.1. Glycosylation 
 
Human AT1aR has three putative glycosylation sites (N
4 at the N-terminus, N
176 and N
188 
in second extracellular loop). A previous study has shown that all three sites are 
glycosylated when the recombinant receptor is expressed in mammalian cells (Jayadev et 
al., 1999). Glycosylation of AT1aR is crucial for its surface localization but does not 
affect ligand binding properties (Lanctot et al., 1999). 
 
1.7.4.2.2 Disulfide bridge 
 
Like other GPCRs, AT1aR also has conserved cysteines in the extracellular loop 1 and 2. 
Reducing agents such as DTT, inhibit angiotensin II binding to the receptor (Chang et al., 
1982). This suggests that these cysteines are involved in a disulphide bridge formation, 
which is crucial for binding of the agonist to the receptor. 
 
1.7.4.2.3. Phosphorylation 
 
Based on site-directed mutagenesis experiments (Hunyady et al., 1994), a cluster of 
serines has been identified in the c-terminus of AT1aR that undergoes agonist induced 
phosphorylation (Fig.1.10). 
 
1.7.4.3 AT1aR interactome 
 
AT1aR interacts with a variety of intracellular proteins, which are listed in Table 3. In 
addition, agonist induced homodimerization of AT1aR has also been reported (Abdalla et 
al., 2004).   24
 
 
 
 
Fig. 1.11 The potential serine and threonine phosphorylation sites (shown in bold letters) 
in AT1aR (from de Gasparo et al., 2000). 
 
 
Interacting partner  Physiological significance  Reference 
Gq/11, G12/13 and Gi/o  - G protein signaling  Tian et al., 1996 & Marcez et al., 1997 
B2R  - Enhanced G protein activation and 
altered receptor sequestration 
Abdalla et al., 2000 
Angiotensin II receptor associated 
protein 
- Enhances internalization of AT1aR  Cui et al., 2000 
Beta-arrestin 2  - Receptor downregulation  Oakley et al., 2001 
Janus kinase 2  - Stimulation of Jak/STAT pathway   Marrero et al., 1995 
Table 3. Interacting partners of AT1aR & physiological significance of these interactions. 
 
1.8 Neuromedin U and its receptors 
 
Neuromedin U (NmU) is a neuropeptide that is found in almost all tissues with high 
levels in gastrointestinal tract and pituitary. NmU was originally isolated from porcine 
spinal cord (Kangawa et al., 1983). Since then, NmU has been isolated and sequenced 
from many different species. NmU isoforms range from 8-25 amino acids but the C-
terminal heptapeptide (Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH2)
  is entirely conserved 
(Fig.1.11). Asparagine-linked amidation at the C-terminus of NmU is crucial for its   25
bioactivity. Physiological roles of NmU include regulation of smooth-muscle contraction, 
blood pressure and local blood flow, ion transport in the gut, stress responses, cancer, 
gastric acid secretion, pronociception and feeding behavior.  NmU activates two G 
protein-coupled  receptors, NmU1R and NmU2R. These receptors were deorphanized 
recently (Howard et al., 2000). Although these two receptors share 45 to 50% homology
 
at the amino acid sequence level and bind to NmU with almost similar affinity, their 
tissue distribution differs significantly. 
 
 
 
Fig. 1.12 Sequence alignment of NmU from different species (Brighton et al., 2004) 
showing a conserved heptapeptide at the C-terminus. 
 
 
1.8.1 Neuromedin U type 2 receptor (NmU2R) 
 
The gene for human NmU2R is localized on chromosome 5q31.1-q31.3 (Raddatz et al., 
2000). NmU2R is expressed in brain, spinal cord, thymus, thyroid and testis and mediate 
a variety of physiological roles of NmU. 
 
1.8.2 Signalling pathway of NmU2R 
 
A recent study suggests that recombinant NmU2R can couple to both Gαq/11 and Gαi when 
expressed in HEK-293 cells (Brighton et al., 2004). Receptor activation leads to pertussis 
toxin-insensitive activation of phospholipase C as well as pertussis toxin-sensitive 
inhibition of adenylyl cyclase.    26
1.8.3 Post-translational modification and receptor interactome 
 
NmU2R was identified only recently and there have not been many studies to characterize 
the post-translational modifications of this receptor. Based on the conserved sequence of 
the N-linked glycosylation motif, three putative glycosylation sites, two at the N-terminus 
(N
9, N
27) and one in the third extracellular loop (N
180) have been predicted. Also, 
interactions of NmU2R with other proteins as well as its dimerization properties have not 
yet been studied in detail. 
 
1.9 Heterologous expression systems for GPCRs 
 
Structural studies on membrane proteins require milligram quantities of pure, 
homogenous and stable samples. Initially, the structure determination was limited to 
naturally abundant membrane proteins. However, the development of molecular cloning 
and recombinant gene expression techniques has allowed large-scale production of 
recombinant membrane proteins. GPCRs are expressed in very low amounts in native 
tissues except rhodopsin, which is highly expressed and densely packed in the retinal 
membranes. Therefore, a number of expression systems have been used for heterologous 
expression of GPCRs.  In some cases, large amounts of receptors have been produced and 
isolated for structural analysis. However, the choice of a suitable host is the crucial step. 
GPCRs, like many other membrane proteins, are largely hydrophobic and require proper 
lipid surrounding for correct folding and insertion into the membrane. GPCRs undergo a 
number of post-translational modifications such as glycosylation, palmitoylation and 
phoshphoryaltion, which might be crucial for their proper function. All of these factors 
should be considered when selecting the appropriate host for overexpression of GPCRs.  
 
1.9.1 E. coli expression system 
 
There are several reports of successful overproduction of functional GPCRs in E. coli. 
These include the neurotensin receptor (Tucker et al., 1996), the adenosine A2A receptor 
(Weiss et al., 2002), the muscarinic M1 receptor ( Hulme et al., 1998), the opioid receptor   27
(Stanasila et al., 1999), the substance K receptor (Muench et al., 1995), the neuropeptide 
Y receptor (Hampe et al., 2000) and the beta-2 adrenergic receptor (Grisshammer et al., 
1994). It has been possible to isolate large amounts of the neurotensin receptor and the 
adenosine A2A receptor from E. coli using affinity chromatography (White et al., 2004 
and Weiss et al., 2002). E. coli based expression is fast, easy, safe and scaleable. 
However, post-translational modifications of some GPCRs are required for their proper 
functioning e.g. the human prostacyclin receptor (Miggin et al., 2003), the chemokine 
CCR8 receptor (Gutierrez  et al., 2004) etc. Therefore, this system can not be used for all 
GPCRs.  
 
1.9.2 Pichia pastoris expression system 
 
Pichia pastoris, a methylotrophic yeast, is capable of metabolizing methanol as its sole 
carbon source. The enzyme alcohol oxidase catalyzes the oxidation of methanol to 
formaldehyde and hydrogen peroxide.  Due to the poor affinity of this enzyme for oxygen 
(Km 0.1-1.0 mM) the yeast cells generate large amounts of this enzyme. In Pichia 
pastoris, two genes namely AOX1 and AOX2 code for alcohol oxidase. The AOX1 gene 
is responsible for approximately 95% of this enzyme in the cell. Expression of the AOX1 
gene is tightly regulated and strongly induced by methanol. Therefore, the AOX1 
promoter is widely used for heterologous expression of proteins in Pichia pastoris. 
Additionally, H2O2 produced during oxidation of methanol is highly toxic and in order to 
protect the cells, this oxidation of methanol takes place in the peroxisomes. The α-factor 
prepro-peptide (a secretion signal peptide from the Saccharomyces cerevisiae) is most 
commonly used for membrane insertion of recombinant membrane proteins. Major 
advantages of Pichia pastoris as an expression system are the strong AOX1 promoter, 
high cell mass generated by fermentation, stable insertion of heterologous genes in Pichia 
pastoris genome and the ability of Pichia pastoris to perform post-translational 
modifications such as glycosylation, phosphorylation, palmitoylation and disulphide bond 
formation (reviewed in Macauley-Patrick et al., 2005).  
GPCRs that have been produced successfully in Pichia pastoris include the 
human dopamine D2S receptor (Grünewald et al., 2004), the CB2 cannabinoid receptor   28
(Feng et al., 2002), the µ-opioid receptor (Sarramegna et al., 2002), and the endothelin-B 
receptor (Schiller et al., 2000). The main problems associated with this system are 
proteolytic degradation of the target protein in some cases, mistargeting of the 
recombinant membrane proteins and different glycosylation (Cereghino et al., 2000) 
compared to the mammalian cells. 
 
1.9.3 Baculovirus expression system 
 
In this system, protein production results from the infection of insect cells by 
recombinant baculovirus encoding the gene(s) that has to be expressed. The gene of 
interest is inserted into a plasmid transfer vector that is introduced into the genome of a 
baculovirus by homologous recombination. In most cases, a very strong polyhedrin 
promoter is used for recombinant protein expression. Recent development of the 
MultiBac system (Berger et al., 2004) offers the possibility of heterologous production of 
multiple subunits of membrane protein complexes in this system. Insect cells are semi-
adherent, can grow in suspension and they can be adapted to serum-free media for large-
scale production of recombinant proteins using bioreactors. Cells derived from 
Spodoptera frugiperda ovarian tissue (Sf9 and Sf21) are the most widely used cell lines. 
High Five™ cells from Trichoplusia ni grow faster than Sf9/Sf21 cells and now they are 
also being used for rapid production of recombinant proteins. Insect cells are able to 
perform post-translational modifications identical to those of mammalian cells and in 
most cases, the recombinant proteins exhibit characteristics very similar to their native 
counterparts.  
Several GPCRs have been produced using the baculovirus system (Akermoun et 
al., 2005, Sarramegna et al., 2003 and reviewed in Massotte et al., 2003). One of the 
problems associated with this expression system is the lipid composition of the plasma 
membranes of insect cells. The plasma membrane of these cells contains mainly 
unsaturated lipids and only low amounts of cholesterol. This is probably to ensure the 
membrane fluidity as the growth temperature ranges from 27 to 28 °C. However, for 
some GPCRs, membrane lipid composition is crucial for ligand binding. In case of the 
human oxytocin receptor (Gimpl et al., 1995) and the human histamine H2 receptor   29
(Beukers et al., 1997), it was found that recombinant receptors were expressed in a low-
affinity state in Sf9 cells. Addition of cholesterol to the isolated membranes increased the 
ligand binding affinity of these receptors. Also, in some cases, overexpression of GPCRs 
leads to their intracellular retention and accumulation of inactive receptors (Vasudevan et 
al., 1991, and Grünewald et al., 1996). 
 
1.9.4 Semliki Forest Virus (SFV) system: 
 
SFV is an enveloped single stranded RNA virus and a member of the alpha virus family. 
This expression system is based on a modified cDNA copy of the SFV viral genome 
where the genome is split and introduced into two plasmid vectors (Liljestrom et al., 
1991). The first plasmid is the cloning vector and contains the four non-structural SFV 
genes (nsP1-4). The subgenomic 26S promoter is located at the 3’ end of the nsP4 gene 
and drives the expression of the foreign gene that is placed downstream of the nsP4. The 
second plasmid is the helper vector that contains the SFV structural genes. Structural 
genes are translated as a polyprotein (C-E3-E2-6K-E1) where C refers to the capsid 
protein and E3, E2, 6K and E1 refer to the envelope proteins. The E3 and E2 proteins are 
derived from their precursor (p62) by the activity of the host cell protease (Liljestrom et 
al., 1994). For the expression of recombinant protein, mRNA from the two vectors (from 
the cloning vector and the helper vector) is synthesized by in vitro transcription and 
transfected into BHK cells by electroporation. Coelectroporation of these two RNA 
species leads to in vivo packaging of recombinant SFV particles. However, only the 
replicase-containing RNA i.e. RNA derived from cloning vector is packaged into viral 
particles, as the helper vector does not contain the packaging signal. As a result, upon 
infection of the host cells, only heterologous gene products are expressed and no new 
virus particles are generated. In the helper vector, three point mutations have been 
introduced in the p62 gene, which do not allow its intracellular cleavage (Smerdou et al., 
1999). This leads to conditionally infectious virus particles, which require in vitro 
activation by α-chymotrypsin treatment.  
Mammalian cells provide most natural environment for the expression of 
recombinant human GPCRs. In these cells, the post-translational modifications are   30
efficiently performed and a relatively high percentage of the total recombinant protein is 
functional. Several GPCRs have been produced in mammalian cells using the SFV 
system (reviewed in Lundstrom et al., 2003 and Hassaine et al., 2005). 
 However, safety concerns and high costs of virus production limit the use of this 
system for large-scale expression of GPCRs in general.  
 
 
 
 
               
 
 
 
Fig. 1.13 Schematic representation of recombinant protein expression using SFV system 
(from Lundstrom et al., 2003). 
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1.10 Aim of the project 
 
1.10.1 Production, characterization and isolation of recombinant GPCRs 
 
The aim of this project was to produce and isolate large amounts of three different G 
protein-coupled receptors namely the human bradykinin B2 receptor (B2R), the human 
angiotensin II type1 receptor (AT1aR) and the human neuromedin NmU2 receptor 
(NmU2R). Three different host systems (i.e. Pichia pastoris, Baculovirus system and 
Semliki Forest Virus system) should be tested in order to select the most suitable system 
for the production of functional recombinant receptors. Recombinant receptors should be 
biochemically characterized in terms of their ligand binding capacity, glycosylation and 
localization in the host cells. Subsequently, the recombinant receptors should be 
functionally solubilized and purified by affinity chromatography. Homogeneity and 
stability of the purified receptors should also be evaluated. 
 
1.10.2 Structural characterization of recombinant GPCRs 
 
Isolated receptor samples should be used for structural characterizations that include 
three-dimensional crystallization trials and solid-state NMR studies. 3-Dimensional 
crystallization attempts aim to determine the structure of receptors while solid-state NMR 
experiments should provide insights into the receptor bound conformation of peptide 
ligands.  
 
1.10.3 Interaction of recombinant GPCRs with their binding partners 
 
Interaction of recombinant receptors with their binding partners should be investigated in 
order to reconstitute a complex of the receptor with an interacting protein. This attempt 
aims to stabilize the receptors and to increase their polar surface area that is available to 
make crystal contacts.   - 31 -
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Chapter 2: Materials and Methods 
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2.1 Materials 
 
2.1.1 General chemicals 
 
General chemicals which are not listed below were purchased from the companies 
Sigma-Aldrich Chemie GmbH, Deisenhofen, Carl Roth & Co. KG, Karlsruhe or Merck 
KgaA, Darmstadt.  
Acrylamide ready-made solution for 
polyacrylamide gels  
Carl Roth GmbH&Co. KG, Karlsruhe  
Agarose, electrophoresis grade   Bethesda Research Laboratories GmbH, Neu 
Isenburg  
Ammonium-persulfate (APS)   Serva Elektrophoresis GmbH, Heidelberg  
Ampicillin, sodium salt   Carl Roth GmbH&Co. KG, Karlsruhe  
Bacto agar   Difco Laboratories, Detroit, Michigan, USA  
Bacto tryptone   Difco Laboratories, Detroit, Michigan, USA  
Bacto yeast extract   Difco Laboratories, Detroit, Michigan, USA 
Biotin   Serva Elektrophoresis GmbH, Heidelberg 
Bovine serum albumin (BSA)   Sigma-Aldrich Chemie GmbH, Deisenhofen  
5-Bromo-4-chloro-3-indolylphosphate 
4-toluidine salt (BCIP)  
Biomol Feinchemikalien GmbH, Hamburg 
Bromophenol blue   Sigma-Aldrich Chemie GmbH, Deisenhofen  
Coomassie brilliant blue R-250   Serva Elektrophoresis GmbH, Heidelberg  
Deoxynucleoside-5’-triphosphates 
(dATP, dGTP, dTTP, dCTP)  
MBI Fermentas GmbH, St. Leon-Rot  
 
1,4-dithiothreitol (DTT)   Serva Elektrophoresis GmbH, Heidelberg  
Ethidium bromide   Bio-Rad Laboratories GmbH, Munich  
Ethylene diamine tetra acetic 
Acid (disodium salt) (EDTA)  
GERBU Biotechnik GmbH, Gaiberg  
Geniticin sulfate G418  Novabiochem GmbH, Bad Soden/Ts.  
Glass beads (0.5 mm)   Biomatik GmbH, Frankfurt  
Glutaraldehyde Sigma-Aldrich Chemie GmbH, Deisenhofen   - 34 -
Glycine   Serva Elektrophoresis GmbH, Heidelberg  
Kanamycin   Carl Roth GmbH&Co. KG, Karlsruhe 
Non-fat milk powder  Carl Roth GmbH&Co. KG, Karlsruhe 
N,N,N’N’-tetramethylethyldiamine 
(TEMED) 
Sigma-Aldrich Chemie GmbH, Deisenhofen  
 
Nitrobluetetrazolium, toluidine salt 
(NBT)  
Biomol Feinchemikalien GmbH, Hamburg  
 
Peptone  Sigma-Aldrich Chemie GmbH, Deisenhofen  
Phenol  Carl Roth GmbH&Co. KG, Karlsruhe 
Polyethyleneglycol 400 
Polyethyleneglycol 4000 
Serva Elektrophoresis GmbH, Heidelberg 
Serva Elektrophoresis GmbH, Heidelberg 
Polyethyleneimine (PEI)  Sigma-Aldrich Chemie GmbH, Deisenhofen 
Silver nitrate (AgNO3)  Sigma-Aldrich Chemie GmbH, Deisenhofen  
Tetracycline-hydrochloride Sigma-Aldrich Chemie GmbH, Deisenhofen 
Tris-(hydroxymethyl)-aminomethane Carl Roth GmbH&Co. KG, Karlsruhe 
Tunicamycin  Sigma-Aldrich Chemie GmbH, Deisenhofen  
Yeast nitrogen base (YNB), w/o 
amino acids, w/o ammonium-sulfate  
 
Difco Laboratories, Detroit, Michigan, USA  
 
2.1.2 Radioactive labeled chemicals 
 
 
[
3H] bradykinin  NEN Life Science Products, Boston, USA  
[
3H] angiotensin II  Amersham Biosciences, USA 
[
125I] neuromedin U  Amersham Biosciences, USA 
[
3H] inositol phosphate 
 
NEN Life Science Products, Boston, USA 
2.1.3 Detergents  
 
 
Sodium-dodecyl-sulfate (SDS)  Carl Roth GmbH&Co. KG, Karlsruhe 
Digitonin  Sigma-Aldrich Chemie GmbH, Deisenhofen    - 35 -
Deoxycholate, sodium salt  Sigma-Aldrich Chemie GmbH, Deisenhofen 
n-Dodecyl-β-D-maltoside (LM)  Glycon Biochemicals, Luckenwalde  
n-Decyl-ß-D-maltoside (DM)  Glycon Biochemicals, Luckenwalde 
n-Undecyl-ß-D-maltoside (UM)  Glycon Biochemicals, Luckenwalde  
n-Octyl-ß-D-glucopyranoside (OG)  Glycon Biochemicals, Luckenwalde  
n-nonyl-ß-D-glucopyranoside (NG)  Glycon Biochemicals, Luckenwalde  
n-Dodecylphosphocholine, Fos12 
n-Tetradecylphosphocholine, Fos14  
Anatrace, Maumee, OH, USA  
Anatrace, Maumee, OH, USA 
n-Hexadecylphosphocholine, Fos16  Anatrace, Maumee, OH, USA  
Tween 20 
 
Koch-Light Ltd., Haverhill, England 
2.1.4 Protease inhibitors  
 
 
Aprotinin  Biomol Feinchemikalien GmbH, Hamburg  
Benzamidine  Sigma-Aldrich Chemie GmbH, Deisenhofen  
Leupeptin  Calbiochem GmbH, Bad Soden  
Pepstatin A  Serva Elektrophoresis GmbH, Heidelberg  
Phenylmethylsulfonylfluoride (PMSF)  Carl Roth GmbH&Co. KG, Karlsruhe  
Complete (EDTA free)  Roche Diagnostis GmbH, Mannheim 
E64  
 
Biomol Feinchemikalien GmbH, Hamburg 
2.1.5 Chromatographic matrices and prepacked columns  
 
Anti-Flag M1/M2 affinity resin  Sigma-Aldrich Chemie GmbH, Deisenhofen 
ImmunoPure immobilized monomeric 
avidin gel  
Pierce, Rockford, USA  
Ni-NTA matrix 
Streptactin agarose 
Qiagen GmbH, Hilden 
IBA, Göttingen, Germany 
Superose
TM 6 PC 3.2/30 
Dowex AG1-X8 columns 
Amersham Pharmacia Biotech, Freiburg 
Bio-Rad Laboratories GmbH, Munich   - 36 -
2.1.6 Enzymes  
 
 
Restriction endonucleases  MBI Fermentas GmbH, St. Leon-Rot  
New England Biolabs GmbH, Schwalbach  
Pfu DNA polymerase 
DNA ligase 
Stratagene GmbH 
New England Biolabs GmbH, Schwalbach  
SP6 RNA polymerase 
 
MBI Fermentas GmbH, St. Leon-Rot  
2.1.7 Antibodies  
 
 
Anti-Flag M2 monoclonal antibody 
Anti-his monoclonal antibody 
AP conjugated streptavidin 
Sigma-Aldrich Chemie GmbH, Deisenhofen  
Sigma-Aldrich Chemie GmbH, Deisenhofen  
Sigma-Aldrich Chemie GmbH, Deisenhofen 
Anti-mouse IgG, AP conjugated  Sigma-Aldrich Chemie GmbH, Deisenhofen  
Anti-B2R antibody 
Anti-AT1R antibody 
Anti-rabbit IgG, HRP conjugated 
 
Calbiochem GmbH, Bad Soden 
Calbiochem GmbH, Bad Soden 
Sigma-Aldrich Chemie GmbH, Deisenhofen  
2.1.8 Kits  
 
 
Qiagen plasmid mini and maxiprep kit  Qiagen GmbH, Hilden  
Qiaquick gel extraction kit  Qiagen GmbH, Hilden  
Qiaquick PCR purification kit  Qiagen GmbH, Hilden  
BCA protein assay kit 
 
Pierce, Rockford, USA  
2.1.9 Marker proteins  
 
 
Pre-stained protein marker  New England Biolabs GmbH, Schwalbach  
Lambda DNA   New England Biolabs GmbH, Schwalbach  
(for Eco RI+Hind III DNA marker)     - 37 -
2.1.10 Buffers and Solutions 
  
   
Agarose gel (1%)  1.0 g agarose  
100 ml 1xTAE buffer  
2.5 µl EtBr (10mg/ml)  
Ampicillin stock solution (1000x)  100 mg/ml in H2O (sterile filtered, stored  
at -20°C)  
AP buffer  100 mM Tris/HCl, pH 9.5  
100 mM NaCl  
5 mM MgCl2  
Aprotinin (40x)  20 mg/ml in PBS  
APS  10% (w/v) in H2O  
BCIP-solution  50 mg BCIP/ml DMF (stored at –20°C)  
Benzamidine (100x)  100 mM in H2O  
Binding assay buffer  
 
 
Breaking buffer   
 
50 mM Hepes, pH 7.4  
100 mM NaCl  
2 mM EDTA, 0.1% BSA  
50 mM Na2HPO4, pH 7.4 
100 mM NaCl 
5 mM EDTA 
Protease inhibitors 
Coomassie solution  1.25 g Coomassie brilliant blue R250  
200 ml H2O  
50 ml acetic acid  
250 ml methanol  
Conditioner (silver gels)  400 mM sodium-acetate, pH 6.0  
0.5 % (v/v) glutaraldehyde  
0.1% (w/v) Na2S2O3  
30% (v/v) ethanol    - 38 -
Destaining solution (coomassie gels)  40% methanol  
10% acetic acid  
50% H2O 
Developer (silver gels)  2.5% (w/v) Na2CO3  
0.04% (v/v) formaldehyde  
Fixer (silver gels)  30% ethanol  
10% acetic acid  
Kanamycin stock solution  30 mg/ml in H2O, stored at –20°C  
Leupeptin (500X)  0.25 mg/ml in H2O 
Loading buffer 4X (SDS-PAGE)  0.25 mM Tris/HCl, pH 6.8  
40% (w/v) glycerol  
20% (v/v) ß-mercaptoethanol  
8% (w/v) SDS  
0.004% (w/v) bromophenol blue  
Loading buffer (DNA)  50 mM Tris/HCl, pH 7.4  
5 mM EDTA  
50% (v/v) glycerol  
0.05% (w/v) bromophenol blue  
NBT solution  50 mg NBT/ml in 70% DMF, stored at 4°C  
Pepstatin A (500X)  0.35 mg/ml in methanol 
PMSF (200X)  200 mM in isopropanol 
Running buffer 10X (SDS 
-PAGE) 
500 mM Tris/HCl 
1.92 M glycine  
1% (w/v) SDS  
NTP mix 
(in vitro transcription) 
10 mM ATP 
10 mM CTP  
10 mM UTP  
 5 mM GTP  
Staining solution (silver gels)  
 
0.1% (w/v) AgNO3  
0.025% (v/v) formaldehyde    - 39 -
TAE buffer (50X) 
 
 
2 M Tris/HCl 
1 M acetic acid  
50 mM EDTA, disodium salt  
TBST buffer  10 mM Tris/HCl, pH 8.0  
150 mM NaCl  
0.1% Tween-20 
Tetracycline stock solution  12.5 mg/ml in 50% ethanol, stored at –20°C 
Transfer buffer 5X (Immunoblot)  190 mM glycine  
50 mM Tris 
Transfer buffer 1X (Immunoblot)  
 
 
Solubilization buffer 
 
 
 
 
2.1.10.1 Buffers for purification 
 
Equilibration buffer (Ni-NTA) 
 
 
 
Washing buffer (Ni-NTA) 
 
 
 
Elution buffer (Ni-NTA) 
 
 
 
38 mM glycine  
10 mM Tris 
20% (v/v) methanol  
50 mM Hepes, pH7.4 
100 mM NaCl 
Protease inhibitors 
Detergents (as indicated in the results section) 
 
 
 
50 mM Hepes, pH 7.4 
100 mM NaCl 
Detergent (3-5x cmc) 
5-10 mM Imidazole, pH 7.4 
50 mM Hepes, pH 7.4 
100 mM NaCl 
Detergent (3-5x cmc) 
40-60 mM Imidazole 
50 mM Hepes, pH 7.4 
100 mM NaCl 
Detergent (3-5x cmc) 
200 mM Imidazole   - 40 -
Equilibration buffer & 
Washing buffer (Mono. avidin) 
 
 
Elution buffer (Mono. avidin) 
Equilibration buffer & 
Washing buffer (Streptactin) 
 
 
Elution buffer (Streptactin) 
Equilibration buffer & 
Washing buffer 
(Anti-Flag matrix) 
 
Elution buffer 
(Anti-Flag matrix) 
 
Regeneration buffer 
 
50 mM Hepes, pH 7.4 
100 mM NaCl 
Detergent (3-5x cmc) 
2-5 mM EDTA, pH 7.4 
Washing buffer + 2-5 mM Biotin 
50 mM Hepes, pH 7.4 
150 mM NaCl 
Detergent (3-5x cmc) 
1-2 mM EDTA, pH 7.4 
Washing buffer + 2.5-5.0 mM desthiobiotin 
50 mM Hepes, pH 7.4 
100 mM NaCl 
Detergent (3-5x cmc) 
2-5 mM EDTA, pH 7.4 
10 mM Glycine, pH 2.8 
100 mM NaCl, 2-5 mM EDTA, pH 7.4 
Detergent (3-5x cmc) 
10 mM Glycine, pH 2.8 
2.1.11 E. coli strain and culture medium 
 
E. coli strain XL1-blue 
 
endA1, hsdR17 (rk-, mk+), supE44, thi-1, λ−, recA1, gyrA96, relA1, ∆(lacZYA-argF) 
U169 [F’: proAB, lacI
q
Z∆M15, Tn10(Tet
r 
)]. Stratagene GmbH, Heidelberg.  
 
E. coli strain DH5-alpha 
 
F'phi80dlacZ, delta(lacZYA-argF)U169,  deoR,  recA1,  endA1,  supE 44, λ-thi-1, 
gyrA96, relA1/F', proAB+, lacIqZdeltaM15 Tn10(tetr). Stratagene GmbH, Heidelberg.   - 41 -
LB medium  
Bacto tryptone                  10 g/l  
Bacto yeast extract             5 g/l  
NaCl                                   5 g/l  
Bacto agar                         15 g/l (for the plates)  
 
SOB medium  
Bacto tryptone                   20 g/l  
Bacto yeast extract              5 g/l  
NaCl                                   10 mM  
KCl                                    2.5 mM  
 
SOC medium  
Bacto tryptone                   20 g/l 
Bacto yeast extract              5 g/l 
NaCl                                  10 mM  
KCl                                      2.5 mM  
MgCl2                                                  10 mM  
MgSO4                                                10 mM  
Glucose                                20 mM  
 
FSB (Frozen storage buffer)  
Sodium-acetate                    10 mM  
Glycerol                               10% (w/v)  
KCl                                      100 mM  
MnCl2x4H2O                       45 mM  
CaCl2x2H2O                        10 mM  
HACoCl3                                            3 mM  
 
   - 42 -
2.1.12 Pichia pastoris strain and culture medium 
 
SMD1163: Mut
+ , His
-,
 
protease-deficient (his4, pep4, prb). Invitrogen Inc., San Diego 
Culture media as described in Multi-Copy Pichia expression kit (K1750-01). 
 
2.1.13 Insect cell lines and culture medium 
 
Sf9 cells  
Sf21 cells 
High Five
TM cells 
American Type Tissue Collection, USA 
Aventis Pharma, Frankfurt am Main 
Aventis Pharma, Frankfurt am Main 
TNM-FH medium  ccPro, Neustadt  
FKS  GibcoBRL, Life Technologies GmbH,  
L-glutamine GibcoBRL,  Life Technologies GmbH,  
Gentamycin  ccPro, Neustadt  
Vitamin B12  Sigma Chemie GmbH, Deisenhofen  
Pluronic-68 
 
Sigma Chemie GmbH, Deisenhofen  
2.1.14 Mammalian cell lines and culture medium 
 
BHK cells  European Collection of Cell Cultures, UK  
CHO cells 
HEK-293 cells 
HF-15 cells 
Aventis Pharma, Frankfurt am Main  
Aventis Pharma, Frankfurt am Main 
Dr. Werner Mueller-Esterl, Frankfurt 
Dulbecco’s modified eagle’s medium 
(DMEM) 
Cell Concepts, Umkirch, Germany  
Iscove’s medium  Cell Concepts, Umkirch, Germany  
Trypsin-EDTA  
 
Cell Concepts, Umkirch, Germany  
 
 
   - 43 -
2.1.15 General apparatus  
 
Cell mill   BioMatik GmbH, Germany 
Electroporation device  Bio-Rad, Munich  
Microscope  Olympus Inc., Japan 
Shakers  Infors AG, Bottmingen, Switzerland 
Spectrophotometer  Thermo Spectronic, Cambridge, UK  
Vortexer  Bender&Hobein AG, Zürich, Switzerland  
Thermomixer 5436 
 
Eppendorf GmbH, Hamburg  
2.1.16 Centrifuges  
 
 
Sorvall RC-5B  Sorvall, Bad Homburg  
Avanti J-20 XPI  Beckman-Coulter, Fullerton, CA, USA  
Optima LE-80K ultracentrifuge  Beckman-Coulter, Fullerton, CA, USA  
Tabletop ultracentrifuge TL100  Beckman Instruments Inc., Palo Alto,USA  
Microfuge 5415D  Eppendorf GmbH, Hamburg  
Sigma tabletop centrifuge   Sigma-Aldrich Chemie GmbH, Deisenhofen 
 
2.1.17 Filters & membranes 
 
GF/C filters for binding assay 
 
 
 
Whatman Intl. LtD, Maidstone, England  
1,2 µM membranes RA  Millipore GmbH, Eschborn  
0,45 µM membranes HA  Millipore GmbH, Eschborn  
Small filters 0,22 µm and 0,45 µm 
Immobilon-P poly vinylidene 
difluoride (PVDF) membranes 
Schleicher&Schuell GmbH, Dassel  
Millipore GmbH, Eschborn 
 
 
 
   - 44 -
2.1.18 Primers  
 
2.1.18.1 For cloning 
 
B2R_Pichia_Fw    5’-CGGGATCCCTCAATGTCACCTTGCAAGGGCCCA-3’ 
B2R_Pichia_Rv   5’-CGGAATTCCTGTCTGCTCCCTGCCCAGTCCT-3’ 
B2R_Baculo_Fw  5’-CGGGATCCCCTCAATGTCACCTTGCAAGGGCCC-3’ 
B2R_Baculo_Rv  5’-CGGAATTCCTGTCTGCTCCCTGCCCAGTCCT-3’ 
B2R_SFV_Fw   5’-CGGGATCCCTCAATGTCACCTTGCAAGGGCCC-3’ 
B2R_SFV_Rv   5’-CGATCAGTCTGTCTGCTCCCTGCCCAGTCCT-3’ 
NmU2R_Pichia_Fw   5’-CGACTAGTTCAG GGATGGAAAAACTTCAGAA-3’ 
NmU2R_Pichia_Rv  5’-GG GAATTCGGTTTTGTTAAAGTGGAAGCT TTG-3’ 
NmU2R_SFV_Fw  5’-CGGGGCCTCAG GGATGGAAAAACTTCAGAA-3’ 
NmU2R_SFV_Rv  5’-GGACTAGGGTTTTGTTAAAGTGGAAGCT TTG-3’ 
AT1aR_Pichia_Fw    5’-CGGGATCCCATTCTCAACTCTTCTACTGAAG-3’ 
AT1aR_Pichia_Rv  5’-CGGAATTCCTCAACCTCAAAACATGGTGC-3’ 
AT1aR_Baculo_Fw  5’-CGGGATCCCCATTCTCAACTCTTCTACTGAAG-3’ 
AT1aR_Baculo_Rv  5’-CGGAATTCCTCAACCTCAAAACATGGTGC-3’ 
AT1aR_SFV_Fw  5’-CGGGATCCCATTCTCAACTCTTCTACTGAAG-3’ 
AT1aR_SFV_Rv  5’-CGACTAGTCTCAACCTCAAAACATGGTGC-3’ 
 
2.1.18.2 For sequencing 
 
pPIC9K based constructs 
 
Alpha_Fw   5’-CTACTATTG  CCAGCATTGCTGC-3’ 
AOX1_Rv    5’-GGCAAATGGCATTCTGACATCC-3’   
 
SFV constructs 
 
CAP_Fw    5’-CTG TCGGTG GTCACC TGG-3’ 
CAP_Rv     5’-CGCGGGCGCCACCGGCGG-3’   - 45 -
Baculovirus constructs  
 
Bac_Fw   5’-AATGATAACCATCTCGCAAATAAATAAG-3’ 
Bac_Rv   5’-GAGGAACTTCAAAGGGACCACAAGTTTC-3’ 
 
2.2 Methods 
 
2.2.1 E. coli cultivation and preparation of competent cells 
 
A single colony of E. coli XL1-blue or DH5-alpha was inoculated into 3-5 ml of LB 
medium with appropriate antibiotic. The culture was incubated overnight at 37°C and 225 
rpm. Large (50-100 mL) E. coli cultures were started from the small overnight pre-
culture. Competent E. coli cells were prepared according to the TFB (transformation 
buffer) based chemical transformation protocol (Hanahan et al., 1991). The E. coli cells 
were grown in LB medium overnight. The cells were then cooled on ice for 15 min, 
pelleted for 15 min at 1000 g and resuspended in 1/3 of the culture volume of TFB. 
Following resuspension, the cells were incubated on ice. Afterwards, the cells were 
pelleted (1000 g, 4°C, 15 min), and resuspended in 1/12.5 of the original culture volume 
of FSB (frozen storage buffer). DMSO was added (7 µl to 200 µl suspension) and the 
suspension was swirled with a pipette. The cells were incubated on ice for 5 min, a 
second aliquot of DMSO was added, followed by 15 min incubation on ice. The 
suspension was aliquoted 200 µl each in pre-cooled eppendorf tubes and flash frozen in 
liquid nitrogen. The aliquots were stored at -80°C.  
 
2.2.2 DNA transformation and isolation 
 
Competent E. coli cells were thawed on ice and 200 µl of cell suspension was mixed with 
10 µl of the ligation reaction or plasmid DNA. After 30 min incubation on ice, the cells 
were subjected to heat shock at 42°C for 2 min. Cells were incubated on ice for 5 min 
after the heat shock. Subsequently, 800 µl of SOC medium was added and the cells were 
incubated for 45-60 min at 37°C with shaking. 100 µl of the suspension was plated on an 
LB plate containing the appropriate antibiotic and the plate was incubated overnight at   - 46 -
37° C. Isolation of plasmid DNA from E. coli, purification of PCR products and 
extraction of DNA fragments from the agarose gel were carried out according to the 
instructions in the relevant Qiagen kits.  
 
2.2.3 Restriction digestion of DNA and ligation 
 
Restriction digestions of plasmid DNA were performed according to the specifications of 
restriction endonucleases (as mentioned in manufacturer’s protocol). Ligation of DNA 
fragments and vectors were carried out using T4 DNA ligase following the instructions in 
manufacturer’s protocol. 
 
2.2.4 Pichia pastoris culture, preparation of competent cells and transformation 
 
As described in Multi-Copy Pichia expression kit (K1750-01, Invitrogen). 
 
2.2.5 Clone selection and expression in Pichia pastoris 
 
Selection of Pichia clones on G 418 plates were done as described in Multi-Copy Pichia 
expression kit (K1750-01) but lower concentrations of G 418 was used (0.025 mg/ml-0.5 
mg/ml). For test expression, pre-cultures were inoculated in BMGY from single colony 
and grown overnight at 30°C. Secondary cultures were inoculated (starting O.D. 1) in 
BMMY, grown at indicated temperatures (22°C or 30°C) and 0.5% methanol was added 
6 h before harvesting. 
 
2.2.6 Insect cell culture 
 
Monolayers of Sf9 and Sf21 cells were grown in TNM-FH medium supplemented with 
5% FKS, 2 mM glutamine and vitamin B12. For suspension culture, 0.1% pluronic was 
added to the culture medium. High Five
TM cells were grown in Express Five
TM medium 
supplemented with 100 ml glutamine (100X). Cells were maintained at 27°C. Suspension 
cultures were grown in Erlenmyer flasks at 27°C with shaking at 125 rpm. 
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2.2.6.1 Transfection 
 
Transfection reaction was set up as follows: 
Expression vector DNA  0.5 µg (5µl) 
BacuGold DNA    0.1 µg (1µl) 
Lipofectin    30  µg (5 µl) 
H2O      3 9 µl 
Reaction mixture was incubated at room temperature for 15 minutes and then 1 ml 
medium (without FKS) was added to this reaction. Subsequently, the reaction mix was 
added to Sf9 cells (approximately 1.28x10
6 cells, in medium with no FKS) in six well 
plates. After 4 hours, medium with 10% FKS was added to the cells. Supernatant was 
collected after 7 days, centrifuged down and used for plaque assay. 
 
2.2.6.2 Plaque assay 
 
Supernatant was diluted (10
-1-10
-6) and added to the Sf9 cells (2.0x10
6) in Petri dishes. 
After 1 h incubation, supernatant was removed and 4 ml of 1:1 mixture of low melting 
agarose and culture medium (with 10% FKS) was added to the cells. Once the agarose 
was solidified, 1-2 ml medium (with 5% FKS) was added and plates were incubated for 
4-5 days at 27°C. Afterwards, medium was removed and 1-2 ml of 1:1 mixture of low 
melting agarose and culture medium (with 10% FKS) was added to the plates. In this step 
X-gal was also added in order to differentiate between wild type and recombinant 
plaques. Next day, plaques were picked and added to Sf9 cells (2.0x10
6) in six well 
plates. After 6-7 days, supernatant was collected (main virus stock), centrifuged and used 
for preparing new virus stocks. 
 
2.2.6.3 Preparation of virus stocks and titer determination 
 
100 µl of main virus stock was added to a monolayer culture of Sf9 cells (in 15 ml flask, 
75-80% confluency). After one week, cells were separated by centrifugation at 6000 g for 
10 min, and supernatant was collected. 100-200 µl of this virus stock was added to a 100 
ml suspension culture of Sf9 cells (0.5x10
6/ml) for preparing large amounts of virus.   - 48 -
Virus titer was determined by end point dilution method (Reed et al., 1938) and 
expressed as the number of plaque-forming units (p.f.u.)/ml.  
 
2.2.6.4 Protein expression in Sf9 cells 
 
Cells were grown in suspension culture at 27°C and infected at density of 2x10
6 cells/ml. 
For optimization, different MOI and expression time was used. For large-scale 
expression, cells were grown in wave bioreactor, infected at MOI 10 and harvested after 
72-96 hours post-infection. 
 
2.2.7 Mammalian cell culture 
 
Monolayer of mammalian cells were maintained in 1:1 mixture of DMEM (Dulbecco’s 
modified eagles medium) and Iscove's modified medium supplemented with 10% FKS 
and 2 mM glutamine. Suspension culture of BHK cells were grown in Glasgow minimum 
essential medium (GMEM) supplemented with 2  mM glutamine, 5% FKS and 10% 
tryptose phosphate broth solution. Cells were maintained at 37°C with 5% CO2 in a 
humidified chamber. 
 
2.2.7.1 In vitro transcription 
 
Plasmid DNA was linearized with appropriate restriction enzyme (NruI for pSFV2 based 
expression vectors and SpeI for pSFV-helper2 vector) for 2 h at 37°C. Restriction 
digestion of plasmid DNA was checked on 1% agarose gel. Linearized DNA was purified 
using Qiaquick PCR purification kit (Qiagen) and used for in vitro transcription. In vitro 
transcription reaction was set up as follows:  
5 µl linearized DNA (5 µg)  
10 µl reaction buffer (5X)  
5 µl CAP (10 mM) 
5 µl DTT (50 mM) 
5 µl NTP mix  
2 µl RNAase inhibitor (40 units)    - 49 -
3 µl SP6 RNA polymerase (60 units)  
15 µl H2O  
Reaction mix was incubated at 37°C for 60 min and afterwards electroporated into BHK 
cells. 
 
2.2.7.2 Electroporation of mRNA into BHK cells 
 
BHK Cells (1-2x10
7) were washed twice with PBS, detached with trypsin/EDTA and 
resuspended in 30 ml of growth medium. Cell suspension was spun down at 1200 g for 5 
min. Subsequently, medium was removed and the cells were resuspended in PBS. The 
centrifugation was repeated as described before and the cells were finally resuspended in 
0.4 ml PBS. Cells were transferred to a 0.2 cm electroporation cuvette. Meanwhile, 25 µl 
of helper mRNA reaction was added into receptor mRNA reaction, mixed and 
immediately added to the cuvette. Cells were electroporated with two pulses under the 
following settings,  
Capacitance 25 µF  
Resistance ∞ 
Voltage 1.5 kV  
A typical time constant of 0.7-0.8 was observed. Cells were transferred to a 25 cm
2 flask 
containing 10 ml of growth medium and incubated for 24 h at 37°C.  
 
2.2.7.3 Collection and activation of virus 
 
Recombinant virus was collected by filtering the supernatant of the cells through a 0.22 
µM filter. Virus was activated by α-chymotrypsin (final concentration 0.5 mg/ml) 
treatment at room temperature for 20-30 minutes. To stop the reaction, aprotinin (final 
concentration 0.25 mg/ml) was added and incubated further for 5-10 minutes. Activated 
virus was used to infect the cells or stored at -80°C until used.  
 
2.2.7.4 Protein expression in mammalian cells 
 
Cells were infected at a density of 1-2x10
6 cells/ml and incubated at 37°C for defined 
time periods. Subsequently, the cells were harvested and membranes were prepared.   - 50 -
2.2.8 Membrane preparation of Pichia pastoris 
 
2.2.8.1 Analytical scale: 
 
For small scale (20 ml culture), cells were centrifuged and the pellet was resuspended in 
1 ml of breaking buffer. Equal volume of acid washed glass beads (0.5 mm in diameter) 
were added to the cells and vortexed for 10 min at 4°C. This leads to mechanical 
disruption of the cells. Glass beads, unbroken cells and cell debris were separated by 
centrifugation in plastic columns with filter. The supernatant was used for 
ultracentrifugation at 100,000 g (4°C) for 40 min. Subsequently, the pellet was 
resuspended in 500 µl of storage buffer and homogenized. Aliquots were flash frozen and 
stored at -80°C until used.  
 
2.2.8.2 Preparative scale 
 
For large-scale membrane preparation, Pichia cells were broken using a cell mill by 
mechanical disruption. Cells (from 6 liter culture) were pelleted and resuspended in 
breaking buffer (30% of their wet weight, e.g. 100 g cells in 300 ml breaking buffer). 100 
ml of acid washed, pre cooled glass beads (0.5 mm) were added to the cells. Cell 
suspension was passed three times through the mill and the cell breakage was checked 
under the microscope. The glass beads were washed with 100 ml of breaking buffer and 
separated from broken cells by vacuum filtration. Broken cells were spun down at 3500 g 
(4°C) for 20 min in order to remove cell debris and unbroken cells. The supernatant was 
subjected to ultracentrifugation at 100,000 g (4°C) for 1.5-2 h. The pellet was 
resuspended in storage buffer and homogenized until it became completely homogenous. 
It was further diluted to 75-100 ml with the storage buffer, aliquots were made and flash 
frozen. Membranes were stored at -80°C until further use.   
 
 
2.2.9 Membrane preparation from insect cells and mammalian cells 
 
 
Cells were washed and resuspended in breaking buffer at a density of 5-6x10
6
 
cells/ml. 
The cells were broken by using nitrogen cavitation procedure. In this method, first the   - 51 -
cells were equilibrated under a high pressure (500 psi) of nitrogen gas for 0.5-1 hour in 
“parr bomb”. During this incubation at high pressure, nitrogen dissolves into the aqueous 
buffers and into the cells. After incubation, the pressure was released from the 
pressurized “parr bomb”. The nitrogen rapidly converts back into the gas and disrupts the 
cells as it leaves (Broekma et al., 1992). The lysate was spun down at 3000 g (4°C) for 10 
min to remove the cell debris and unbroken cells. The supernatant was subjected to 
centrifugation at 100000 g for 1-2 h at 4°C. The pelleted membrane fraction was 
resuspended and homogenized in storage buffer. Membranes were aliquoted and frozen 
in liquid nitrogen. Aliquots were stored at -80°C until further use.  
 
2.2.10 Determination of protein concentration 
 
For the determination of protein concentration, the BCA protein assay was used (Smith et 
al., 1985) following the instructions of BCA protein assay kit (Pierce).  
 
2.2.11 SDS-PAGE analysis 
 
Analytical separation of proteins was carried out on denaturing polyacrylamide gels (10-
15%) following the standard protocol (Fling et al., 1986). But the samples were not 
subjected to heat denaturation, as it may result in aggregation of membrane proteins. The 
proteins in the gel were either stained with coomassie brilliant blue, silver nitrate or 
electrotransferred to PVDF membranes for Western blot analysis.  
 
2.2.12 Western blot analysis 
 
After electrophoresis, the proteins were transferred to a PVDF membrane by 
electroblotting following the standard procedure (Towbin et al., 1979). Protein transfer 
was carried out at the constant current of 50-60 mA per gel for 1.5-2 h. After the transfer, 
antibody staining was carried out according to the manufacturer’s protocol. Briefly, the 
PVDF membrane was blocked for 1-2 h at room temperature in TBST buffer and 
subsequently, washed three times (5 min each) with TBST buffer. Afterwards, the 
membrane was incubated with appropriate antibodies for 0.5-1 h at room temperature. 
Again, the membrane was washed three times with TBST buffer and then incubated in   - 52 -
secondary antibody (Alkaline Phosphatase/Horse Raddish Peroxidase conjugated goat 
anti-mouse IgG) for 0.5-1 h at room temperature. The membrane was then washed three 
times with TBST buffer. Finally, 10 ml of alkaline phosphatase buffer containing 66 µl of 
NBT solution and 33 µl of BCIP solution was added to the membrane and incubated till 
the bands appeared. The reaction was stopped by washing the membrane with water.  
 
2.2.13 Radioligand binding assays 
 
Radioligand binding assays were carried out to check the functionality of recombinant 
receptors. 
 
2.2.13.1 Binding assay on membranes 
 
For ligand binding assay, membranes were diluted in binding buffer. 5-20 µg of total 
protein/assay point was used. Membranes were incubated for 45-60 min at 4°C/25°C with 
radioactive ligand (at a concentration of approximately 10x Kd). Non-specific binding 
was determined in the presence of 1 µM non-radioactive ligand. For saturation binding 
experiments, different concentrations of radioactive ligands (0.1 nM-50 nM) were used. 
After incubation, the reaction was terminated by rapid filtration through GF/C glass-fiber 
filters (presoaked in 0.3% polyethyleneimine). These filters were washed four times with 
cold binding buffer or water. Subsequently, the filters were transferred to the counting 
vials. Radioactivity was measured using a Wallac microbeta counter or gamma counter 
(for 
125I NmU).  Dissociation constants (Kd) and Bmax  values  were calculated using 
“KaleidaGraph” software by non-linear regression and a single site model.  
 
2.2.13.2 Binding assay on solubilized and purified receptors 
 
Ligand binding of solubilized and purified receptor was measured by calcium phosphate 
precipitation method. Samples were incubated for 40-45 min at 4°C with radioactive 
ligand (as described above) and after incubation, 200 µl of Ca3(PO4)2 was added. Bound 
ligand was separated from free ligand in three washing steps using centrifugation at 2000 
rpm (4°C). Finally, the precipitate was resuspended in washing buffer and transferred to   - 53 -
the counting vials. Non-specific binding was determined in the presence of 1-10 µM of 
non-radioactive ligand. 
 
2.2.14 G protein coupling assay (inositol phosphate release) 
 
BHK cells expressing B2R were incubated with [
3H] myoinositol (0.25 µCi/well) for 16 h 
in 6 well plates. Following incubation, cells were washed twice with PBS, resuspended in 
PBS containing 10  mM LiCl and incubated for 10  min at 37  °C. Cells were then 
incubated either with 1 µM bradykinin for different time intervals (5-20 min) or with 
different concentrations of bradykinin (1 pM-0.1 mM) for 10 min. The reaction was 
terminated by the addition of 0.1% tricholoroacetic acid (TCA). Afterwards, the cells 
were lysed and total inositol phosphate was isolated using ion-exchange column (Dowex 
AG1-X8, pre-washed with 20 mM ammonium formate). [
3H] inositol phosphates were 
eluted with 1 M ammonium formate/0.1 M formic acid solution and radioactivity was 
determined by liquid scintillation counting.  
 
2.2.15 Localization of recombinant receptors 
 
Localization of the recombinant receptors in the host cells was investigated by either 
confocal microscopy (using eGFP fusion construct) or immunogold labeling experiment 
(using Flag-tagged construct). 
 
2.2.15.1 Confocal Microscopy 
 
For localization experiments, cells were grown on sterile cover slips, infected with virus 
and 16-24 h post infection,
  fixed for 15 min at room temperature (RT) with 4% 
paraformaldehyde. Subsequently, the cells were rinsed three times with PBS, 
permeabilized with digitonin (50 µg/ml in DMSO) for 15 min at RT. Then the cells were 
washed and incubated with either anti-Flag/anti-Myc monoclonal antibodies (in BHK 
cells) or with receptor specific antibodies (in HF-15 cells) for 1 h at RT. Afterwards, the   - 54 -
cells were rinsed with PBS and incubated with Cy3/cy5 coupled Goat anti-mouse or Goat 
anti-rabbit IgG secondary antibody for 1 h at RT. The cells were washed three times with 
PBS and then mounted onto slides by using Gel Mount aqueous mounting medium. For 
internalization experiments, the cells were stimulated with appropriate ligands at 37°C for 
indicated time. Subsequently, the cells were fixed, permeabilized and stained for confocal 
microscopy as described above. Cells were scanned with a Zeiss LSM 510 laser
 scanning 
confocal microscope. eGFP, Cy3 and Cy5 were detected at wavelengths of 488 nm, 550 
nm and 650 nm, respectively.  
 
2.2.15.2 Electron microscopy (fixation, embedding and immunogold staining) 
 
For immunogold labeling experiments, cells were fixed with sodium phosphate buffer 
containing 4% (v/v) paraformaldehyde for 2 h at room temperature.
 After incubation, 
cells were washed and then treated
 with 2% (w/v) glycine in sodium phosphate buffer in 
order to block unreacted
 aldehyde groups. For post-embedding immunostaining, glycine-
treated
 cells were dehydrated with ethanol, embedded in LR White resin,
 and samples 
were polymerized at 58°C. Immunogold staining
 was performed on thin sections using 
the anti Flag M2 antibody (1:300 dilution). A gold-coupled goat anti-mouse
 Ig (1:60 
dilution, 90 min room temperature) was used as secondary antibody. 
  For pre-embedding immunostaining, fixed and glycine treated
  cells were 
incubated first with 1% (w/v) BSA, then
 with 0.1% (w/v) BSA and finally incubated with 
the anti-Flag M2 antibody at 4°C overnight. Subsequently,
  cells were washed and 
incubated with gold-coupled goat
 anti-mouse Ig for 90 min at room temperature. After 
immunogold
 labeling, the cells were washed and fixed with 1% (v/v)
 glutardialdehyde for 
30 min and subsequently
 treated with 1% (w/v) OsO4 in 100 mM sodium cacodylate 
buffer.
 Cells were further treated with 2% (w/v) uranyl acetate, dehydrated with ethanol, 
embedded in Spurr's resin,
 and polymerized at 70 °C. Thin sections were analyzed by
 
electron microscopy (EM 208S, Philips, the Netherlands). 
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2.2.16 Solubilization of receptors from the membranes 
 
In order to solubilize the receptors, membranes (at a concentration of 5 mg/ml) were 
resuspended in the solubilization buffer containing appropriate detergent (as indicated in 
results section) and 0.2% cholesterol hemisuccinate (CHS). The suspension was 
incubated for 2 hours with gentle mixing at 4°C. Following solubilization, the suspension 
was subjected to ultracentrifugation at 100,000 g for 1-2 h, and the supernatant 
containing solubilized receptor was used for receptor purification.  
 
2.2.17 Purification of recombinant receptor 
 
Recombinant receptors were purified by affinity chromatography using different affinity 
tags fused to the receptors. 
 
2.2.17.1 Immobilized metal affinity chromatography (IMAC) 
 
Solubilizate (20-200 ml) was filtered through 0.65 µm filter and mixed with previously 
equilibrated (1-10 ml) Ni-NTA matrix. Binding to the affinity resin was carried out at 
4°C for two hours. The mixture was packed into a column and washed with 10-15 
column volumes of the washing buffer. Receptor protein was eluted with 5-10 column 
volumes of the elution buffer. Ni-NTA matrix was regenerated with the regeneration 
buffer, washed with water and stored in 20% ethanol.  
 
2.2.17.2 Purification on monomeric avidin matrix 
 
Non-specific binding sites on monomeric avidin resin were blocked according to the 
manufacturer’s protocol. Subsequently, the matrix was equilibrated with 5-10 column 
volumes of the equilibration buffer. The elution fraction from the Ni-NTA matrix was 
applied to this pre-equilibrated monomeric avidin matrix. The column was washed with 
10-15 column volumes of the washing buffer and the receptor protein was eluted by 5-10 
column volumes of the elution buffer. Monomeric avidin resin was regenerated with the 
regeneration buffer and stored in 20% ethanol.    - 56 -
2.2.17.3 Purification on anti-Flag antibody matrix 
 
Anti-Flag antibody matrix was pre-equilibrated according to the manufacturer’s protocol. 
The eluate from Ni-NTA column was applied to this pre-equilibrated anti-Flag antibody 
matrix, washed with 5-6 column volumes of the washing buffer and finally, the receptor 
protein was eluted with 5 column volumes of the elution buffer. For purification on M1 
matrix, 5 mM CaCl2 was added in all the buffers as the binding of Flag-tagged protein to 
this matrix is calcium dependent. The matrix was regenerated with the regeneration 
buffer and stored in 20% ethanol. 
 
2.2.17.4 Purification on streptactin matrix 
 
Pre-equilibrated streptactin resin was mixed with the eluate from Ni-NTA column and 
incubated for 1-2 h at 4°C on the rolling wheel. Subsequently, the material was packed 
into the column and washed with 6-10 column volumes of the washing buffer. Receptor 
protein was eluted with the elution buffer containing 2.5-5.0 mM desthiobiotin.  
 
2.2.18 Concentration of proteins 
 
Purified protein was concentrated using Vivaspin concentration tubes (cut off 50 kDa). 
The tubes with the protein solution were spun down at 3000 g at 4°C until the desired 
concentration of purified protein was achieved. Alternatively, proteins were concentrated 
by using TCA precipitation method (Tornqvist et al., 1976).  
 
2.2.19 Coomassie and silver staining of proteins 
 
For Coomassie staining, the gels were incubated for 1 h in Coomassie Brilliant Blue 
solution. Afterwards, the gels were placed into the destaining solution (changed 2-3 
times) until the bands became clearly visible. 
  For silver staining, the gels were fixed for 15 min in the fixer followed by 15 
minute incubation in the conditioner. Then, the gels were washed 3 times (5 min each) in 
water. After washing, the gels were incubated in the silver nitrate solution for 10 min,   - 57 -
washed twice in water (30 sec each) and developed using the developer solution. The 
reaction was stopped by adding 50 mM EDTA solution. 
 
2.2.20 Analytical gel filtration 
 
Molecular sieve chromatography (gel filtration or size-exclusion) was used to separate 
the proteins based on their molecular mass and to check the dispersity (homogeneity) of 
the purified receptors. For this purpose mainly Superose 6 PC 3.2/30 column (Pharmacia) 
was used on a Smart Chromatography station. Purified protein in 50-100 µl (5-10 mg/ml) 
was applied to the pre-equilibrated column. The flow rate was set to 50 µl/min and 
temperature was set to 4°C.   
 
2.2.21 Sample preparation for ss-NMR analysis 
 
Recombinant B2R was purified from BHK cells or Sf9 cells using affinity 
chromatography. Either of the three 
13C/
15N variants of bradykinin was added to the 
elution fraction and incubated for 2-3 hour at 4°C. Subsequently, the eluate was 
concentrated as described in section 2.2.18. In order to remove extra detergent and free 
peptide, repeated dilution and concentration was performed using a detergent free buffer. 
Subsequently, the receptor-ligand complex was transferred to a 4 mm MAS rotor, flash 
frozen and stored at -80°C until further use. 
 
2.2.22 Three-dimensional crystallization trials 
 
Purified receptor samples were concentrated up to 10 mg/ml and then used for 3-D 
crystallization screening in 300 nl drops (using Cartesian Crystallization Robot). Initially, 
a wide range of pH (4.0-9.0), precipitants (PEG 400 and PEG 4000), salts (acetate, 
sulphate and malonate) and two different temperatures (4°C and 18°C) were tested (detail 
scheme is shown in appendix). Commercially available crystallization kits (from Sigma 
and Jena Biosciences) were also used.   57
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Chapter 3: Production, characterization and isolation of 
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3.1 Production and isolation of B2R from Pichia pastoris 
 
3.1.1 Sub-cloning of B2R gene in Pichia expression vector 
 
The coding region of B2R gene was amplified from cDNA vector (pB2R from Aventis) 
with the primers B2R_ Pichia_Fw/Rv using the Pfu DNA polymerase. PCR products 
were checked on a 1% agarose gel (Fig. 3.1), purified using a PCR purification kit and 
then digested with BamHI and EcoRI enzymes. After restriction digestion, PCR product 
was ligated to BamHI-EcoRI digested pPIC9K (modified) vector.   
 
         
 
 
 
Fig. 3.1 Amplification of B2R gene from cDNA vector by PCR under the following 
conditions: 94°C = 5 min, 94°C = 40 sec, 66°C = 40 sec, 72°C = 90 sec and 72°C = 10 
min. Total 30 cycles (from step 2 to step 4) were used for amplification. PCR products 
were analyzed on 1% agarose gel. M = Lambda DNA marker (EcoRI + HindIII), C = 
control (no template), 1-5 = different amounts (50 ng-200 ng) of template DNA. 
 
3.1.2 Expression construct 
 
A modified pPIC9K expression vector (Fig. 3.2) was used for the production of B2R in 
Pichia pastoris. This vector contains the alcohol-oxidase I (AOXI) promoter for 
heterologous production of recombinant proteins and a coding region for the α-mating 
factor prepro-peptide (α-factor) of Saccharomyces cerevisiae. The α-factor is used as a 
secretion signal for soluble proteins. It was previously reported that an N-terminal fusion 
of this factor enhances the production of GPCRs in Pichia pastoris (Weiss et al., 1998). 
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The protease-cleavage site, inserted between the α-factor sequence and the receptor, is 
recognized by the Kex-2 protease of Pichia pastoris and should lead to an efficient 
cleavage of the α-factor. The coding region of B2R receptor gene was cloned into the 
Multiple Cloning Site (MCS) of the modified pPIC9K vector (modified from original 
pPIC9K vector by Markus Weiss). The modified pPIC9K vector contains a Flag tag and a 
Histidine10 tag at the N-terminus of the MCS and a biotinylation domain of 
Propionibacterium shermanii transcarboxylase (Cronan et al., 1990) at the C-terminus of 
the MCS. The tags were separated from the receptor coding region by a TEV protease 
cleavage site. The Flag and His10 tags can be used for immunological detection and 
receptor purification. Previous studies have shown a positive effect of biotinylation 
domain on recombinant expression of GPCRs in Pichia pastoris (Weiss et al., 1998). 
Additionally, this domain also serves as an affinity tag for receptor purification via 
monomeric avidin matrix.  
 
 
 
 
 
Fig. 3.2 Expression construct for production of recombinant B2R in Pichia pastoris. 
AOX1 = alcohol oxidase 1 promoter, α-factor = α-mating factor prepro-peptide of S. 
cerevisiae, Flag = coding sequence for Flag epitope, His10 = coding sequence for 
histidine 10 tag, B2R = coding sequence of B2R gene, TEV = cleavage site for TEV 
protease, Bio = biotinylation domain of Propionibacterium shermanii transcarboxylase. 
 
3.1.3 Production of recombinant receptor 
 
Pichia cultures were grown in shake flasks (as described in Multi-Copy Pichia 
expression kit, Invitrogen), membranes were prepared (after 24 h of induction with 
methanol) and subjected to Western blot analysis and ligand binding assay.  
 
3.1.3.1 Western blot analysis 
 
Western blot with anti-Flag M2 antibody was performed to check the expression of 
recombinant receptor. As shown in Fig. 3.3, a band of approximately 55 kDa was seen in 
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membranes from Pichia cells expressing B2R. This corresponds well with the calculated 
size of the recombinant receptor fusion protein (50.7 kDa). An additional band of 
approximately 75 kDa was also observed that probably represents the unprocessed
# 
receptor. 
 
 
 
 
 
Fig. 3.3 Western blot analysis of the recombinant B2R produced in Pichia pastoris. 
Proteins were separated using 10% SDS-PAGE and probed with anti-Flag M2 antibody.  
Lane 1 = 10 µg of control Pichia membranes and lane 2 = 10 µg of membranes from 
Pichia cells expressing FlagHis10B2RBio fusion protein.  
 
 
3.1.3.2 [
3H] bradykinin binding 
 
In order to check the functionality of the recombinant receptor and to calculate the total 
amount of functional receptor in membranes, a saturation binding experiment using [
3H] 
bradykinin was performed. [
3H] bradykinin binding was saturable and revealed a Bmax 
value of 0.5 pmol recombinant B2R per mg membrane protein (Fig. 3.4). A high affinity 
binding of [
3H] bradykinin to the recombinant receptor was observed with a Kd value of 
0.87 nM. This Kd value is similar to that reported for B2R in native tissues (see 
appendix). 
 
 
#Unprocessed receptor represents the fusion of recombinant receptor and α-factor as 
Kex-2 endopeptidase of Pichia failed to cleave the α-factor completely. 
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Fig. 3.4 Saturation curve for [
3H] bradykinin binding to the recombinant B2R produced in 
Pichia pastoris. Graph was generated using the single site model in KaleidaGraph 
software. 
 
3.1.4 Optimization of functional expression of B2R 
 
It has been reported previously (Aleksandra Ivanovic, PhD thesis) that the addition of 
DMSO (dimethylsulphoxide) during expression of recombinant GPCR in Pichia pastoris 
results in significant increase in the amount of functional receptor. Therefore, in order to 
increase the functional expression of B2R, DMSO was added to the Pichia cultures 
during the methanol induction step. As shown in Fig. 3.5, approximately seven-fold 
increases in the functional expression of recombinant B2R was observed by the addition 
of DMSO. Maximum expression level was obtained in presence of 2% DMSO and it 
Bmax = 0.50 pmol/mg
Kd = 0.87 nM   63
corresponds to 3.5 pmol of recombinant B2R per mg of membrane protein (~0.1 mg of 
receptor per liter culture). 
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Fig. 3.5 Effect of DMSO on the expression level of recombinant B2R in Pichia pastoris. 
DMSO was added to the cultures, membranes were prepared and [
3H] bradykinin binding 
was measured. 
 
 
3.1.5 Glycosylation analysis 
 
There are three putative glycosylation sites
# in B2R, two at the N-terminus (N
3, N
12) and 
one in the third extracellular loop (N
180). In order to analyze the glycosylation state of the 
recombinant receptor, enzymatic deglycosylation using PNGaseF and EndoH was 
performed on Pichia membranes expressing B2R, followed by Western blot analysis. As 
shown in Fig. 3.6, the recombinant receptor band was shifted to lower molecular weight 
size upon enzymatic deglycosylation. This reveals that the recombinant B2R produced in 
Pichia was glycosylated. The band corresponding to the unprocessed receptor was also 
reduced in size upon enzymatic deglycosylation. 
 
 
#These sites are predicted on the basis of conserved N-linked glycosylation motif (Asn-
Xaa-Ser/Thr). 
  Fold expression 
 
         
           DMSO (%)                 0                           1                              2                           3   64
 
 
   
 
 
Fig. 3.6 Glycosylation analysis of the recombinant B2R produced in Pichia. 10 µg of 
Pichia membranes expressing B2R were treated with 0.5 units of PNGaseF (lane 2) or 0.5 
units of EndoH (lane3) at 4°C for 2 h. The lane “C” is untreated control Pichia 
membranes (10 µg). Proteins were separated by 10% SDS-PAGE and Western blot 
analysis was performed using anti-Flag M2 antibody.  
 
 
3.1.6 Solubilization of recombinant B2R 
 
In order to solubilize the recombinant B2R from Pichia membranes, different detergents 
were tested. As shown in Fig. 3.7, B2R was solubilized with most of the detergents. 
However, proteolytic degradation of B2R during solubilization was also observed (bands 
at approximately 40 kDa). [
3H] bradykinin binding on solubilizate was used to monitor 
the functional solubilization of B2R from Pichia membranes. It revealed that 
approximately 20-25 % of the [
3H] bradykinin binding sites were solubilized with n-
dodecyl-β-D-maltoside (LM) and Foscholine14. Recovery with other detergents was 
lower. It has been previously reported (Markus Weiss, Ph.D. thesis and Weiss et al., 
2002) that addition of Cholesterol hemisuccinate (CHS) exerts a positive effect on 
functional solubilization of GPCRs from Pichia membranes. Therefore, 0.2% CHS was 
added during solubilization. As shown in Fig. 3.8, addition of CHS resulted in a 
significant increase in the solubilization of functional B2R.  
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Fig. 3.7 Solubilization of recombinant B2R from Pichia membranes (5 mg/ml). Lane 1-
10 = LM, UM, DM, NG, OG, Fos12, Fos14, Fos 16, CHAPS, Digitonin and LDAO. All 
the detergents were used at the concentration of 1% except OG (2%). Proteins in the 
supernatant were separated by 10% SDS-PAGE and Western blot analysis was performed 
using anti-Flag M2 antibody. 
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Fig. 3.8 Effect of CHS on solubilization of [
3H] bradykinin binding sites from Pichia 
membranes. 
 
3.1.7 Purification of recombinant B2R 
 
The N-terminal His10 tag enabled the purification of the recombinant receptor by Ni-NTA 
resin. Receptor was solubilized from the membranes (5 mg/ml) with 1% LM in presence 
of 0.2% CHS. Solubilizate was applied to Ni-NTA matrix (batch binding). Subsequently, 
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the column was washed with washing buffer (see materials and methods) and finally the 
receptor was eluted with elution buffer containing 200 mM imidazole. As a second step 
of purification, Ni-NTA eluate was then applied to monomeric avidin matrix. The 
recombinant receptor binds to this matrix via its biotinylated bio tag. B2R from this 
column was eluted with 2 mM biotin. The eluates from Ni-NTA and monomeric avidin 
were analyzed on a 10% silver stained SDS-polyacrylamide gel. As depicted in Fig. 3.9 
(lane 1), after two-step affinity purification, the recombinant receptor was >85 % pure 
(band at 55 kDa, indicated by the arrow head).  
In order to check the homogeneity of purified B2R, eluate from monomeric avidin 
column was analyzed by gel filtration using a superose 6 column (PC3.2/30) in the 
SMART chromatography system. A main peak at the retention volume of 1.60 ml 
(indicated by the arrow head) was observed. It corresponds to the homogenous 
population of purified B2R. In addition to this main peak, some aggregated receptor (peak 
at retention volume of 0.89 ml and 1.3 ml) was also observed.  
 
 
 
                                             
 
 
 
Fig. 3.9 Purification of recombinant B2R from Pichia pastoris. A. Silver stained 10% 
SDS-PAGE showing the eluate from Ni-NTA (lane 1, 1 µg) and monomeric avidin (lane 
2, 0.5 µg). B. Analytical gel filtration of purified B2R (eluate from monomeric avidin 
column, 0.5 mg at a concentration of 10 mg/ml) using superose 6 column. 
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[
3H] bradykinin binding was also measured on different fractions during purification. As 
shown in Table 3.1, recovery of the active receptor was approximately 20% after two-
step purification. 
 
 [
3H]bradykinin binding   
(nmol) 
Specific  activity   
(nmol/mg) 
  Total protein  (mg) 
BCA/[
3H]BK binding 
Recovery (%) 
Membrane             9.00           0.0030           3000/(0.45)             100 
Solubilisate             6.72           0.0041           1640/(0.33)                74 
Ni-NTA eluate             3.51           0.417            8.41/(0.18)             39 
Mon.Avidin eluate             1.71           0.987            1.71/(0.09)            19 
 
Table 3.1. Recovery of functional B2R during different steps of purification based on 
[
3H] bradykinin binding analysis and BCA quantification. 
  
Due to the low production level of receptor in Pichia pastoris, baculovirus 
mediated expression of B2R in insect cells was tested. 
 
3.2 Production and isolation of B2R from insect cells using the baculovirus system 
 
3.2.1 Sub-cloning of the B2R gene in the baculovirus expression vectors 
 
The coding region of B2R gene was cloned into the MCS of modified pVL vectors (the 
original pVL1392 vector was a kind gift from Max D. Summers, Texas, USA) between 
BamHI and EcoRI enzyme sites. Amplification of the receptor gene (with 
B2R_Baculo_Fw/Rv primers using Pfu DNA polymerase) and ligation to the expression 
vectors was carried out as described in section 3.1.1.
  
 
3.2.2 Expression constructs 
 
The baculovirus constructs used for the expression of B2R in insect cells are shown in 
Fig. 3.10. The first construct was made by Dr. Helmut Reiländer (in collaboration with 
Dr. Schroeder, University of Mainz, Germany) and the modified pVL1392 vectors for the 
other two constructs were provided by Gabi Maul. In the baculovirus constructs, the   68
receptor expression was driven by a polyhedrin promoter and a prepro-mellitin sequence 
from honey bee was used as a signal peptide. This signal sequence is expected to drive 
the recombinant receptor to the plasma membrane and later it gets cleaved off by an 
insect cell signal peptidase (Tessier et al., 1991). For detection and purification of 
recombinant receptor, Flag and His10 tag at the N-terminus and a biotinylation domain at 
the C-terminus of the MCS were engineered. The construct with an eGFP fusion at the C-
terminus of the receptor was also made that can be used for receptor localization studies 
using confocal microscopy. 
 
 
 
Fig. 3.10 Expression constructs for production of the recombinant B2R in insect cells. 
PHP = polyhedrin promoter, Mel = prepro-mellitin signal sequence of honey bee, Flag = 
coding sequence for Flag epitope, His10 = coding sequence for histidine 10 tag, B2R = 
coding sequence for B2R gene, Bio = biotinylation domain of Propionibacterium 
shermanii transcarboxylase and eGFP = coding sequence of enhanced green fluorescent 
protein. 
 
 
3.2.3 Production of the recombinant receptor 
 
In order to check the expression of B2R, Sf9 cells were infected at MOI 10 with one of 
the recombinant baculovirus constructs (pVLMelFlagHis10B2RBio). 72 h post-infection, 
membranes were prepared and subjected to Western blot analysis and [
3H] bradykinin 
binding analysis. 
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3.2.3.1 Western blot analysis 
 
Western blots with anti-Flag M2 antibody and alkaline phosphate-coupled streptavidin 
were performed to check the expression of recombinant receptor. As shown in Fig. 3.11, 
a band of approximately 55 kDa was seen in Sf9 membranes expressing B2R. This 
apparent molecular mass closely corresponds to the calculated size of the receptor fusion 
protein (49.3 kDa). However, on anti-Flag M2 immunoblot (Fig. 3.11 A), in addition to 
the full length receptor band, another band of approximately 40 kDa was also observed. 
This band probably represents a proteolytic degradation product of B2R. Interestingly, 
this band was not observed on anti-strep blot (Fig. 3.11 B). Therefore, this band 
represents an N-terminal fragment of B2R.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.11 Western blot analysis of the FlagHis10B2RBio construct produced in Sf9 cells 
using 10% SDS-PAGE. C = 10 µg membranes from non-infected Sf9 cell, lane 1 & 2 = 
10 µg membranes from Sf9 cells expressing FlagHis10B2RBio fusion protein. A = anti-
Flag M2 blot, B = anti-strep blot.                                                                           
 
3.2.3.2 [
3H] bradykinin binding 
 
In order to check the functionality of the recombinant receptor and to calculate the total 
amount of functional receptor in membranes, a saturation binding experiment using [
3H] 
bradykinin was performed. Suspension culture of Sf9 was grown and infected with 
baculovirus corresponding to three different constructs (shown in Fig. 3.10) at an MOI of 
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10. 72 h post-infection, membranes were prepared and saturation binding was performed 
using [
3H] bradykinin. As shown in Fig. 3.12, the construct pVLMelFlagHis10B2RBio 
exhibited the highest expression level and therefore it was used for further studies.  
         
    
 
 
 
Fig. 3.12 Saturation curves for [
3H] bradykinin binding to recombinant B2R produced in 
Sf9 cells
#. A: pVLB2R, B: pVLMelFlagHis10B2RBio and C: pVLMelFlagHis10B2ReGFP. 
(C). Graphs were made using the single site model in Kaleidagraph software. 
 
 
 
 
 
#For receptor expression studies, Sf9/Sf21 cells were infected at a density of 2.5x10
6 
cells/ml and H5 cells at 2.0x10
6 cells/ml.
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3.2.4 Optimization of functional production level of B2R 
 
The expression conditions (such as MOI, cell line and expression time) are known to 
influence the production of recombinant GPCRs in the baculovirus system (reviewed in 
Massotte et al., 2003). Therefore, in order to maximize the expression level of B2R in this 
system, three different parameters, namely cell type, MOI and expression time were 
investigated. The results are shown in Fig. 3.13. Significant effect of expression time on 
functional expression of B2R was observed. [
3H] bradykinin binding was detected as 
early as 24 h after infection and it reached to a maximum level 96 h post-infection (in Sf9 
cells). A similar time course of CXCR1 expression in insect cells has been reported 
earlier (Maeda et al., 2005). Effect of MOI on B2R expression was moderate in Sf9 cells 
but more significant in H5 cells. However, the maximum expression level in Sf9 cells 
using MOI 5 or 10 was almost similar. Use of low MOI for receptor expression makes 
the scale-up feasible. Sf9 cells showed maximal expression of B2R among the three 
different cell lines that were tested. Although, in some cases the production level of 
recombinant proteins is better in H5 cells compared to Sf9 cells (personal 
communication, Ingo Focken, Aventis), it was not observed for B2R.  
  For further characterization and large-scale production, Sf9 cells were infected at 
MOI of 5 and harvested 96 h post-infection. Under these expression conditions, a typical 
expression level of 10 pmol/mg for B2R (0.3 mg/liter culture) was obtained.   
 
3.2.5 Glycosylation analysis of recombinant B2R 
 
In order to analyze the glycosylation state of the recombinant receptor, either enzymatic 
deglycosylation (using PNGaseF or EndoH) was performed on Sf9 membranes or 
tunicamycin was added to the culture medium, followed by Western blot analysis. As 
shown in Fig. 3.14, the recombinant receptor band was shifted to a lower molecular 
weight size upon deglycosylation. This reveals that the recombinant B2R produced in Sf9 
cells was glycosylated. In addition, size of the degradation product was also reduced 
indicating that it represents an N-terminal fragment of B2R. 
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Fig. 3.13 Effect of cell type, MOI and expression time on the expression of recombinant 
B2R in baculovirus system. Upper panel = Sf9 cells, middle panel = H5 cells and lower 
panel = Sf21 cells.  
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Fig. 3.14 Glycosylation analysis of the recombinant B2R produced in Sf9 cells. 10 µg of 
membranes from Sf9 cells expressing B2R were treated with 0.5 units of PNGaseF (lane 
1) or 0.5 units of EndoH (lane 2) at 4°C for 2 h. Tunicamycin (10 mg/ml) was added to 
the Sf9 cell cultures. The lane “C” is untreated control Sf9 membranes (10 µg). Proteins 
were separated by 10% SDS-PAGE and Western blot analysis was performed using anti-
Flag M2 antibody.  
 
 
3.2.6 Localization of the recombinant B2R 
 
In order to check the localization of recombinant receptor, immunogold labeling 
experiments were carried out using the pVLMelFlagHis10B2RBio construct. Additionally, 
confocal microscopy using the pVLMelFlagHis10B2ReGFP construct was also performed. 
 
3.2.6.1 Immunogold labeling experiment
 
 
Sf9 cells expressing B2R were analyzed by pre- and post-embedding as described in 
materials and methods section. As shown in Fig. 3.15, most of the recombinant receptors 
were localized in intracellular membranes, probably in the endoplasmic reticulum. Only 
few receptor molecules were found in the plasma membrane.  
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Fig. 3.15 Localization of the recombinant B2R in insect cells using immunogold labeling 
experiment
#. A&B = post-embedding labeling, C&D = control non-infected cells. 
 
 
 
#This experiment was performed by Dr. Winfried Haase. 
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3.2.6.2 Localization analysis of B2R by confocal microscopy 
 
Receptor-eGFP fusion protein is a fast and efficient tool to check the receptor expression 
and localization in the host cells. Confocal microscopy was performed on Sf9 cells and 
H5 cells expressing the pVLMelFlagHis10B2ReGFP construct. The recombinant 
receptor appeared to be localized mainly in the perinuclear membranes (Fig. 3.16), most 
probably in the endoplasmic reticulum. Only little fluorescence was observed on the 
plasma membrane.  
 
 
                    
 
 
Fig. 3.16 Confocal imaging of Sf9 (A) & H5 (B) cells expressing B2R-eGFP. The cells 
were grown and infected on cover slips. 48 h post-infection, cells were fixed and scanned 
(488 nm) with a Zeiss laser
 scanning confocal microscope. 
 
3.2.7 Large-scale production of recombinant B2R
 
 
For structural studies, large amounts of receptor are needed. Therefore, a 25 liter wave 
bioreactor (shown in Fig. 3.17) was used for large-scale culture of Sf9 cells. Cells were 
initially grown in shake flasks and later transferred to the wave bioreactor. Cells were 
infected at a density of 2-2.5x10
6 cells/ml and harvested 96 h post-infection. Membranes 
were prepared using the nitrogen cavitation method and the amount of recombinant 
 PM 
 
       ER 
A                                                                             B   76
receptor was estimated by [
3H] bradykinin binding assay. Later, the membranes were 
used for isolation of the recombinant receptor. 
 
 
      
 
 
Fig. 3.17 Wave bioreactor (SYSTEM20/50 from WAVE BIOTECH) used for large-scale 
culture of Sf9 cells. Production of B2R in wave bioreactor was carried out by Ingo 
Focken at Sanofi-Aventis. 
 
 
From a 25 liter Sf9 cell culture, approximately 15 g of membrane was obtained. [
3H] 
bradykinin binding on the membranes from the bioreactor was similar to that of small 
cultures in Erlenmeyer flasks. As estimated from [
3H] bradykinin binding analysis, a total 
of  7-8 mg of recombinant B2R was obtained in membranes (Table 3.2) 
 
 Culture volume (L)  Total  membrane  (mg)  
(BCA) 
[
3H] bradykinin binding   (pmol/mg)  Total  functional  B2R in 
membranes (mg) 
                     25                    12-15x10
3                       8-10                          7-8 
  
Table 3.2: Estimation of functional B2R produced in Sf9 cells using the wave bioreactor. 
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3.2.8 Solubilization and purification of B2R 
 
LM and Fos14 were the most effective detergents for the solubilization of B2R from 
Pichia membranes (see section 3.1.6). Therefore, to solubilize B2R from Sf9 membranes, 
either of these two detergents was used. Solubilization efficiency, as assessed by [
3H] 
bradykinin binding, was approximately 65-70%.  
 
3.2.8.1 Purification of B2R via Ni-NTA and monomeric avidin 
 
It has been reported earlier that addition of a high affinity ligand (endothelin) during 
solubilization and purification stabilizes the endothelin B receptor (Danka Elez, PhD 
thesis). Therefore, membranes from Sf9 cells expressing B2R were incubated with 
bradykinin (1 µM) for two hours. Subsequently, membranes were solubilized and applied 
to Ni-NTA resin. Eluate from Ni-NTA column was analyzed by silver stained 10% SDS-
PAGE. Recombinant receptor band at 55 kDa was enriched (Fig. 3.18 A, lane 4). 
However, other impurities were also detected. As a second step of purification, the eluate 
from Ni-NTA was loaded on to the monomeric avidin column. The eluate from 
monomeric avidin column (lane 5) revealed mainly two bands on silver stained SDS- 
polyacrylamide gel, one at 55 kDa that represents B2R and another band at approximately 
65 kDa. Purified B2R was present in homogenous form (Fig. 3.18 B, peak at 1.61 ml) as 
revealed by analytical gel filtration.  
 
3.2.8.2 Purification of B2R via Ni-NTA and anti-Flag antibody matrix 
 
Alternatively, the eluate from Ni-NTA column was applied to anti-Flag M1 or M2 
antibody resins. As shown in Fig. 3.19 (A), in addition to the recombinant B2R at 55 kDa, 
two more bands (65 kDa and 35 kDa respectively) were also observed in the eluates of 
M1 and M2 resins (lane 2 & 3). The band at 65 kDa was also observed in the eluate of 
monomeric avidin (Fig 3.18, lane 5). However, the 35 kDa band probably represents the 
proteolytic cleavage product of B2R. Western blot (with alkaline phosphatase-coupled   78
streptavidin) of the eluate from M2 resin revealed a single band at approximately 55 kDa 
corresponding to B2R (Fig. 3.19B).
#  
 
 
 
                                    
 
 
Fig. 3.18 Purification of recombinant B2R from Sf9 cells. A. Silver stained 10% SDS-
PAGE showing membranes (lane 1, 0.2 µg), solubilisate (lane 2, 0.2 µg), flow through 
(lane 3, 0.2 µg), eluate from Ni-NTA (lane 4, 1 µg) and monomeric avidin (lane 2, 0.5 
µg). B. Analytical gel filtration of purified B2R (eluate from monomeric avidin column, 
0.15 mg at a concentration of 3 mg/ml) using superose 6 column. 
 
 
 
 
 
 
 
 
#The band of approximately 35 kDa was stained with anti-Flag antibody on the Western 
blot (see section 3.2.3.1) but not with AP-conjugated streptavidin. As described before, 
this represents an N-terminal fragment of B2R. The C-terminal fragment after proteolytic 
degradation is not seen on the gel as it is smaller in size (10-12 kDa). 
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Fig. 3.19 Purification of recombinant B2R from Sf9 cells. A. Coomassie stained 10% 
SDS-PAGE showing the eluate from anti Flag M1 resin (lane 1 and 2, 0.5 and 1 µg 
respectively) and anti-Flag M2 resin (lane 3, 1 µg). B. Western blot analysis of the eluate 
from M2 resin using AP-conjugated streptavidin. 
 
 
Here, it was not possible to follow receptor purification by ligand binding 
(receptor was purified with high affinity ligand bradykinin). Therefore, estimation of 
purification yield is based on the total protein quantification by BCA assay. It was 
estimated that the receptor yield after two-step purification was 15-20% (BCA 
quantification) of the starting amount in membranes (based on ligand binding).  
 
3.2.8.3 Identification of 65 kDa band as a protein tyrosine phosphatase 
 
As shown in Fig. 3.18 and 3.19, a 65 kDa protein was copurified with the recombinant 
B2R on three different affinity resins (Ni-NTA, monomeric avidin and anti-Flag antibody 
resins). It is likely that this band is just not a contamination but rather a specific 
interaction partner of B2R. In order to identify this protein, mass spectrometric analysis 
was performed. The peaks obtained (shown in Table 3.3) during mass spectrometric 
analysis were analyzed by PeptIdent programme (EXPASY tools, www.expasy.org/tools 
/peptident). In this analysis, the 65 kDa band was identified as protein-tyrosine 
phosphatase SHP-2. Interaction of this protein with B2R has been documented earlier by 
using surface plasmon resonance technique. Interaction of B2R and SHP-2 is important in 
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the anti-proliferative effect of bradykinin in primary culture renal mesangial cells 
(Duchene et al., 2002).  
 
Peaks obtained (Da)                                                Corresponding peptide 
         919.66                                                         MEQRAER 
         887.65                                                         QQCELLK 
         865.60                                                         FKYCQAK 
         774.90                                                         EFDKQAK 
         693.86   
         676.49                                                             WSDLR 
 
Table 3.3 Peaks obtained during mass spectrometry analysis of the 65 kDa protein and 
corresponding peptides (analyzed by EXPASY tools, www.expasy.org/tools /peptident). 
 
It is important to mention that the copurification of this receptor tyrosine 
phosphate was observed only during purification of B2R from insect cells in the presence 
of bradykinin (receptor agonist). This protein gets copurified with B2R even after three 
affinity columns suggesting a strong interaction with the receptor. Therefore, it can be 
advantageous during the crystallization of B2R. 
 
3.3 Production and isolation of the B2R from mammalian cells 
 
Next, SFV based expression of B2R in mammalian cells was tested. Mammalian cells 
provide the most natural environment for heterologous expression of recombinant human 
GPCRs. 
 
3.3.1 Sub-cloning of B2R gene in SFV expression vectors 
 
B2R gene was amplified with the primers B2R_SFV_Fw/Rv and ligated to modified SFV 
vectors between BamHI and SpeI site using standard cloning procedure.  
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3.3.2 Expression constructs 
 
For expression of B2R in mammalian cells, the modified SFV expression vectors were 
provided by Christoph Reinhart. In this system, expression of recombinant proteins is 
driven by a subgenomic 26 S promoter. These vectors contain either a Kozak sequence 
(K) and a self-cleavable signal sequence from influenza haemaglutinin (HA) gene or a 
capsid sequence (a translation enhancer element from 5’ end of capsid gene from SFV) at 
the  N-terminus. Additionally, these vectors also contain affinity tags as described before 
in section 3.1.2. An e-GFP fusion construct of B2R was also made for localization 
analysis. 
 
 
 
 
 
 
 
 
 
 
Fig. 3.20 Expression constructs for production of recombinant B2R in mammalian cells. 
PSG = subgenomic 26S promoter, K = Kozak sequence, HA = signal sequence from 
influenza haemaglutinin (HA) gene, Flag = coding sequence for Flag epitope, CAP = 
capsid sequence, B2R = coding sequence for B2R  gene, His10 = coding sequence for 
histidine 10 tag, TEV = cleavage site for TEV protease, Bio = biotinylation domain of 
Propionibacterium shermanii transcarboxylase, eGFP = enhanced green fluorescent 
protein. 
 
 
 
         PSG              K       HA     Flag                                           B2R                                           TEV     His10                 Bio 
         PSG              K       HA     Flag                                           B2R                                           TEV     His10                 
         PSG                      CAP                                                      B2R                                             TEV     His10               Bio 
         PSG                      CAP                                                       B2R                                            TEV    His10                
PSG                       CAP                                                             B2R                                                                  eGFP   82
3.3.3 Production of the recombinant receptor 
 
Recombinant virus particles were generated and activated as described in materials and 
methods section. Monolayer cultures of BHK cells were grown and infected at 
approximately 75-80 % confluency. 
 
3.3.3.1 Comparison of different construct for B2R production in BHK cells 
 
In order to select the best construct, [
3H] bradykinin binding was performed on 
membranes from BHK cells expressing different constructs. As shown in Fig. 3.21, best 
expression of B2R was observed in the membranes from BHK cells expressing the 
pSFVCAPB2RTEVHis10Bio construct. Therefore, this construct was used for further 
studies. A positive effect of the biotinylation domain (Grunewald et al., 1996) and capsid 
sequence (Lundstrom et al., 2001) on the expression of recombinant GPCRs has been 
reported. Also in this study, a significant effect of the biotinylation domain and capsid 
sequence on expression of B2R was observed (construct 1 vs. construct 2 and construct 3 
vs. construct 4).  
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Fig. 3.21 [
3H] bradykinin binding on BHK cell membranes expressing different 
constructs of B2R. 1 = pSFVGenFlagB2RTEVHis10, 2 = pSFVGenFlagB2RTEVHis10Bio, 
3 = pSFVCAPB2RTEVHis10 and 4 = pSFVCAPB2RTEVHis10Bio. 
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3.3.3.2 Western blot analysis of B2R 
 
Western blot analysis of membranes from BHK cells expressing B2R using anti-his 
antibody revealed a major band of approximately 50 kDa (Fig. 3.22). It corresponds well 
to the calculated size of recombinant receptor fusion protein (50.1 kDa). An additional 
band of approximately 75 kDa was also observed. This probably represents a fusion of 
recombinant B2R with capsid protein although an efficient cleavage of capsid protein 
from the recombinant protein is generally expected (Lundstrom et al., 2003). This band 
of 75 kDa was not always observed on the Western blots and its presence probably 
depends on expression conditions. 
 
 
          
 
 
Fig. 3.22 Western blot analysis of the recombinant B2R produced in BHK cells. Proteins 
were separated by 10% SDS-PAGE and probed with anti-his antibody. Lane 1 = 10 µg of 
BHK membranes expressing B2R, lane 2 =  5 µg of BHK membranes expressing B2R. 
 
3.3.3.3 [
3H] bradykinin binding 
 
In order to calculate the total amount of functional receptor in membranes, a saturation 
binding experiment using [
3H] bradykinin was performed. As shown in Fig. 3.23, [
3H] 
bradykinin binding was saturable and revealed a Bmax value of 5 pmol recombinant B2R 
per mg membrane protein. A high affinity binding of [
3H] bradykinin to the recombinant 
receptor was observed with a Kd value of 0.12 nM. This Kd value is similar to those 
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reported for B2R in native tissues (see appendix). The non-specific binding was 
determined in presence of 1 µM bradykinin and it was less than 10% of total binding.  
 
                     
 
Fig. 3.23 Saturation curve for [
3H] bradykinin to recombinant B2R produced in BHK 
cells. The graph was generated using single site model in Kaleidagraph software. 
 
3.3.4 Optimization of functional expression of B2R 
 
In an attempt to optimize the expression level of B2R in mammalian cells, following 
parameters were tested. 
 
3.2.4.1 Adherent cells vs. suspension culture 
 
For large-scale production of recombinant receptor, a suspension culture is needed. 
Therefore, BHK cells were grown in suspension culture and infected at a density of 1-
Bmax = 5 pmol/mg 
Kd = 0.12 nM   85
2x10
6 cells/ml. Interestingly, [
3H] bradykinin binding on membranes of BHK cells grown 
in suspension culture revealed an expression level of 11 pmol/mg (compared to 5 
pmol/mg with adherent BHK cells). Further expression studies were carried out using 
suspension cultures of BHK cells.  
 
3.2.4.2 Time scale of B2R expression in BHK cells 
 
In order to find an optimal time point for B2R expression in BHK cells, time dependence 
of B2R expression was determined. BHK cells were grown and infected as described 
before. Subsequently, the cells were harvested at different time intervals, membranes 
were prepared and [
3H] bradykinin binding was measured. As shown in Fig. 3.24, there 
was only a moderate effect of expression time on B2R expression level in BHK cells. For 
further experiments, cells were harvested 24 h post-infection. 
 
 
                                                        
 
 
Fig. 3.24 Effect of expression time on recombinant B2R expression in BHK cells as 
measured by [
3H] bradykinin binding assay.  
 
3.3.4.3 Effect of DMSO on B2R expression 
 
In an attempt to further increase the functional expression of B2R, DMSO was added to 
the BHK cell cultures during expression. 24 h post-infection, membranes were prepared 
and subjected to [
3H] bradykinin binding analysis. As shown in Fig. 3.25, a five-fold 
Expression time (h)        24            36              48   86
increase in functional expression of recombinant B2R was achieved by the addition of 2% 
DMSO. A maximum expression level of 55-60 pmol/mg for recombinant B2R (0.3 
mg/liter culture) was observed. 
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Fig. 3.25 Effect of DMSO on the expression level of recombinant B2R in BHK cells. 
DMSO was added to the cultures, membranes were prepared and [
3H] bradykinin binding 
was measured. 
 
3.3.4.4 Effect of cell type on B2R expression 
 
It has been previously reported that expression level of a recombinant GPCR may vary 
among different cell lines (Lundstrom et al., 2003). Four different cell lines (BHK-21, 
CHO-K1, Cos-7 and HEK-293) were tested for B2R expression. However, no significant 
difference in the expression level of B2R was observed in these cell lines. Therefore, for 
large-scale production, BHK cells were used. 
 
3.3.5 Glycosylation analysis of recombinant B2R 
 
To check the glycosylation state of the recombinant receptor in BHK cells, enzymatic 
deglycosylation using PNGaseF or EndoH was performed. As shown in Fig. 3.26, there 
was no change in the migration of the recombinant B2R suggesting that the receptor was 
not glycosylated in BHK cells. 
     Fold increase 
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Fig. 3.26 Glycosylation analysis of the recombinant B2R produced in BHK cells. 10 µg 
of membranes from BHK cells expressing B2R were treated with 0.5 units of PNGase F 
(lane 1) or 0.5 units of EndoH (lane 2) at 4°C for 2h. The lane “C” is untreated control 
membranes from BHK cells (5 µg). The proteins were separated using 10% SDS-PAGE 
and probed with anti-his antibody.  
 
3.3.6 Localization of recombinant B2R 
 
In order to check the localization of recombinant B2R, immunogold labeling experiments 
were carried out using BHK cells expressing pSFVGenFlagB2RHis10Bio construct. 
Additionally, B2R-eGFP fusion protein was used to check the receptor localization by 
confocal microscopy. 
 
3.3.6.1 Immunogold labeling experiment
 
 
BHK cells expressing B2R were fixed for pre- and post-embedding as described (see 
materials and methods. As shown in Fig. 3.27, most of the recombinant receptors were 
localized in the intracellular membranes (most probably in the endoplasmic reticulum). 
Only very few receptor molecules were found in the plasma membrane (Fig. 3.27 D&F). 
Similar intracellular localization of recombinant beta-2 adrenergic receptor was observed 
in BHK cells (Darui Huo, Ph.D. thesis).  
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Fig. 3.27 Localization of recombinant B2R in BHK cells using immunogold labeling 
experiment. A&B = control BHK cells, C&E = post-embedding labeling of BHK cells 
expressing B2R and D&F = pre-embedding labeling of BHK cells expressing B2R. This 
experiment was performed by Dr. Winfried Haase. 
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3.3.6.2 Localization analysis of B2R by confocal microscopy 
 
Localization of B2R-eGFP fusion protein was checked by confocal microscopy. As 
shown in Fig. 3.28, recombinant B2R was mainly localized in the perinuclear membranes 
(most probably in the endoplasmic reticulum). Only low levels of fluorescence were 
observed on the plasma membrane. A similar intracellular retention has been observed in 
BHK cells for the overexpressed alpha-2B adrenergic receptor (Sen et al., 2003). 
 
 
                          
 
 
Fig. 3.28 Confocal imaging of BHK cell (A) or CHO cell (B) expressing B2R-eGFP. 
Cells were grown and infected on cover slips. 24 h post-infection, cells were fixed and 
scanned (488 nM) with a Zeiss laser
 scanning confocal microscope. 
 
 
3.3.7 G protein coupling (inositol phosphate release assay) of B2R 
 
In order to check the G protein coupling of recombinant B2R, bradykinin induced 
phosphatidyl inositol turnover was measured. BHK cells expressing B2R were pre-
labeled with [
3H] inositol and then stimulated with 1 µM of bradykinin for different time 
intervals. Also, the effect of bradykinin concentration on IP3 accumulation was analyzed 
by stimulating the BHK cells expressing B2R with different concentrations of bradykinin 
(1 pM-0.1mM) for 10 min and subsequently, IP3 accumulation was monitored. As shown 
in Fig. 3.29, rapid accumulation of IP3 was observed in response to bradykinin.  
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Fig. 3.29 G-protein coupling of recombinant B2R.  A. Concentration dependence 
(bradykinin) of IP3 accumulation in BHK cells expressing B2R.  B. Time course of 
bradykinin (1 µM) induced IP3 response in BHK cells expressing B2R.  
 
 
3.3.8 Solubilization and purification of B2R 
 
Recombinant B2R was solubilized from membranes (5 mg/ml) using 1% LM or Fos-14 in 
presence of 0.2% CHS. Approximately, 65-70% of [
3H] bradykinin binding sites were 
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solubilized from membranes. Solubilized receptor was purified using Ni-NTA resin. 
Eluate from Ni-NTA column was analyzed by silver stained 10% SDS-PAGE. As shown 
in Fig. 3.30 (A), >80% pure receptor was obtained after Ni-NTA purification. In order to 
check the homogeneity of purified receptor, the eluate from Ni-NTA column was 
analyzed by gel filtration on a superose 6 column. As revealed in Fig. 3.30 (B), purified 
B2R was present mainly in homogenous form (peak at 1.61 ml). In addition to the main 
peak, some aggregation of purified B2R was also observed (the peaks at 0.9 ml and 1.2 
ml). However, when B2R was purified in presence of bradykinin, no aggregation of the 
receptor was observed (Fig. 3.31). 
 
                                                                 
 
                
 
 
Fig. 3.30 Purification of recombinant B2R from BHK cells. A. Silver stained 10% SDS-
PAGE showing membranes (lane 1, 0.2 µg), solubilisate (lane 2, 0.2 µg), flow through 
(lane 3, 0.2µg), wash (lane 4, 0.2 µg), eluate from Ni-NTA (lane 5, 0.8 µg) and gel 
filtration fraction (lane 6, 0.8 µg). B. Analytical gel filtration of purified B2R (eluate from 
Ni-NTA column, 0.5 mg at a concentration of 10 mg/ml) using superose 6 column. 
 
[
3H] bradykinin binding was measured on different fractions during purification 
steps. As shown in Table 3.4, recovery of the active receptor was approximately 32% 
after Ni-NTA purification. A similar purification profile was observed when the 
recombinant receptor was solubilized and purified with Foscholine 12 or Foscholine 14. 
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 [
3H]bradykinin 
binding (nmol) 
Specific activity         
(nmol/mg) 
Total protein  (mg) 
BCA/[
3H]BK binding 
Yield (%) 
Membrane          61.8            0.032    1932 (3.09)       100 
Solubilisate          43.5            0.037    1176 (2.16)         69 
Ni-NTA eluate          19.6            10.3    1.9 (0.98)         32 
 
Table 3.4 Recovery of functional B2R during different steps of purification based on [
3H] 
bradykinin binding analysis. 
 
 
3.3.9 Stability analysis of purified B2R 
 
In order to check the long-term stability, recombinant B2R was purified (in the presence 
of bradykinin) and stored at 4°C. After a defined time period, homogeneity of the 
receptor was investigated by analytical gel filtration. Purified receptor was stable for at 
least two weeks as shown in Fig. 3.31. Therefore, it can be used for three-dimensional 
crystallization attempts. 
 
                                            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.31 Stability analysis of purified B2R by analytical gel filtration. Purified B2R was 
stored at 4°C for 3 or 15 days and subsequently analyzed by using superpose 6 column 
(50 µg at a concentration of 1 mg/ml). 
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4.1 Solid-state NMR analysis of receptor bound conformation of bradykinin
# 
 
High resolution solid-state NMR techniques based on rapid sample rotation about the 
magic angle (magic angle spinning, MAS) under ultra high magnetic fields provide an 
excellent tool to study ligand-receptor systems. It has already been used successfully to 
investigate the backbone structure of neurotensin when bound to its cognate GPCR, the 
neurotensin receptor (Luca et al., 2003). The active conformation of a GPCR ligand may 
provide useful information for designing potent and specific drugs acting on that 
particular receptor. As shown in section 3.2.5 and 3.3.5, recombinant B2R can be isolated 
in milligram quantities. Therefore, in parallel to crystallization trials, a part of isolated 
B2R was used for ss-NMR studies in order to understand the conformation of receptor 
bound bradykinin. 
 
4.1.1 Sample preparation (peptides and receptor) 
 
Three differently labeled variants of bradykinin (
13C/
15N labeled peptides
!) have been 
used for ss-NMR experiments. These peptides are shown in Fig. 4.1. Selectively labeled 
peptides (R
1F
5 and F
8R
9) are required in order to differentiate between individual 
arginines and phenyl alanines in the 2-dimensional spectra. 
 
   U
1       R-P*-P*-G*-F*-S*-P*-F*-R 
   R
1F
5      R*-P-P-G-F*-S-P-F-R 
   F
8R
9      R-P-P-G-F-S-P-F*-R* 
 
 
Fig. 4.1 Differently labeled bradykinin variants that are being used in ss-NMR study. The 
asterisks represent 
13C/
15N labeled amino acids.  
 
 
#These experiments are carried out by Jakob Lopez and Clemens Glaubitz at the Center 
for Biomolecular Magnetic Resonance, Frankfurt. 
 
!The 
13C/
15N labeled peptides are synthesized and characterized by Karin  Heidemann (in 
the group of Harald Schwalbe) at the Center for Biomolecular Magnetic Resonance, 
Frankfurt.  
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The receptor was isolated as described in sections 3.2.8 and 3.3.8. Purified B2R was 
incubated with 
13C/
15N labeled peptides in a molar ratio of 1:10. Subsequently, the 
receptor was concentrated to 50-60 µl (at 18-20 mg/ml). In order to remove the free 
ligand, repeated dilution (up to 1:100, in detergent free buffer) and concentration was 
performed. This complex of B2R-bradykinin was transferred to a 4 mm MAS rotor and 
used for ss-NMR measurements. As control experiments, ss-NMR measurements were 
also performed on lyophilized bradykinin and bradykinin in detergent solution.  
 
4.1.2 
13C-Cross-polarization spectrum of lyophilized bradykinin 
 
Fig. 4.2 shows 
13C-CP spectrum of uniformly labeled bradykinin (U
1). Assignments were 
carried out with the help of previous measurements and double quantum/single quantum 
spectroscopy. Double quantum filtering (DQF) was used in order to measure only those 
signals which belong to two adjacent 
13C nuclei, eliminating the large background signal 
due to detergent and the protein. 
 
                    
 
 
Fig. 4.2 
13C-CP spectrum and assignments using lyophilized bradykinin (2 mg of 
13C/
15N 
labeled bradykinin in a 4 mm MAS rotor).  
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4.1.3 Two-dimensional double quantum/single quantum 
13C NMR spectrum 
 
Next, two-dimensional double quantum/single quantum experiments were performed 
using lyophilized bradykinin (U
1). Here, the assignments were carried out by starting 
with a known peak and assigning peaks at the same horizontal chemical shift coordinate 
to nuclei which are known to be covalent neighbors of the first peaks nucleus. One 
assignment walk for a proline residue is indicated in the Fig. 4.3. 
 
              
 
 
Fig. 4.3 2-D double quantum/single quantum 
13C NMR spectrum of bradykinin (U
1,
 2 mg 
of peptide). 
 
 
4.1.4 Comparison of 1-dimensional spectra of bradykinin in different states 
 
The main goal of this study was to monitor the conformational changes in bradykinin 
upon binding to B2R in order to obtain the backbone structure of receptor bound 
bradykinin. Therefore, the one-dimensional spectrum of 
13C/
15N labeled lyophilized 
bradykinin was compared to that of bradykinin in detergent solution and bradykinin in 
receptor bound state. As indicated in Fig. 4.4, significant changes in the chemical shifts 
were observed for bradykinin after binding to the receptor. 
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Fig. 4.4 1-D spectra of lyophilized bradykinin, bradykinin in detergent solution and 
bradykinin bound to B2R. The shaded part shows some of the changes in chemical shifts 
that occur upon binding of bradykinin to B2R.  
 
 
 
  
  98
4.1.5 Reducing the measurement time 
 
In order to translate the chemical shifts observed in 1-D spectra into the structural 
constraints, 2-D NMR analysis is necessary. However, 1 mg of B2R will bind to 
approximately 25 µg of 
13C/
15N bradykinin. Therefore, it requires long measurement 
times to get a good signal/noise ratio in 2-D spectra. In order to reduce the measurement 
time, either the receptor amount was increased to 2.5 mg (thus increasing the amount of 
bound 
13C/
15N bradykinin) or measurements were carried out at low temperature (180 K). 
 
4.1.5.1 Receptor aggregation at high concentration 
 
One of the limitations of ss-NMR is the small volume (50-60 µl) of MAS rotors. 
Therefore, in order to increase the amount of receptor in the rotor, it should be highly 
concentrated (e.g. up to 50 mg/ml for 2.5 mg of receptor). Unfortunately, the purified 
B2R aggregated (as revealed by gel filtration analysis) when concentrated to 45 mg/ml 
(Fig. 4.5). 
 
                                
                               
 
Fig. 4.5 Purified B2R aggregates at high concentration. Receptor homogeneity was 
analyzed at indicated concentrations by gel filtration using superose 6 column. The peaks 
at 0.90 ml and 1.3 ml represent aggregated receptor while the peak at 1.6 ml shows 
homogenous receptor.                
0 
0,2 
0,4 
0,6 
0,8 
1 
1,2 
0,5 1 1,5 2 2,5 3 
19 mg/ml 
45 mg/ml 
A(280 nm) 
                                                                Retention volume (ml)  
  99
4.1.5.2 Effect of temperature on signal/noise ratio 
 
Performing ss-NMR measurements at low temperatures (<200K) results in a better 
signal/noise ratio, presumably due to a better magnetization from 
1H to 
13C via cross-
polarization and reduces the chances of overheating the samples. Therefore, effect of 
lowering the temperature on the signal to noise ratio in 1-D 
13C DQF spectra was 
examined. As depicted in Fig. 4.6, approximately four-fold improvement in overall 
signal/noise ratio was observed when the temperature was lowered from 210 K to 180 K. 
 
                                
 
 
Fig. 4.6 Improvement of signal/noise ratio in 1-D 
13C DQF spectra (
13C/
15N bradykinin 
bound to B2R) at lower temperature. The shaded part shows increased intensity of one of 
the peaks in 1-D spectra.  
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4.1.6 Two-dimensional spectrum of 
13C/
15N bradykinin bound to B2R 
 
Under optimized conditions (25 µg bound to 1 mg B2R, 180K), the two dimensional 
double quantum 
13C NMR spectrum of 
13C/
15N bradykinin (U
1) bound to B2R can be 
measured within three days (Fig. 4.7). Similar experiments with selectively labeled 
bradykinin variants (R
1F
5 and F
8R
9) are in progress. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.7 Two-dimensional double quantum/single quantum 
13C NMR spectrum of 
bradykinin (U
1) bound to B2R. A typical experiment requires a measurement time of 
approximately 3 days. 
 
 
4.2 Three-dimensional crystallization trials of B2R 
 
 
For 3-dimensional crystallization screening, B2R was purified as described in sections 
3.2.8 and 3.3.8. The purified B2R was concentrated up to 10 mg/ml. In order to remove 
the free detergent micelles, gel filtration was performed. The initial screening scheme has  
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been given in the appendix. Initially, a pH (4-9) and temperature (4°C and 18°C) screen 
combined with different PEGs (as precipitant) was used. The protein in crystallization 
drops was stable over a wide range of pH and some microcrystalline precipitates were 
obtained with PEG 400 (concentration 12-18%, w/v). With PEG 4000, the crystallization 
drops remained mostly clear and no protein precipitation was observed even at high 
concentrations (20-22%, w/v) and over a long period of time (3-4 weeks). Commercially 
available screening kits (from SIGMA and Jena Biosciences) were also used in order to 
screen the combinations of different precipitants and buffers. As shown in Fig. 4.8, some 
crystalline structures were observed. However, these are too small to verify either by 
Western blot analysis or by X-ray beam. It has not been possible so far to reproduce them 
under the same conditions. Further crystallization screening is ongoing to obtain 
reproducible and bigger crystals. 
 
           
 
Fig. 4.8 Some crystal-like structures (A & B) obtained during 3-D crystallization 
attempts of B2R. Often, heavy detergent crystallization was observed (C). 
 
4.3 Interaction of B2R with β-arrestin 
 
β-arrestin is a soluble protein that binds to the agonist activated GPCRs and blocks the G 
protein coupling. This results in downregulation of G protein dependent signalling 
pathways mediated via GPCRs. A complex of GPCR-β-arrestin might be useful for 
cocrystallization attempts. Purified B2R from BHK cells was mixed with purified β-
arrestin-2 in a molar ratio of 1:10 and incubated at room temperature for 2 h. 
Subsequently, a pull-down assay was performed using Ni-NTA resin. The flow through 
A                                                               B                                                                    C  
  102
and elution fractions were analyzed by 10% silver stained SDS-PAGE. As shown in Fig. 
4.9 (A), β-arrestin was present in the flow through fraction and was not observed in the 
elution fraction with B2R. This indicates that there was no interaction between purified 
B2R and β-arrestin in vitro.  
Recently, it was observed that B2R-V2R chimera binds to β-arrestin with high 
affinity in vivo (Simaan et al., 2005). This B2R-V2CT chimera contains the first 324 
amino acids of the human B2R (Met-1 to Cys-324) fused to the last 29 amino acids of the 
V2R (Ala-343 to Ser-371). Therefore, attempts were made to reconstitute the B2R-V2R 
chimera with β-arrestin in vitro. As shown in Fig. 4.9 (B), β-arrestin was present with 
B2R-V2R in the elution fraction of Ni-NTA resin. No binding of purified β-arrestin alone 
to the Ni-NTA resin was detected (Fig. 4.9 C). Further studies are ongoing to examine the 
stability of this complex by analytical gel filtration. 
 
 
                                                         
               
Fig. 4.9 Interaction of B2R-β-arrestin
# by pull down assay using Ni-NTA resin followed 
by 10% silver stained SDS-PAGE. A. Using wild type B2R, flow through (lane 1, 0.3 µg) 
and elution (lane 2, 0.3 µg). B. Using B2R-V2R mutant
*, flow through (lane 1, 0.2 µg) 
and elution (lane 2, 0.4 µg). C. Using β-arrestin alone, flow through (lane 1, 0.2 µg) and 
elution (lane 2, 0.3 µg).  
 
 
 
#Purified β-arrestin-2 was provided by Jan Griesbach, MPI Biophysics, Frankfurt. 
 
*The gene for B2R-V2R mutant was a kind gift from Dr. S.A. Laporte (Montreal, Canada). 
This mutant was expressed and purified similar to the wild type B2R. 
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5.1 Production and isolation of the AT1aR using Pichia pastoris 
 
5.1.1 Sub-cloning of the AT1aR gene in Pichia expression vector 
 
The coding region of AT1aR gene was amplified from cDNA vector (pAT1aR from 
Aventis) with the primers AT1aR_Pichia_Fw/Rv (Fig. 5.1) and ligated into the pPIC9K 
(modified) vector between BamHI and EcoRI sites using the standard cloning techniques.   
         
   
 
Fig. 5.1 Amplification of the AT1aR gene from the cDNA vector by PCR under 
following conditions: 94°C = 5 min, 94°C = 40 sec, 69°C = 40 sec, 72°C = 90 sec and 
72°C = 10 min. Total 30 cycles (step 2 to step 4) were used for amplification. PCR 
products were analyzed on 1% agarose gel. M= Lambda DNA (EcoRI + HindIII) 
marker, C= control (no template), 1-4 = different amounts (50 ng-200 ng) of template 
DNA. 
 
5.1.2 Expression constructs 
 
A modified pPIC9K expression vector was used for the production of the AT1aR in 
Pichia pastoris. This vector has been described earlier in section 3.1.2. In some cases, it 
has been observed that the elution of recombinant proteins from monomeric avidin 
column is not very efficient
# (personal experience and communication with other 
colleagues). Therefore, an expression construct with a Strep II tag (instead of Bio tag) 
was also made (Fig. 5.2). Strep II tag allows purification of the recombinant receptor on 
streptactin agarose resins.  
 
 
#After repeated use of monomeric avidin resin, the recovery of bound proteins goes down 
and the binding capacity of the resin also decreases. 
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Fig. 5.2 Expression construct for production of recombinant AT1aR in Pichia pastoris. 
AOX1 = alcohol oxidase 1 promoter, α-factor = α-mating factor prepro-peptide of S. 
cerevisiae, Flag = coding sequence for Flag epitope, His10 = coding sequence for 
histidine 10 tag, TEV = cleavage site for TEV protease, AT1aR = coding sequence for 
AT1aR, Bio = biotinylation domain of Propionibacterium shermanii transcarboxylase, 
StrepII = coding region of strep II tag. 
 
5.1.3 Production of the recombinant receptor 
 
Pichia cultures were grown in shake flasks (as described in Multi-Copy Pichia 
Expression Kit, Invitrogen), membranes were prepared (after 24 h of induction with 
methanol) and subjected to Western blot analysis and ligand binding assay.  
 
5.1.3.1 Western blot analysis 
 
Western blot with anti-Flag M2 antibody was performed to check the expression of 
recombinant receptor. As shown in Fig. 5.3, a band of approximately 55 kDa was 
observed in membranes from Pichia cells expressing AT1aR. This corresponds well with 
the calculated size of recombinant receptor fusion protein (52.9 kDa).  
 
5.1.3.2 [
3H] angiotensin II binding 
 
In order to check the functionality of the recombinant receptor and to calculate the total 
amount of functional receptor in membranes, a saturation binding experiment using [
3H] 
angiotensin II was performed. [
3H] angiotensin II binding was saturable and revealed a 
Bmax value of 57 pmol recombinant AT1aR per mg membrane protein (Fig. 5.4). A high 
affinity binding of [
3H] angiotensin II to the recombinant receptor was observed with a 
Kd value of 1.3 nM. This Kd value is similar to those reported for AT1aR in native tissues 
(see appendix). 
       
AOX 1          α-Factor      Flag  His10      TEV                                    AT1aR                                  TEV               Bio 
AOX 1          α-Factor      Flag  His10     TEV                                     AT1aR                                  StrepII   106
 
 
                   
 
Fig. 5.3 Western blot analysis of the FlagHis10AT1aRBio construct produced in P. 
pastoris. Proteins were separated using 10% SDS-PAGE and probed with anti-Flag M2 
antibody. Lane 1: 10 µg of control Pichia membranes, lane 2: 10 µg of membranes from 
Pichia cells expressing FlagHis10B2RBio fusion protein.  
 
 
 
                        
 
Fig. 5.4 Saturation curve for [
3H] angiotensin II binding to recombinant AT1aR produced 
in Pichia pastoris. The graph was generated using the single site model in KaleidaGraph 
software. 
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5.1.4 Optimization of functional production level of AT1aR 
 
In order to increase the functional expression of AT1aR, DMSO was added to the Pichia 
cultures during methanol induction step. As shown in Fig. 5.5, approximately three-fold 
increase in the functional expression of recombinant AT1aR was observed by the addition 
of DMSO. Maximum expression level was obtained by the addition of 2% DMSO and it 
corresponds to 167 pmol/mg of recombinant AT1aR (3-4 mg/liter culture). 
 
 
0
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Fig. 5.5 Effect of DMSO on expression levels of recombinant AT1aR in Pichia pastoris. 
DMSO was added to the cultures, membranes were prepared and [
3H] angiotensin II 
binding was measured. 
 
 
[
3H] angiotensin II binding revealed an expression level of 30 pmol/mg for the 
FlagHis10AT1aRStrep II construct. Low expression level has been observed for the strep-
tagged constructs in comparison to the bio-tagged constructs for several other GPCRs 
(Christoph Reinhart, personal communication). 
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5.1.5 Glycosylation analysis 
 
There are three putative glycosylation sites
# in AT1aR, one at the N-terminus (N
4), and 
two in the second extracellular domain (N
176  and N
188). In order to analyze the 
glycosylation state of the recombinant receptor, enzymatic deglycosylation using 
PNGaseF or EndoH was performed on Pichia membranes expressing AT1aR, followed by 
Western blot analysis. As shown in Fig. 5.6, the recombinant receptor band was shifted to 
lower molecular weight size upon enzymatic deglycosylation. This result reveals that the 
recombinant B2R produced in Pichia was glycosylated. 
 
 
  
   
 
 
Fig. 5.6 Glycosylation analysis of the recombinant AT1aR produced in Pichia. 10 µg of 
Pichia membranes expressing AT1aR were treated with 0.5 units of PNGaseF (lane 1) or 
0.5 units of EndoH (lane 2) at 4°C for 2 h. The lane “C” is untreated control Pichia 
membranes (10 µg). The proteins were separated by 10% SDS-PAGE and Western blot 
analysis was performed using anti-Flag M2 antibody.  
 
 
 
 
#These sites are predicted based on conserved N-linked glycosylation motif (Asn-Xaa-
Ser/Thr). Previous reports suggest that these sites are glycosylated when the recombinant 
AT1aR is expressed in mammalian cells and play a significant role in trafficking of the 
receptor (Lanctot et al., 1999 and Jayadev et al., 1999). 
 
  
  M          C        1        C       2   
(kDa) 
 
 
     
    
 
       
      62 
 
      48    109
5.1.6 Solubilization of recombinant AT1aR 
 
In order to solubilize the recombinant AT1aR from Pichia membranes, different 
detergents (in presence of 0.2% CHS) were tested. As shown in Fig. 5.7, AT1aR was 
solubilized with most detergents.   
 
    
                     
 
 
Fig. 5.7 Solubilization of the recombinant AT1aR from Pichia membranes (5 mg/ml). 
Lane 1-11 = DM, UM, LM, DG, NG, OG, CHAPS, LDAO, Fos12, Fos14, and Fos16. All 
the detergents were used at a concentration of 1% except OG (2%). Solubilizate was 
loaded on a 10% SDS-polyacrylamide gel and Western blot analysis was performed using 
anti-Flag M2 antibody. 
 
[
3H] angiotensin II binding on solubilizate was used to monitor the functional 
solubilization of the AT1aR from Pichia membranes. Best functional solubilization (60-
70%) was observed with LM. Therefore, the recombinant AT1aR was solubilized with 
LM for further purification. 
 
5.1.7 Purification of the recombinant AT1aR 
 
In order to stabilize the active conformation of the receptor, angiotensin II (1 µM) was 
added to the Pichia membranes expressing AT1aR. Subsequently, the receptor was 
solubilized with 1% LM in the presence of 0.2% CHS. 
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5.1.7.1 AT1aR purification using Ni-NTA and monomeric avidin 
 
Recombinant AT1aR (FlagHis10AT1aRBio fusion protein) was purified from Pichia 
membranes by a combination of Ni-NTA and monomeric avidin resins. In the first step, 
solubilizate was applied to Ni-NTA resin. Subsequently, the column was washed with 
washing buffer (see materials and methods) and finally the receptor was eluted with 
elution buffer containing 200 mM imidazole. As a second step of purification, Ni-NTA 
eluate was applied to monomeric avidin matrix. The recombinant receptor binds to this 
matrix via its biotinylated bio tag. The receptor was eluted with 2 mM biotin and 
analyzed by 10% silver stained SDS-PAGE. As shown in Fig. 5.8 (lane 2), the 
recombinant receptor was >85 % pure.  
In order to check the homogeneity of purified AT1aR, the eluate from the 
monomeric avidin column was analyzed by gel filtration on a superose 6 column in the 
SMART chromatography system. A main peak was observed at a retention volume of 
1.61 ml (indicated by the arrow head). It corresponds to the homogenous population of 
purified AT1aR. In addition to this main peak, some aggregated receptor (peak at 
retention volume of 0.89 ml) was also observed. An additional peak at a retention volume 
of 1.8 ml was also observed that probably represents the free detergent micelles. 
 
5.1.7.2 AT1aR purification using Ni-NTA and streptactin 
 
The recombinant AT1aR from the membranes of Pichia cells expressing 
FlagHis10AT1aRStrepII construct, was purified using two-step affinity purification (Ni-
NTA and streptactin agarose) procedure. As shown in Fig 5.9, after streptactin 
purification, recombinant receptor was >90 % pure. 
As the receptor was purified in presence of the high affinity ligand angiotensin II, 
it was not possible to measure [
3H] angiotensin II binding on purified fractions. Based on 
BCA quantification, approximately, 25-30% yield was obtained i.e. approximately 3 mg 
of recombinant AT1aR in membrane (based on ligand binding) yielded roughly 1 mg of 
pure AT1aR (based on BCA quantification) after two-step affinity purification. 
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Fig. 5.8 Purification of the recombinant AT1aR from Pichia pastoris. Samples were 
analyzed by silver stained 10% SDS-PAGE. A. The eluate from Ni-NTA (lane 1, 1 µg) 
and monomeric avidin (lane 2, 0.5 µg). B. Analytical gel filtration of purified B2R (eluate 
from monomeric avidin column, 0.4 mg at a concentration of 10 mg/ml) using superose 6 
column. 
 
 
 
                                                      
 
 
 
Fig. 5.9 Purification of the recombinant AT1aR from Pichia pastoris. Purified fractions 
were analyzed by silver stained 10% SDS-PAGE. Lane 1 = eluate from Ni-NTA (1.2 µg) 
and lane 2 = eluate from streptactin (0.6 µg).  
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5.1.7.3 Fluorescein labeled angiotensin II as a probe to monitor AT1aR purification 
 
In order to determine whether angiotensin II remains bound to AT1aR during purification 
steps, fluorescein labeled angiotensin II was used during purification. Membranes were 
incubated with fluorescent angiotensin II (1 µM) for two hours, subsequently solubilized 
and purified by a combination of Ni-NTA and streptactin resins. Purified receptor was 
analyzed by gel filtration analysis. As shown in Fig. 5.10, absorbance peak of the 
fluorescent angiotensin II (490 nm) was aligned with AT1aR peak (280 nm). This shows 
that fluorescein angiotensin II remains bound to AT1aR during purification. A complex of 
AT1aR-fluorescein angiotensin II provides an efficient tool for identifying protein crystals 
in the crystallization drops. 
 
                      
 
Fig. 5.10 Analytical gel filtration of AT1aR purified in the presence of fluorescent-
angiotensin II. The eluate from streptactin column (50 µg at a concentration of 1 mg/ml) 
was analyzed by using a superose 6 column.  
 
  
5.1.8 Stability of the purified receptor 
 
Stability of the purified protein is a crucial point before it can be subjected to 
crystallization trials. In order to check the long-term stability, recombinant AT1aR was 
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purified and stored at 4°C. After a defined time period, the homogeneity of receptor was 
investigated by analytical gel filtration. Purified receptor was stable for at least two 
weeks as shown in Fig. 5.11. Therefore, it can be used for three-dimensional 
crystallization attempts. 
  
                                          
 
 
Fig. 5.11 Stability analysis of purified AT1aR by analytical gel filtration. Purified AT1aR 
was stored at 4°C for 3 or 15 days and subsequently analyzed using superose 6 column 
(100 µg at a concentration of 2 mg/ml). 
 
 
Although AT1aR was expressed in Pichia at high level, for reasons of comparison AT1aR 
was also expressed in Sf9 cells and BHK cells.  
 
5.2 Production and isolation of AT1aR from insect cells using the baculovirus system 
 
5.2.1 Sub-cloning of AT1aR gene in baculovirus expression vectors 
 
The coding region of AT1aR gene was cloned into the MCS of modified pVL vectors 
between  BamHI and EcoRI enzyme sites. Amplification of receptor gene (with 
AT1aR_Baculo_Fw/Rv primers using Pfu DNA polymerase) and ligation to the 
expression vectors was carried out using the standard cloning procedures. 
3 days 
14 days 
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5.2.2 Expression constructs 
 
The baculovirus constructs used for the expression of AT1aR in insect cells are shown in 
Fig. 5.12. The modified pVL vectors were provided by Gabi Maul. The first construct 
was used for isolation of recombinant receptor using Flag and His10 tag at the N-terminus 
and a bio tag at the C-terminus while the construct with eGFP fusion at the C-terminus 
can be used for receptor localization studies using confocal microscopy. 
 
 
 
Fig. 5.12 Expression constructs for production of the recombinant AT1aR in insect cells. 
PHP = polyhedrin promoter, Mel = prepro-mellitin signal sequence of honey bee, Flag = 
coding sequence for Flag epitope, His10 = coding sequence for histidine 10 tag, AT1aR = 
coding region of AT1aR, Bio = biotinylation domain of Propionibacterium shermanii 
transcarboxylase and eGFP = coding sequence of enhanced green fluorescent protein. 
 
 
5.2.3 Production of the recombinant receptor 
 
In order to check the expression of AT1aR, Sf9 cells were infected at MOI 10 with the 
recombinant baculovirus constructs (pVLMelFlagHis10AT1aRBio). 72 h post-infection, 
membranes were prepared and subjected to Western blot analysis and [
3H] angiotensin II 
binding analysis. 
 
5.2.3.1 Western blot analysis 
 
Western blot with anti-Flag M2 antibody was performed to check the expression of 
recombinant receptor. As shown in Fig. 5.13, a major band of approximately 55 kDa was 
seen in the membranes from Sf9 cells expressing AT1aR. This apparent molecular mass 
closely corresponds with the calculated size of AT1aR fusion protein (51.5 kDa). In 
        PHP                    Mel           Flag     His10                                         AT1aR                                                    Bio 
        PHP                    Mel           Flag     His10                                         AT1aR                                                    eGFP   115
addition to the main receptor band, some proteolytic degradation products of smaller 
sizes were also observed.                                           
 
 
                                                                      
 
 
 
Fig. 5.13 Western blot analysis of the FlagHis10AT1aRBio construct produced in Sf9 
cells. Proteins were separated by 10% SDS-PAGE and probed with anti-Flag M2 
antibody. C = 10 µg of membranes from non-infected Sf9 cells, lane 1 = 10 µg of 
membranes from Sf9 cells expressing the FlagHis10AT1aRBio fusion protein.   
 
 
5.2.3.2 [
3H] angiotensin II binding 
 
In order to check the functionality of the recombinant receptor and to calculate the total 
amount of functional receptor in membranes, a saturation binding experiment using [
3H] 
angiotensin II was performed. A suspension culture of Sf9 was grown and infected with 
baculovirus corresponding to FlagHis10AT1aRBio construct (shown in Fig. 5.12) at MOI 
10. 72 h post-infection, membranes were prepared and saturation binding was performed 
using [
3H] angiotensin II. [
3H] angiotensin II binding was saturable and revealed a Bmax 
value of 29 pmol recombinant AT1aR per mg membrane protein (Fig. 5.14). A high 
affinity binding of [
3H] angiotensin II to the recombinant receptor was observed with a 
Kd value of 0.98 nM. This Kd value is similar to those reported for AT1aR in native 
tissues (see appendix).    
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Fig. 5.14 Saturation curve for [
3H] angiotensin II binding to recombinant AT1aR 
(pVLMelFlagHis10AT1aRBio) produced in Sf9 cells. Graph was generated using the 
single site model in Kaleidagraph software. 
 
 
5.2.4 Glycosylation analysis of the recombinant AT1aR 
 
In order to analyze the glycosylation state of the recombinant receptor, enzymatic 
deglycosylation using PNGaseF or EndoH was performed on Sf9 membranes expressing 
AT1aR. As shown in Fig. 5.15, the recombinant receptor band was shifted to a lower 
molecular weight size upon deglycosylation. This reveals that the recombinant AT1aR 
produced in Sf9 cells was glycosylated. However, complete deglycosylation did not occur 
(a band of higher molecular size than the completely deglycosylated AT1aR was also 
observed, shown by asterisk).  
 
Bmax = 29 pmol/mg 
Kd = 0.98 nM   117
 
 
 
  
 
 
 
Fig. 5.15 Glycosylation analysis of the recombinant AT1aR produced in Sf9 cells. 10 µg 
of Sf9 membranes expressing AT1aR were treated with 0.5 units of PNGaseF (lane 1) or 
0.5 units of EndoH (lane 2) at 4°C for 2h. The lane “C” is untreated control SF9 
membranes (10 µg). The proteins were separated by 10% SDS-PAGE and Western blot 
analysis was performed using anti-Flag M2 antibody.  
 
 
5.2.5 Solubilization and purification of AT1aR 
 
Recombinant receptor was solubilized from the membranes (5 mg/ml) using 1% LM in 
the presence of 0.2% CHS. Solubilization efficiency, as assessed by [
3H] angiotensin II 
binding, was approximately 60-70%. For purification, membranes from Sf9 cells 
expressing AT1aR were incubated with angiotensin II (1 µM) for two hours. 
Subsequently, the receptor was solubilized and purified by a combination of Ni-NTA and 
monomeric avidin. The eluate from monomeric avidin revealed >90% pure receptor (Fig. 
5.16). Further studies are ongoing to evaluate the homogeneity and stability of purified 
AT1aR.  
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Fig. 5.16 Purification of recombinant AT1aR from Sf9 cells. Silver stained 10% SDS-
polyacrylamide gel showing the eluate from Ni-NTA (lane 1, 0.7 µg) and monomeric 
avidin (lane 2, 0.5 µg).  
 
 
5.3 Production and isolation of AT1aR from BHK cells 
 
Next, the SFV based expression of AT1aR in BHK cells was performed. Mammalian cells 
provide most natural environment for heterologous expression of recombinant human 
GPCRs. 
 
5.3.1 Sub-cloning of AT1aR gene in SFV expression vectors 
 
AT1aR gene was amplified with the primers AT1aR_SFV_Fw/Rv and cloned into the 
MCS of modified SFV vectors between BamHI and SpeI enzyme sites using the standard 
cloning procedure.  
 
5.3.2 Constructs 
 
Expression constructs for production of AT1aR in mammalian cells are shown in Fig. 
5.17. The first construct was used for isolation of the recombinant receptor while the 
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second construct was used for investigating the localization of recombinant receptor by 
confocal microscopy. 
        
 
 
 
 
Fig. 5.17 Expression constructs for the production of recombinant AT1aR in mammalian 
cells. PSG = subgenomic 26 S promoter, CAP = capsid sequence, AT1aR = coding 
sequence for AT1aR gene, His10 = coding sequence for histidine 10 tag, TEV = cleavage 
site for TEV protease, Bio = biotinylation domain of Propionibacterium shermanii 
transcarboxylase, eGFP = enhanced green fluorescent protein. 
 
 
5.3.3 Production of the recombinant AT1aR in BHK cells 
 
Recombinant virus particles were generated and activated as described in the materials 
and methods section. Suspension cultures of BHK cells were grown in spinner flasks and 
infected at a density of 1-2x10
6 cells/ml. During infection 2% DMSO was added
#. 24 h 
post-infection, membranes were prepared and subjected to Western blot analysis and [
3H] 
angiotensin II binding assay. 
 
5.3.3.1 Western blot analysis of AT1aR produced in BHK cells 
 
Western blot analysis of BHK cell membranes expressing AT1aR using anti-his antibody 
revealed a major band of 55 kDa (Fig. 5.18). This corresponds well with the calculated 
size of recombinant receptor fusion protein (51.6 kDa).  
 
 
 
#Addition of 2% DMSO was found to increase the expression level of recombinant B2R 
and NmU2R (see sections 3.3.4.3 and 7.3.3.3, respectively). 
         PSG                      CAP                                                      AT1aR                                       TEV     His10                 Bio 
PSG                       CAP                                                             AT1aR                                                                  eGFP   120
 
 
                                                                 
 
 
Fig. 5.18 Western blot analysis of the recombinant AT1aR produced in BHK cells. 
Proteins were separated by 10% SDS-PAGE and probed with anti-his antibody. Lane 1 = 
10 µg of membranes from non-infected BHK cells, lane 2 = 10 µg of membranes from 
BHK cells expressing AT1aR. 
 
 
5.3.3.2 [
3H] angiotensin II binding 
 
In order to calculate the total amount of functional receptor in membranes, a saturation 
binding experiment using [
3H] angiotensin II was performed. As shown in Fig. 5.19, [
3H] 
angiotensin II binding was saturable and revealed a Bmax value of 32 pmol recombinant 
receptor per mg membrane protein. A high affinity binding of [
3H] angiotensin II to the 
recombinant receptor was observed with a Kd value of 1.1 nM. This Kd value is similar to 
those reported for AT1aR in native tissues (see appendix). The non-specific binding was 
determined in presence of 1 µM angiotensin II and it was less than 20% of total binding.  
 
5.3.4 Glycosylation analysis of the recombinant AT1aR in BHK cells 
 
To check the glycosylation state of the recombinant receptor in BHK cells, enzymatic 
deglycosylation using PNGaseF or EndoH was performed. As shown in Fig. 5.20, the 
recombinant receptor band was shifted to lower molecular weight size upon 
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deglycosylation. This reveals that the recombinant AT1aR produced in BHK cells was 
glycosylated. Interestingly, B2R and NmU2R were not glycosylated when expressed in 
BHK cells using SFV vectors. 
 
                    
 
 
Fig. 5.19 Saturation curve for [
3H] angiotensin II binding to the recombinant AT1aR 
produced in BHK cells. The graph was generated using single site model in Kaleidagraph 
software. 
 
 
5.3.5 Localization of the recombinant AT1aR by confocal microscopy 
 
In order to check the localization of recombinant receptor, BHK cells were infected with 
recombinant virus coding for AT1aR-eGFP fusion protein. 16 h post-infection cells were 
fixed and analyzed by confocal microscopy. As shown in Fig. 5.21, recombinant AT1aR 
appeared to be localized predominantly in the plasma membrane.  
Bmax = 32 pmol/mg 
Kd = 1.1 nM   122
   
                    
 
 
Fig. 5.20 Glycosylation analysis of the recombinant AT1aR produced in BHK cells. 10 µg 
of membranes from BHK cells expressing AT1aR were treated with 0.5 units of PNGaseF 
(lane 2) or 0.5 units of EndoH (lane 3) at 4°C for 2 h. Lane “C” is untreated control 
membranes (5 µg). Proteins were separated by 10% SDS-PAGE and Western blot 
analysis was performed using anti-his antibody.  
 
 
                                      
 
 
Fig. 5.21 Confocal imaging of BHK cells expressing AT1aR-eGFP. Cells were grown and 
infected on sterile cover-slips. 16 h post-infection, cells were fixed and scanned (488 nM) 
with a Zeiss laser
 scanning confocal microscope. 
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5.3.6 Solubilization and purification of AT1aR from BHK cells 
 
Recombinant AT1aR was solubilized from membranes (5 mg/ml) using 1% LM in the 
presence of 0.2% CHS. Approximately, 75-80 % of [
3H] angiotensin II binding sites were 
solubilized from membranes. Solubilized receptor was purified using Ni-NTA resin. The 
eluate from Ni-NTA column was analyzed by silver stained 10% SDS-PAGE. As shown 
in Fig. 5.22 (A), >70% pure receptor was obtained after Ni-NTA purification. In order to 
check the homogeneity of the purified receptor, the eluate from Ni-NTA column was 
analyzed by gel filtration on a Superose 6 column. As revealed in Fig. 5.22 (B), purified 
AT1aR was present in a nearly homogenous form (peak at 1.61 ml), although significant 
aggregation was also detected (peak at 0.91 ml). It has been observed previously that the 
biotinylation of the bio domain is not complete in mammalian cells (Helmut Reiländer, 
personal communication). Therefore, purification via monomeric avidin was not tried as 
it may result in significant loss of the receptor in flow through fraction.  
 
                              
 
 
 
Fig. 5.22 Purification of recombinant AT1aR from BHK cells. A.  Silver stained 10% 
SDS-PAGE showing membranes (lane 1, 0.2 µg), solubilizate (lane 2, 1 µg), flow 
through (lane 3, 1 µg), and eluate from Ni-NTA (lane 4, 0.5 µg).  B. Analytical gel 
filtration of purified AT1aR (eluate from Ni-NTA column, 0.4 mg at a concentration of 10 
mg/ml) using a superose 6 column, inset shows main peak of the gel filtration analyzed 
by 10% siver stained SDS-PAGE (M = marker and lane 1 = 0.2 µg AT1aR after gel 
filtration). 
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5.3.7 Proteolytic degradation of purified AT1aR 
 
The purified AT1aR showed proteolytic degradation when stored at 4°C for three days 
(Fig. 5.23). It may be due to copurification of a protease with AT1aR. This problem of 
proteolytic degradation was not addressed in detail as sufficient amount of stable AT1aR 
could be obtained from Pichia (section 5.1.8). 
 
 
                                                                 
 
Fig. 5.23 Proteolytic degradation of AT1aR after purification. Purified AT1aR was stored 
at 4°C and subsequently analyzed by 10% silver stained SDS-PAGE. Lane 1 = AT1aR 
immediately after purification (0.3 µg) and lane 2 = AT1aR after three days at 4°C (0.3 
µg). 
 
5.3.8 Three-dimensional crystallization trials of AT1aR 
 
Purified AT1aR from Pichia pastoris was used for 3-D crystallization attempts. As shown 
in Fig. 5.24, some crystalline structures were observed. However, these are too small to 
verify either by Western blot analysis or by X-ray beam. It has not been possible so far to 
reproduce them under the same conditions. Further crystallization screening is ongoing to 
obtain reproducible and bigger crystals. 
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Fig. 5.24 Crystal like structures obtained during 3-D crystallization attempts of AT1aR. 
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Chapter 6: Coexpression of B2R and AT1aR and isolation of 
the heterodimer complex 
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6.1 Coexpression of B2R and AT1aR 
 
Human B2R is known to form a stable heterodimer with human AT1aR (Abdalla et al., 
2000). Coexpression of B2R and AT1aR was performed in order to isolate the heterodimer 
complex for crystallization. The heterodimer complex should have an extended polar 
surface area compared to the monomer and thus represents a better object for 3-D 
crystallization. Additionally, the three-dimensional structure of a heterodimer should lead 
to a better understanding of the dimerization interface. SFV based expression is an 
efficient way of coexpressing two or more proteins in mammalian cells. Coexpression of 
a GPCR (α-1b-AR) and G-proteins using SFV system has already been described (Scheer 
et al., 1999). In this study, coexpression of B2R and AT1aR in BHK cell was performed 
using the SFV system. 
 
6.1.1 Constructs for coexpression of B2R and AT1aR 
 
The genes for B2R and AT1aR were amplified from respective cDNA vectors by PCR and 
cloned into modified SFV expression vectors (see section 3.3.2). The resulting constructs 
are shown in Fig. 6.1. Other constructs used in this study have already been described in 
chapter 3 and chapter 5 (see sections 3.3.2 and 5.3.2). 
 
 
 
 
 
 
 
Fig. 6.1 Expression constructs for coexpression of recombinant B2R and AT1aR in BHK 
cells. PSG = promoter, K = Kozak sequence, HA = signal sequence from influenza 
haemaglutinin (HA) gene, Flag = coding sequence for Flag epitope, B2R = coding 
sequence for B2R gene, AT1aR = coding sequence for AT1aR gene, Strep II = coding 
sequence for strep tag II. 
  PSG              K         HA     Flag                                           B2R                                         
  PSG              K         HA     Flag                                           AT1aR                                             StrepII                                   
  PSG                   CAP          Myc                                           AT1aR                                            128
6.1.2 Coinfection of BHK cells with B2R and AT1aR virus 
 
 
Virus particles were generated and activated as described in the materials and methods 
section. The amount of virus used for coexpression was optimized in order to obtain a 1:1 
expression ratio of both receptors (based on radioligand binding assay).  
 
6.2 Coexpression with AT1aR results in trafficking of B2R to
 the plasma membrane 
 
As shown in section 3.3.6.2, the B2R-eGFP fusion protein shows intracellular retention 
when expressed in BHK cells. During coexpression of B2R and AT1aR it was noticed that 
heterodimerization of B2R and AT1aR leads to surface trafficking of B2R. This effect of 
heterodimerization was investigated using radioligand binding assay, confocal 
microscopy and cointernalization of the two receptors. Although heterodimerization of 
B2R and AT1aR has been reported previously (Abdalla et al., 2000), the effect of 
heterodimerization on surface trafficking of individual receptors was not addressed.  
 
6.2.1 Surface expression analysis based on radioligand binding assay 
In order to check the expression of receptors, [
3H] bradykinin and or [
3H] angiotensin II 
binding assay was performed on intact cells. Surprisingly, it was found that when AT1aR 
was coexpressed with B2R, the number of [
3H] bradykinin binding sites on the surface of 
intact cells was increased four times compared to the expression of B2R alone (Fig. 6.2). 
In order to confirm that the increase in [
3H] bradykinin binding is specific to 
coexpression of AT1aR, coexpression of B2R with AT2R was also performed. AT2R is 30-
35% identical to AT1aR in amino acid sequence and binds to angiotensin II with almost 
the same affinity.  However, coexpression of AT2R did not lead to an increase in [
3H] 
bradykinin binding sites on the cell surface. This finding indicates that the increase in 
surface expression of B2R is specific to AT1aR coexpression. Surface expression of 
AT1aR or AT2R, as measured by [
3H] angiotensin II binding assay, remains unaltered by 
coexpression of B2R. There was no significant [
3H] bradykinin or [
3H] angiotensin II 
binding in non-infected BHK cells.
   129
                                                 
 
Fig. 6.2 Coexpression of the AT1aR increases cell surface binding sites of [
3H] 
bradykinin. BHK cells were infected with virus encoding Flag-B2R, Myc-AT1aR and 
Myc-AT2R separately or together (Flag-B2R with either Myc-AT1aR or Myc-AT2R). 24 h 
post-infection ligand binding assay was performed on the intact cells using [
3H] 
bradykinin or [
3H] angiotensin II.  
 
 
6.2.2 Surface expression analysis based on confocal microscopy 
 
In order to determine if the increase in [
3H] bradykinin binding sites was due to surface 
translocation of B2R in response to heterodimerization with AT1aR, BHK cells 
coexpressing B2R-eGFP
# and Myc-AT1aR were examined by confocal microscopy. As 
shown in Fig 6.3, B2R was translocated to the plasma membrane when coexpressed with 
AT1aR. Again, coexpression of AT2R had no effect on the localization of B2R (Fig. 6.3 C) 
revealing specificity of B2R-AT1aR interaction. B2R and AT1aR were found to exhibit 
clear colocalization when coexpressed (Fig. 6.3 D-F). Flag-B2R also exhibited 
intracellular localization like B2R-eGFP, while AT1aR-eGFP and Myc-AT1aR were 
localized on the cell surface (Fig. 6.3 G-I). 
 
 
 
#As described in section 3.3.6.2, B2R-eGFP was mainly localized intracellulary when 
expressed alone in BHK or CHO cells.   130
            
Fig. 6.3 Coexpression of AT1aR and B2R translocates B2R to the plasma membrane as 
revealed by confocal microscopy. B2R-eGFP was intracellularly retained when expressed 
alone (A), while it reached the cell surface upon coexpression with myc-AT1aR (B). 
Coexpression of myc-AT2R (C) had no effect on the trafficking of B2R. Clear 
colocalization of B2R and AT1aR was observed (D-F) in BHK cells coexpressing both 
receptors. Flag-tagged B2R also exhibited intracellular localization (G) when expressed 
alone, while AT1aR-eGFP (H) and Myc-AT1aR (I) were localized on the cell surface. The 
scale bar represents 10 µm. 
 
6.3 Selective agonist induced cointernalization of B2R and AT1aR 
 
After agonist stimulation, both B2R and AT1aR are known to internalize rapidly (Kule et 
al., 2004 and Bachvarov et al., 2001).  To determine whether B2R
 and AT1aR remain 
physically associated throughout this process,
 agonist induced internalization of these 
receptors was monitored. As shown
  in Fig. 6.4 D-F, stimulation of BHK cells 
coexpressing B2R-eGFP and Myc-AT1aR with 1 µM bradykinin resulted in significant 
internalization of B2R-eGFP as well as Myc-AT1aR. Internalized receptors exhibited clear 
colocalization. Similarly, stimulation of BHK cells coexpressing Flag-B2R and AT1aR-  131
eGFP with 1 µM angiotensin II resulted in robust internalization of Flag-B2R in addition 
to AT1aR-eGFP (Fig. 6.4 G-H). Again, internalized B2R and AT1aR were found to be 
colocalized. These studies suggest that B2R and AT1aR persistently associate on the cell 
surface as well
 as during the endocytic process that follows agonist stimulation. Non-
stimulated BHK cells expressing B2R-eGFP and Myc-AT1aR are shown as control (Fig. 
6.4 A-C) 
               
Fig. 6.4 Cointernalization of B2R and AT1aR in response to individual agonist ligands.  
Non-stimulated cells are shown as control (A-C). BHK cells coexpressing B2R-eGFP and 
Myc-AT1aR were stimulated either with 1 µM bradykinin (D-F) or 1 µM angiotensin II 
(G-I), for 15 min at 37°C. Subsequently, the cells were fixed, permeabilized and stained 
with either anti-Flag M2 monoclonal antibody or anti-Myc monoclonal antibody 
followed by Cy3/Cy5 coupled anti-mouse/anti-rabbit IgG secondary antibody. The cells 
were visualized by confocal microscopy (488 nm for eGFP, 550 nm for Cy3 and 650 nm 
for Cy5). The scale bar represents 5 µm. 
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6.4 B2R and AT1aR colocalize in human foreskin fibroblasts 
Human foreskin fibroblasts are known to express both B2R (Ochsenbein et al., 1999) and 
AT1aR (Nickenig et al., 1997). To determine whether B2R and AT1aR are colocalized in 
these cells, human foreskin fibroblasts were incubated with antibodies directed against 
the C-terminus of B2R and AT1aR. Afterwards, the cells were stained with Cy3/Cy5- 
coupled secondary antibodies, fixed and subsequently used for confocal microscopy. As 
shown in Fig. 6.5, B2R and AT1aR were found to be colocalized in line with the 
possibility that heterodimerization also drives surface localization of B2R in native tissues. 
                                
Fig. 6.5 Endogenously expressed B2R and AT1aR are colocalized at the plasma 
membrane in human foreskin fibroblasts. The cells were grown on sterile cover slips, 
fixed and permeabilized with digitonin. Subsequently, the endogenous receptors were 
stained with B2R and AT1aR specific monoclonal antibodies followed by Cy3/Cy5 
coupled anti-mouse/ant-rabbit IgG secondary antibody. Receptors were visualized by 
confocal microscopy (A-C) at the wavelengths of 550 nm (Cy3) and 650 nm (Cy5). The 
scale bar represents 10 µm. 
 
6.5 Isolation of the heterodimer complex 
 
For the isolation of the heterodimer complex, BHK cells were infected with recombinant 
SFV coding for B2R-His10 and AT1aR-strepII. 24 h post-infection, membranes were 
prepared and receptors were solubilized with 1% LM in presence of 0.2% CHS. A two-
step procedure comprising Ni-NTA followed by streptactin column was used for the 
purification. 
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6.5.1 Analysis by silver stained SDS-PAGE and Western blot 
 
The eluate from streptactin column was analyzed by 10% silver stained SDS-PAGE. As 
shown in Fig. 6.6 (A), two major bands of 45 kDa and 40 kDa were observed. These 
bands correspond well with the size of AT1aR and B2R, respectively. The eluate from 
streptactin column was also analyzed by anti-his antibody and AP-conjugated 
streptavidin. As shown in Fig. 6.6 (B-C), a band of approximately 40 kDa was observed 
in anti-his blot that represents the B2R-His10 fusion protein and a band of 45 kDa was 
seen in an anti-strep blot that represents the AT1aR-strepII fusion protein.   
 
 
                                                                  
 
 
Fig. 6.6 Purification of B2R-AT1aR heterodimer complex from BHK cells. The eluate 
from streptactin was loaded on a 15% SDS-polyacrylamide gel. A. Silver staining of the 
gel (1 µg).  B. Western blot with anti-his antibody. C. Western blot with anti-strep 
antibody. 
 
6.5.2 Analysis by gel filtration 
 
In order to check the integrity and homogeneity of the purified heterodimer complex, the 
eluate from streptactin matrix was analyzed by gel filtration on a superose 6 column in 
the SMART chromatography system. A main peak at a retention volume of 1.50 ml was 
observed (Fig. 6.7). This peak was analyzed by silver staining on a 15% SDS-
polyacrylamide gel. It showed two bands corresponding to AT1aR and B2R (as in Fig. 
6.6). In addition to this main peak, two additional peaks (at retention volume 1.2 ml and 
1.3 ml) were also observed, which probably represent aggregated material.  
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Fig. 6.7 Analytical gel filtration of purified AT1aR-B2R heterodimer complex (eluate 
from streptactin column, 0.1 mg at a concentration of 2 mg/ml) using superose 6 column. 
 
6.5.3 Ligand biding analysis of heterodimer complex 
 
Radioactive ligand assay was performed on the eluates from Ni-NTA and streptactin 
columns. As shown in Fig. 6.8, [
3H] angiotensin II binding on Ni-NTA eluate and [
3H] 
bradykinin binding on streptactin eluate was detected. The eluate after two columns (Ni-
NTA followed by streptactin) revealed approximately 1:1 binding of [
3H] angiotensin II 
and [
3H] bradykinin. These data agree with the isolation of a B2R-AT1aR heterodimer 
complex.  
 
6.6 Stability analysis of the heterodimer complex 
 
In order to check the stability of B2R-AT1aR complex over time, the complex was stored 
at 4°C and after three days, a pull down assay was performed using either Ni-NTA resin 
or streptactin resin. Unfortunately, AT1aR was found in the flow through of Ni-NTA resin 
and B2R was present in the flow through of streptactin resin (Fig. 6.9). This indicates that 
the complex dissociates when stored after purification. Further attempts to stabilize the 
complex are underway. 
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Fig. 6.8 Radioligand binding analysis during isolation of heterodimer complex. A. [
3H] 
bradykinin biding (1) and [
3H] angiotensin II binding (2) on the eluate from Ni-NTA 
column, B. [
3H] angiotensin II biding (1) and [
3H] bradykinin biding (2) on streptactin 
eluate, and C. [
3H] bradykinin binding (1) and [
3H] angiotensin II binding (2) after two 
steps of purification. 
 
 
 
                                                           
 
 
Fig. 6.9 Analysis of the B2R-AT1aR heterodimer complex stability over time. After 
purification, the B2R-AT1aR heterodimer complex was stored at 4°C followed by a pull 
down assay using either Ni-NTA or streptactin resin. A 15% silver stained SDS-
polyacrylamide gel showing flow through of Ni-NTA (lane 1, 0.4 µg), eluate of Ni-NTA 
(lane 2, 0.4 µg), flow through streptactin (lane 3, 0.4 µg), and eluate from streptactin 
resin (lane 4, 0.4 µg ). 
A                                                            B                                                                            C 
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7.1 Production and isolation of NmU2R from Pichia pastoris 
 
7.1.1 Sub-cloning of NmU2R gene in Pichia expression vector 
 
The coding region of NmU2R gene was amplified from cDNA vector (pNmU2R, from 
Aventis) with the primers NmU2R_Pichia_Fw/Rv using Pfu DNA polymerase. PCR 
products were checked on 1% agarose gel (Fig.7.1), purified using PCR purification kit 
and then digested with SpeI and EcoRI enzymes. After restriction digestion, the PCR 
product was ligated to SpeI-EcoRI digested pPIC9K (modified) vector. The resulting 
construct was verified by DNA sequencing. 
 
                  M     C       1         2        3        4        5 
 
 
Fig. 7.1 Amplification of NmU2R gene from cDNA vector by PCR under following 
conditions: 94°C = 5 min, 94°C = 40 sec, 68°C = 40 sec, 72°C = 90 sec and 72°C = 10 
min. Total 30 cycles (step 2 to step 4) were used for amplification. PCR products were 
analyzed on 1% agarose gel. M = Lambda DNA (EcoRI + HindIII) marker, C= control 
(no template DNA), 1-5 = different amounts (50 ng-200 ng) of template DNA. 
 
7.1.2 Expression construct 
 
The modified pPIC9K expression vector used for production of NmU2R in Pichia 
pastoris has been described before (section 3.1.2). This vector contains a Flag tag and a 
histidine 10 tag at the N-terminus and a biotinylation domain of Propionibacterium 
shermanii transcarboxylase at the C-terminus. The resulting construct is shown in Fig. 7.2 
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Fig. 7.2 Expression construct for production of recombinant NmU2R in Pichia pastoris. 
AOX1 = alcohol oxidase 1 promoter, α-factor = α-mating factor prepro-peptide of S. 
cerevisiae, Flag = coding sequence for Flag epitope, His10 = coding sequence for 
histidine 10 tag, NmU2R = coding sequence of NmU2R gene, TEV = cleavage site for 
TEV protease, Bio = biotinylation domain of Propionibacterium shermanii 
transcarboxylase. 
 
 
7.1.3 Production of the recombinant receptor 
 
Pichia cultures were grown in shake flasks (as described in Multi-Copy Pichia expression 
kit, Invitrogen), membranes were prepared (after 24 h of induction with methanol) and 
subjected to Western blot analysis and ligand binding assay.  
 
7.1.3.1 Western blot analysis 
 
Western blot with anti-Flag M2 antibody was performed to check the expression of 
recombinant receptor. As shown in Fig. 7.3, a band of approximately 55 kDa was seen in 
the membranes of Pichia cells expressing NmU2R. The size of this band corresponds well 
to the calculated size of recombinant receptor fusion protein (52.3 kDa). An additional 
band of approximately 75 kDa was also seen which probably represents unprocessed
 
receptor. The
 unprocessed receptor is the fusion of recombinant receptor and alpha-factor 
as Kex-2 endopeptidase of Pichia pastoris failed to cleave the alpha-factor completely. 
 
7.1.3.2 [
125I] NmU binding 
 
In order to check the functionality of the recombinant receptor and to calculate the total 
amount of functional receptor in membranes, a saturation binding experiment using [
125I] 
NmU was performed. [
125I] NmU binding was saturable and revealed a Bmax value of 1.5 
pmol recombinant NmU2R per mg membrane protein (Fig. 7.4). A high affinity binding 
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of [
125I] NmU to the recombinant receptor was observed with a Kd value of 0.79 nM. This 
Kd is similar to a previously reported value for NmU2R in COS-7 cell (see appendix). 
 
 
         
 
Fig. 7.3 Western blot analysis of the FlagHis10NmU2RBio construct produced in P. 
pastoris. Proteins were separated by 10% SDS-PAGE and probed with anti-Flag M2 
antibody. Lane 1 = 5 µg of membranes from Pichia pastoris expressing 
FlagHis10NmU2RBio protein and lane 2 = 5 µg of control Pichia membranes.   
 
 
                                
 
Fig. 7.4 Saturation curve for [
125I] NmU binding to the recombinant NmU2R produced in 
Pichia. The Graph was generated using a single site model in KaleidaGraph software. 
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7.1.4 Optimization of functional production level of NmU2R 
 
In order to increase the functional expression of NmU2R, DMSO was added to the Pichia 
cultures during the methanol induction step. As shown in Fig. 7.5, approximately four-
fold increase in functional expression of recombinant NmU2R was observed upon 
addition of DMSO. Maximum expression level was obtained in presence of 2% DMSO 
and it corresponds to approximately 6 pmol/mg (0.2 mg/l culture) of recombinant 
NmU2R. 
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Fig. 7.5 Effect of DMSO on the expression level of recombinant NmU2R in Pichia 
pastoris. DMSO was added to the cultures, membranes were prepared and [
125I] NmU 
binding was measured. 
 
 
7.1.5 Glycosylation analysis 
 
There are three putative glycosylation sites
# in NmU2R, two at the N-terminus (N
9, N
27) 
and one in the third extracellular loop (N
180). In order to analyze the glycosylation state of 
the recombinant receptor, enzymatic deglycosylation using PNGaseF or EndoH was 
performed on Pichia membranes expressing NmU2R, followed by Western blot analysis. 
 
 
#These sites are predicted based on the conserved N-linked glycosylation motif (Asn-
Xaa-Ser/Thr). 
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As shown in Fig. 7.6, the recombinant receptor band was shifted to lower molecular 
weight size upon enzymatic deglycosylation. This result reveals that the recombinant 
NmU2R produced in Pichia was glycosylated. 
 
 
 
                                        
 
 
Fig. 7.6 Glycosylation analysis of the recombinant NmU2R produced in Pichia. 5 µg of 
Pichia membranes expressing NmU2R were treated with 0.5 units of PNGaseF (lane 1) or 
0.5 units of EndoH (lane2) at 4°C for 2h. The lane “C” is untreated control Pichia 
membranes (5 µg). The proteins were separated by 10% SDS-PAGE and Western blot 
analysis was performed using anti-Flag M2 antibody.  
 
 
7.1.6 Solubilization of the recombinant NmU2R 
 
In order to solubilize the recombinant NmU2R from Pichia membranes, different 
detergents (with 0.2 % CHS) were tested. As shown in Fig. 7.7, NmU2R was solubilized 
with most of the detergents. [
125I] NmU binding on solubilizate was used to monitor the 
functional solubilization of NmU2R from Pichia membranes. It revealed that 
approximately 50-60 % of the [
125I] NmU binding sites were solubilized with maltoside 
detergents (LM, UM and DM). The recovery with other detergents was lower. Therefore, 
for further studies, NmU2R was solubilized with 1% LM in presence of 0.2% CHS. 
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Fig. 7.7 Solubilization of the recombinant NmU2R from Pichia membranes (5 mg/ml). 
Lane 1-11 = LM, UM, DM, NG, OG, Fos12, Fos14, Fos16, CHAPS, LDAO, digitonin. 
All the detergents were used at the concentration of 1% except OG (2%). Solubilizate 
was loaded on a 10% SDS-polyacrylamide and Western blot analysis was performed 
using anti-Flag M2 antibody. 
 
7.1.7 Purification of recombinant NmU2R 
 
Pichia membranes expressing NmU2R were saturated with NmU (1 µM) in order to 
stabilize the active conformation of the receptor. Subsequently, the receptor was 
solubilized and purified on Ni-NTA resin. As a second step of purification, the eluate 
from Ni-NTA was applied to monomeric avidin matrix. The recombinant receptor from 
this column was eluted with 2 mM biotin. The eluates from Ni-NTA and monomeric 
avidin columns were analyzed by 10% silver stained SDS-PAGE. As shown in Fig. 7.8 
A, the recombinant receptor was >75 % pure after monomeric avidin purification.  
In order to check the homogeneity of purified NmU2R, the eluate from monomeric 
avidin column was analyzed by gel filtration on a Superose 6 column in the SMART 
chromatography system. A main peak at a retention volume of 1.60 ml (indicated by the 
arrow head) was observed (Fig. 7.8 B). It corresponds to a homogenous population of 
purified NmU2R. In addition to this main peak, some aggregated receptor (peak at 
retention volume of 0.89 and shoulder at 1.4-1.5 ml) and a peak at a retention volume of 
1.79 ml was also observed. The peak at 1.79 ml contained no protein (as analyzed by 
silver stained SDS-PAGE) and probably represents free detergent micelles. 
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Fig. 7.8 Purification of the recombinant NmU2R from Pichia pastoris. A. Silver stained 
10% SDS-polyacrylamide gel showing the eluate from Ni-NTA (lane 1, 1µg) and 
monomeric avidin (lane 2, 0.8 µg). B. Analytical gel filtration of purified NmU2R (eluate 
from monomeric avidin column, 25 µg at a concentration of 0.5 mg/ml) using superose 6 
column. 
 
 
Here, it was not possible to follow the receptor purification by ligand binding 
(receptor was purified with high affinity ligand NmU). Therefore, the estimation of 
purification yield is based on the total protein quantification by BCA assay. It was 
estimated that the receptor yield after two-step affinity purification was 20-25% (BCA 
quantification) of the starting amount in membranes (based on ligand binding).  
 
7.2 Production and isolation of the NmU2R from BHK cells 
 
7.2.1 Sub-cloning of NmU2R gene in SFV expression vectors 
 
The coding region of NmU2R gene was amplified with the primers NmU2R_SFV_Fw/Rv 
and ligated into the modified SFV vector between SmaI and SpeI enzyme sites, using the 
standard cloning procedure.  
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7.2.2 Expression construct 
 
For the expression of NmU2R in mammalian cells, the modified SFV expression vector 
(described in section 3.3.2) was provided by Christoph Reinhart. The expression 
construct of NmU2R is shown in Fig. 7.9. Here, expression of the recombinant NmU2R 
protein is driven by a subgenomic 26S promoter. This vector contains a capsid sequence 
(a translation enhancer element from 5’ end of the capsid gene from SFV) and affinity 
tags for detection and purification of NmU2R.  
 
 
 
 
 
Fig. 7.9 Expression constructs for production of recombinant NmU2R in mammalian 
cells. PSG = subgenomic 26S promoter, CAP = capsid sequence, NmU2R = coding 
sequence for NmU2R gene, His10 = coding sequence for histidine 10 tag, TEV = cleavage 
site for TEV protease, Bio = biotinylation domain of Propionibacterium shermanii 
transcarboxylase. 
 
 
7.2.3 Production of recombinant NmU2R in BHK cells 
 
Recombinant virus particles were generated and activated as described in the materials 
and methods. Suspension cultures of BHK cells were grown and infected at a density of 
1-2x10
6 cells/ml. 24 h post-infection, membranes were prepared and subjected to Western 
blot analysis and [
125I] NmU binding analysis. 
 
7.2.3.1 Western blot analysis of NmU2R 
 
Western blot analysis of membranes from BHK cells expressing NmU2R revealed a band 
of approximately 55 kDa (Fig. 7.10). It corresponds well with the calculated size of 
recombinant receptor fusion protein (50.1 kDa).  
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Fig. 7.10 Western blot analysis of the recombinant NmU2R produced in BHK cells. 
Proteins were separated by 10% SDS-PAGE and probed with anti-his antibody. Lane 1 = 
10 µg of membranes from non-infected BHK cells and lane 2 =  10 µg of membranes 
from BHK cells expressing NmU2R.                                  
 
 
7.2.3.2 [
125I] NmU binding analysis 
 
In order to calculate the total amount of functional receptor in membranes, a saturation 
binding experiment using [
125I] NmU was performed. [
125I] NmU binding was saturable 
and revealed a Bmax value of 2.3 pmol recombinant NmU2R per mg membrane protein 
(Fig. 7.11). A high affinity binding of [
125I] NmU to the recombinant receptor was 
observed with a Kd value of 1.2 nM. This Kd is similar to a previously reported value for 
NmU2R in COS-7 (see appendix). The non-specific binding was determined in presence 
of 1µM NmU and it was less than 20% of total binding.  
 
7.2.3.3 Effect of DMSO on NmU2R expression 
 
In an attempt to further increase the functional expression of NmU2R, DMSO was added 
to the BHK cell cultures during expression step. 24 h post-infection, membranes were 
prepared and subjected to [
125I] NmU binding analysis. As shown in Fig. 7.12, 
approximately four-fold increases in functional expression of recombinant NmU2R was 
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achieved in the presence of 2% DMSO and this corresponds to approximately 9 pmol/mg 
(0.1 mg/liter culture) of NmU2R.  
 
                           
 
 
Fig. 7.11 Saturation curve for [
125I] NmU to recombinant NmU2R produced in BHK 
cells. The graph was generated using the single site model in KaleidaGraph software. 
 
 
7.2.4 Glycosylation analysis 
 
In order to analyze the glycosylation state of the recombinant receptor, enzymatic 
deglycosylation using PNGaseF or EndoH was performed on membranes from BHK cells 
expressing NmU2R, followed by Western blot analysis. As shown in Fig. 7.13, there was 
no change in the migration of the recombinant NmU2R band suggesting that the receptor 
was not glycosylated. Similarly, recombinant B2R, when produced in BHK cells, was 
also not glycosylated. 
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Fig. 7.12 Effect of DMSO on the expression level of recombinant NmU2R in BHK cells. 
DMSO was added to the cultures, membranes were prepared and [
125I] NmU binding was 
measured. 
 
 
 
                                                                
 
 
 
Fig. 7.13 Glycosylation analysis of the recombinant NmU2R produced in BHK cells. 10 
µg of membranes from BHK cells expressing NmU2R were treated with 0.5 units of 
PNGaseF (lane 2) or 0.5 units of EndoH (lane 3) at 4°C for 2 h. The lane “C” is untreated 
control membranes (5 µg). The proteins were separated by 10% SDS-PAGE and Western 
blot analysis was performed using anti-his antibody.  
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7.2.5 Localization analysis of NmU2R 
 
 
Localization of NmU2R in BHK cells (using fluorescein labeled NmU) was checked by 
confocal microscopy. As shown in Fig. 7.14, recombinant NmU2R was mainly localized 
in the perinuclear membranes (most probably in the endoplasmic reticulum). Only low 
levels of fluorescence were observed on the plasma membrane. Similar intracellular 
retention of overexpressed alpha-2B adrenergic receptor (Sen et al., 2003) and 
recombinant B2R (this study, section 3.3.6.2) was observed in BHK cells. 
 
 
 
                    
 
 
 
Fig. 7.14 Confocal imaging of BHK cell expressing NmU2R. Cells were grown and 
infected on cover slips. 24 h post-infection, cells were permeabilized and stained with 
fluorescein labeled NmU. Subsequently, the cells were fixed and scanned (488 nm) with 
a Zeiss laser
 scanning confocal microscope. 
 
 
7.2.6 Solubilization and purification of NmU2R 
 
Recombinant NmU2R was solubilized from membranes (5 mg/ml) using 1% LM in the 
presence of 0.2% CHS. Approximately, 55-60% of the [
125I] NmU binding sites were 
solubilized from membranes.  
For purification, membranes were first saturated with NmU (1 µM) in order to 
stabilize the active conformation of the receptor. Subsequently, the receptor was 
solubilized (1% LM in presence of 0.2% CHS) and purified using Ni-NTA resin. Eluate 
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from the Ni-NTA column was analyzed by silver stained 10% SDS-PAGE. As shown in 
Fig. 7.15 (A), >80% pure receptor was obtained after Ni-NTA purification.  
In order to check the homogeneity of purified receptor, the eluate from Ni-NTA 
column was analyzed by gel filtration on a Superose 6 column. As shown in Fig. 7.15 
(B), purified NmU2R was present mainly in homogenous form (peak at 1.60 ml).  Some 
aggregation of the purified NmU2R was also detected (peak at 0.9 ml and shoulder at 1.2 
ml). Additionally, a peak at a retention volume of 1.75 ml was also observed which 
possibly corresponds to the free detergent micelles. 
  It was estimated that receptor yield after Ni-NTA purification was 30-32% 
(BCA quantification) of the starting amount in membranes (based on ligand binding).  
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Fig. 7.15 Purification of recombinant NmU2R from BHK cells. A. Silver stained 10% 
SDS-polyacrylamide gel showing membranes (lane 1, 0.2 µg), solubilizate (lane 2, 0.2 
µg), flow through (lane 3, 0.2 µg), eluate from Ni-NTA (lane 4 & 5, 0.1 µg & 0.8 µg, 
respectively). B. Analytical gel filtration of purified B2R (eluate from Ni-NTA column, 
0.1 mg at a concentration of 2 mg/ml) using superose 6 column. 
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8.1 Structural studies on GPCRs 
G protein-coupled receptors (GPCRs) are involved in many important cellular signal 
transduction processes such as differentiation, proliferation, angiogenesis, cancer, 
development and cell survival. GPCRs represent an important class of drug targets with 
proven therapeutic value. Over 200 major prescription drugs target GPCRs, representing 
over 30% of the total drugs on the market (Wise et al., 2002). However, due to the lack of 
a three-dimensional structure (except bovine rhodopsin), structure-based drug design has 
not been possible. It should be noted that the only GPCR crystallized till date, the bovine 
rhodopsin (Palczewski et al., 2000), was obtained from the natural source (bovine retina) 
where it is found in large amounts. The reasons for the extremely low success rate in 
structure determination of GPCRs are their low abundance in native tissues and the 
complications related to the expression of recombinant receptors in heterologous systems. 
These complications include inefficient transport and insertion in the plasma membrane 
as well as their toxic effect on the host cell. Additionally, isolation of large amounts of 
stable receptor proteins for structural characterization has also been a challenging task. 
Due to the lack of 3-D structures, a number of biochemical and biophysical techniques 
have been used to get some information about GPCRs. One of the most common 
approaches is site-directed mutagenesis coupled to functional analysis. Additionally, 
electron paramagnetic resonance (EPR) spectroscopy, NMR spectroscopy and Cys-
crosslinking experiments have also been carried out on rhodopsin (see papers by Khorana 
and coworkers). These studies have resulted in some insights into the GPCR mechanism.  
More recently, the bovine rhodopsin structure has been used as a template for molecular 
modeling of other GPCRs. However, all the above mentioned studies do not provide 
sufficient details of GPCR activation and signalling mechanism. Therefore, it is 
necessary to obtain three-dimensional structures of GPCRs and more importantly, in 
different states (i.e. agonist/antagonist bound, in complex with G protein and in complex 
with beta-arrestin etc.). The first step towards this goal is to produce and isolate sufficient 
amounts of GPCRs that can be used for structural characterization. This has been the 
major focus during my PhD work. Although the number of structures of membrane 
proteins are growing (97 unique structures until October 2005), it is interesting to note   152
that the X-ray crystal structure of only one human recombinant membrane protein i.e. 
monoamine oxidase (MAO)  has been determined until now (Binda et al., 2000). 
Monoamine oxidase is a monotopic membrane protein and therefore, it has little 
hydrophobic surface (MAO has a single transmembrane helix that anchors it to the outer 
membrane). The bulk of this 520 residue protein, including the active site, is outside the 
membrane. This example reflects the fact that large-scale production and isolation of 
recombinant human membrane proteins has been a difficult task. It is not surprising that 
heterologous production of membrane proteins in general is more difficult than the the 
cytoplasmic proteins. Membrane proteins require a complicated set of events for their 
targeting and insertion into the membrane. It may happen that when overproduced in a 
heterologous system, membrane proteins can saturate the secretory pathway of the cell. 
This might lead to the accumulation of unfolded and inactive protein inside the host cell. 
Therefore, overproduction and isolation of GPCRs represent the main bottlenecks for 
structural characterization. Once a given GPCR can be produced and isolated in sufficient 
quantities, the next focus should be long-term stability and trials to increase its polar 
surface area for making crystal contacts.  
8.2 Heterologous production of B2R in different host systems 
B2R plays a crucial role in cardiovascular system and it is a major target for the treatment 
of a wide spectrum of cardiovascular disorders. Understanding the receptor structure and 
the receptor bound conformation of bradykinin would be a great help in designing more 
specific and potent drugs to treat cardiovascular diseases. During this study, human B2R 
was produced in three different hosts namely Pichia pastoris, insect cells and mammalian 
cells.  
Among different heterologous expression systems for GPCR production, the 
methylotrophic yeast Pichia pastoris has been described as an efficient one. In this 
system, the genes coding for the heterologous proteins are placed under the control of  
alcohol oxidase-1 (AOX1) promoter (Cregg et al., 1993). The AOX1 promoter is highly 
inducible by methanol and tightly regulated. In the presence of methanol, the promoter 
activity is maximal and it may contribute up to 30% of the total protein content of the cell   153
(Cregg  et al., 1993). Since, P. pastoris is a eukaryotic system, its intracellular 
environment is more suitable for expression and correct folding of eukaryotic proteins. 
Several GPCRs have been successfully expressed in Pichia, such as the β2-adrenergic 
receptor and the 5HT5A-serotoninergic receptor (Weiss et. al. 1998), the human CB1 
cannabinoid receptor (Kim et al., 2005), the human D2S dopamine receptor (Grünewald 
et al., 2004), the CB2 cannabinoid receptor (Feng et al., 2002), the human mu-opioid 
receptor (Sarramegna et al., 2002), and the human ET(b) endothelin receptor (Schiller et 
al., 2000). Previous successes with GPCR production in Pichia pastoris make it the first 
choice for the production of a given GPCR. However, the expression level of 
recombinant B2R in Pichia pastoris was low (0.3 pmol/mg) under basic culture 
conditions (see result section 3.1.3.2). By addition of DMSO, the expression level was 
increased up to 3.5 pmol/mg (0.1 mg of receptor in membrane per liter culture), but still 
too low for large-scale production. Pichia pastoris can be grown in the fermentor, which 
results in large biomass. This makes it possible to obtain significant amount of receptor 
despite its low expression level. However, it has also been noticed in some cases that 
expression level of GPCRs in Pichia decreases when fermentor is used (Christoph 
Krettler, personal communication). As mentioned before, the main goal of this study was 
to isolate large amounts of the receptor. With low expression level of the receptor, large 
amounts of detergent will be required during solubilization step. Therefore, production of 
B2R in Pichia using fermentor was not considered and other expression systems were 
tested. 
Among the different factors that may influence the ligand binding of a given 
receptor, the non-appropriate lipid environment is particularly relevant. It has already 
been reported that ligand binding of some GPCRs was significantly affected by the 
surrounding lipid environment (Burger at al., 2000, Chattopadhyay et al., 2005, and 
Lagane et al., 2000). In yeast, the major sterol of the plasma membrane is ergosterol. A 
recent study suggests that cholesterol and ergosterol have quite opposite effects with 
respect to the ligand binding properties of the human µ-opioid receptor (Lagane et al., 
2000). Ergosterol was found to constrain the µ-opioid receptor in an inactive state and 
could not replace cholesterol in activating it. In view of these observations, it is likely   154
that due to inappropriate lipid environment, the recombinant B2R produced in Pichia can 
not bind to its ligand. Additionally, it is also possible that B2R requires certain molecular 
chaperones for proper folding and activity, which are not present in Pichia pastoris. 
Therefore, one can consider coexpressing the receptor with molecular chaperones such as 
calnexin and BiP. Although it has been found that the coexpression of calnexin improves 
the yield of functional Shaker potassium channel (Higgins et al., 2003), coexpression of 
GPCRs (substance P receptor and adenosine A2a receptor) with molecular chaperones did 
not improve their expression level in (Butz et al., 2003). 
  Next, baculovirus mediated expression of B2R in insect cells was tested. The 
baculovirus system has also been very efficient for heterologous production of several 
membrane proteins. Baculovirus based expression has resulted in functional production 
of several GPCRs such as the dopamine D2 receptor ( Grünewald et al., 1996 and Javitch 
et al., 1994), serotonin receptors (Parker et al., 1994, Butkerait et al., 1995 and Mulheron 
et al., 1994), muscarinic receptors (Parker et al., 1994 and Rinken et al., 1991), the β2-
adrenergic receptor (Reiländer et al., 1991), the adenosine A2a receptor (Murphree et al., 
2002 and Robeva et al., 1996), cannabinoid receptors (Glass et al., 1999) and opioid 
receptors (Massotte et al., 1997). It has been observed that post-translational 
modifications in insect cells are identical to mammalian cells. Therefore, this system is a 
good choice for those GPCRs where the receptor function is influenced by post- 
translation modifications.  
The expression level of B2R in insect cells using the baculovirus system was 10 
pmol/mg (0.3 mg of the receptor per liter culture). Interestingly, there was no increase in 
the receptor expression level by addition of DMSO in cell culture medium. However, it 
was possible to obtain 6-8 mg of recombinant receptor in membranes by using a 25 liter 
wave bioreactor. Thus, the baculovirus mediated expression of B2R in insect cells 
provides a suitable system for large-scale production and further characterization of this 
receptor. 
  For the heterologous production of human GPCRs, mammalian cells provide 
most natural environment. Therefore, SFV based expression of B2R in mammalian cells   155
was also tested. It has been demonstrated that the SFV based system leads to high levels 
of expression (50–150 pmol/mg) of several GPCRs (Lundstrom et al., 2003). The 
expression level of B2R in mammalian cells was 10-11 pmol/mg under basic conditions 
(see result section 3.3.3), which was further increased to 60 pmol/mg (0.6 mg/liter) by the 
addition of DMSO in culture medium. This expression level of B2R is the maximum 
reported so far in any expression system. Previous studies using stable or transient cell 
lines have resulted in only low (100-200 fmol/mg) or moderate expression levels (1-3 
pmol/mg). Although it was observed that the expression level of B2R in the bioreactor 
(30-32 pmol/mg) was relatively lower than in the spinner flasks (55-60 pmol/mg), it was 
possible to obtain up to 5-6 mg of receptor in membrane by using a 20 liter wave 
bioreactor. One advantage of using the SFV system is the broad range of host cells that 
can be infected by SFV. The choice of appropriate host cells has also been shown to play 
a significant role in the expression of some receptors. For example, rat odorant receptors 
were retained intracellularly when expressed in BHK cells but showed plasma membrane 
localization when expressed in olfactory epithelial cell line OLF442 (Monastyrskaia et al., 
1999). In some cases, the expression levels also vary depending on the host cell. For 
instance, the expression levels of the rat κ and µ opioid receptors were higher in rat C6 
glioma cells compared to BHK or CHO cells (Simmen et al., 1998). During this study, 
four different cell lines (BHK-21, CHO-K1, COS-7 and HEK-293) were tested for 
expression of B2R but no significant difference was observed. Although, the expression 
level of B2R is best in mammalian cells, the high cost of virus production does not allow 
the use of this system on a routine basis for large-scale production of the recombinant 
receptor.    
8.3 Characterization of the recombinant B2R 
Immunoblot analysis of recombinant B2R from Pichia and BHK cells showed a single 
band of 55 kDa and 50 kDa respectively. These sizes correspond well with the calculated 
molecular masses of the recombinant receptor with or without glycosylation. However, 
recombinant B2R from insect cells showed two bands of 55 kDa and 35 kDa. While the 
major band of 55 kDa represents a full length receptor fusion protein, the smaller band of 
35 kDa is a proteolytic degradation product.  Due to the long expression time in the   156
baculovirus system and because it is a lytic system (i.e. producer cells are lysed at the end 
of the virus life cycle), proteins expressed in this system often show proteolytic cleavage. 
Similar proteolytic degradation of overexpressed rat thrombin receptor (Chinni et al., 
1998) and human histamine H1 receptor (Ratnala et al., 2004) in insect cells has been 
reported. However, unlike the H1 receptor, addition of leupeptin in the culture medium 
did not prevent proteolytic cleavage of B2R.  
 In human fibroblasts and platelets which naturally express B2R, this receptor has 
been found to be a protein of 69 kDa (Blaukat et al., 2003). This molecular weight is 
higher than predicted from the receptor coding region (40 kDa) and may represent a 
heavily glycosylated (at N
3, N
12 and N
180) form of the receptor. The recombinant receptor 
produced in Pichia and insect cells was in glycosylated form, although heavy 
glycosylation like native tissue was not observed. During deglycosylation, size of the 
proteolytic cleavage product observed in Sf9 cells was also reduced, indicating that the 
degradation product is the N-terminal part of the recombinant receptor. It was surprising 
that recombinant B2R was not glycosylated when produced using the SFV system. For 
some members of GPCR family, glycosylation is required for optimal cell surface 
expression and receptor function while for some other members, cell surface localization 
and function are not affected glycosylation state of the receptor (reviewed in Wu et al., 
2005). Interestingly, when murine CB2 cannabinoid receptor was produced in the SFV 
system using similar constructs, it was only partially glycosylated (Olson et al., 2003).  
The presence of non-glycosylated receptor molecules may represent the saturation of rate 
limiting step of carbohydrate processing in the host cells. Alternatively, fast replication of 
the recombinant virus may also interfere with the glycosylation machinery of the host cell.  
Saturation binding analysis on membranes revealed that the ligand binding 
affinity of the recombinant B2R from different host cells was similar to that of native 
tissues. High affinity of the recombinant B2R for bradykinin provides a useful tool to 
stabilize the receptor during solubilization and purification steps, as the receptor-ligand 
complex should be more stable than the receptor alone. 
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8.4 Intracellular localization of recombinant B2R 
 
In order to check the localization of recombinant B2R in insect cells and mammalian cells, 
confocal microscopy using eGFP fusion constructs and immunogold labeling 
experiments using Flag-tagged constructs were performed. Both methods revealed 
localization of B2R in the intracellular membranes, probably representing the 
endoplasmic reticulum. Only a minor fraction of the recombinant receptor was detected 
on the plasma membrane. The baculovirus constructs contain a prepro-mellitin signal 
sequence, which is supposed to result in efficient targeting of the membrane proteins to 
the cell surface. But it was not the case for recombinant B2R. However, previous reports 
also indicate intracellular retention of overexpressed GPCRs in insect cells (Blaukat et al., 
1999, Grünewald et al., 1996, Maeda et al., 2004 and Sen et al., 2005). 
In the constructs of SFV system, a signal sequence from influenza hemagglutinin 
(HA) gene was fused at the N-terminus of the receptor, still the receptor was retained 
intracellularly. Similar intracellular retention was observed for the beta-2 adrenergic 
receptor (Darui Huo, Ph.D. Thesis), human neurokinin 1 receptor (Lundstrom et al., 
2001) and human alpha-2b adrenergic receptor (Sen et al., 2003), when expressed using 
SFV system. Nevertheless, as here, in many case even the intracellular retained receptor 
is capable of ligand binding. Localization of B2R in Pichia was not checked. Previous 
reports strongly suggest intracellular localization of different GPCRs when expressed in 
Pichia pastoris (Grünewald et al., 2004, Schiller et al., 2000 and Weiss et al., 1998).  
 It is generally assumed that over production of GPCRs or membrane proteins in 
general, saturates the secretion machinery of the host cell. This often leads to the 
accumulation of recombinant membrane proteins in the intracellular membrane 
compartments such as the endoplasmic reticulum and Golgi. However, as discussed later 
in this section, co-expression of B2R and AT1aR in BHK cells resulted in the cell surface 
targeting of the recombinant B2R. 
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8.5 Isolation of recombinant B2R 
 
The most commonly used approach for purification of recombinant membrane proteins is 
affinity purification based on the affinity tags fused to the protein. Two-step purification 
based on affinity tags is a suitable approach for large-scale isolation of recombinant 
GPCRs. Immobilized metal affinity chromatography is most widely used as the first step 
because it is generally robust and inexpensive. Large amounts of solubilizate can be 
applied on these columns and the recombinant protein can be eluted with an excess of 
imidazole. As a second step, either monomeric avidin column or streptactin column can 
be used. Recombinant B2R was successfully purified using a combination of Ni-NTA and 
monomeric avidin columns (from Pichia  and Sf9) or in a single step by a Ni-NTA 
column (from BHK cells). Homogeneity of the purified membrane protein is an 
important issue before it can be subjected to the crystallization trails. Analytical gel 
filtration revealed that purified B2R from Pichia was partially aggregated while it was 
mainly in homogenous state (at concentration of 10-20 mg/ml) when purified from BHK 
cells or Sf9 cells. However, purified B2R from BHK cells showed aggregation at high 
concentrations (section 4.1.5.1). Aggregation of recombinant GPCRs upon purification is 
a common problem (personal communication with colleagues and Danka Elez, Ph.D. 
thesis). Non-specific interaction of hydrophobic domains can be one of the reasons for 
receptor aggregation. Leaking of some Ni
+2 ions from the Ni-NTA affinity matrix during 
purification may also lead to receptor aggregation (via binding to histidine tags). Another 
problem associated with purification of membrane protein purification is delipidation. 
Lipids can have a stabilizing effect on membrane proteins and severe delipidation during 
purification may result in instability and aggregation of these proteins.  
An interesting observation during the purification of B2R from Sf9 cells was 
copurification of a protein-tyrosine phosphatase SHP-2. Interaction of this protein with 
B2R has been reported previously (Duchene et al., 2002). This interaction is crucial for 
the anti-proliferative effect of bradykinin in primary culture renal mesangial cells. It is 
generally thought that a complex of a GPCR with one of its interacting partners may be a 
valuable tool for crystallization of the receptor. This is due to the fact that such a complex 
not only stabilizes the receptor in one conformation but also increases the polar surface   159
area of the receptor available for making crystal contacts. Therefore, the complex of B2R 
and SHP-2 provides a unique opportunity for cocrystallization. However, the endogenous 
pool of the SHP-2 in Sf9 cells might be limited in comparison to the overexpressed B2R. 
Therefore, coexpression of recombinant human SHP-2 and B2R should be tested. By 
using different tags fused to B2R and SHP-2, it should be possible to separate the 
complex of B2R-endogenous SHP-2 and B2R-recombinant SHP-2.  
One problem associated with the baculovirus system is incomplete biotinylation 
of the biotinylation domain. It has been previously observed that only 30-40% of total 
recombinant receptor is botinylated in insect cells (Helmut Reiländer, personal 
communication). This results in a significant loss of recombinant receptor during 
purification on a monomeric avidin column. On the other hand, anti-Flag antibody matrix 
is expensive and can not be used repeatedly as its binding capacity decreases with 
repeated use. Therefore, an alternative strategy for purification of recombinant B2R from 
insect cells should be explored. One possibility is a construct with Strep II tag and 
purification based on a combination of Ni-NTA and streptactin columns.  
 
8.6 Structural studies with isolated B2R 
 
The main goal of this study was to use the isolated receptors for three-dimensional 
crystallization trials. However, as mentioned in the earlier, crystallization of recombinant 
human membrane proteins still remains a challenge. Therefore, a part of the isolated 
receptor was used for solid-state NMR studies and the other part for crystallization trials. 
Solid-state NMR studies aim to understand the receptor bound conformation of 
bradykinin as discussed later in this section.  
 
8.6.1 Three-dimensional crystallization trails 
 
The purified B2R from BHK cells and Sf9 cells was used for three-dimensional 
crystallization screening. The protein in crystallization drops was stable over a wide 
range of pH and some microcrystalline precipitates were obtained with PEG 400. One of 
the major problems associated with crystallization trials was heavy detergent   160
crystallization. It often made analysis of the drops difficult. It can also be the case that 
tiny protein crystals are masked by the detergent crystals. Therefore, it is necessary to 
remove extra free detergent after purification. Dialysis is one of the most commonly used 
methods to remove detergents. However, due to low cmc of n-dodecyl-β-D-maltoside, 
dialysis may not be very efficient. Another option is removal of the detergent via Bio-
Beads. For this method, a precise way to measure the detergent concentration is required. 
In addition, use of rhodamine labeled bradykinin during purification of the receptor can 
be helpful. It should result in colored protein crystals and therefore, it should be possible 
to differentiate the protein crystals from detergent crystals.  
  As discussed before, the complex of B2R-β-arrestin, B2R-SHP-2 or B2R-AT1aR 
represent valuable tools for cocrystallization of B2R. Further attempts are required to 
characterize and stabilize these complexes before they can be used for crystallization 
attempts. 
 
8.6.2 Solid-state NMR analysis of receptor bound bradykinin 
 
Solid-state NMR is a general method to study molecular structure and dynamics in a non-
crystalline environment. Recent progress in the field has led to the development of high 
resolution ss-NMR techniques (magic angle spinning, MAS) which are based on rapid 
rotation of the sample at a fixed angle under ultra high magnetic field. Although it has not 
been possible so far to study a full-length GPCR by ss-NMR, this technique offers a 
unique possibility to probe the conformational changes in the ligand upon binding to the 
receptor. In order to investigate the receptor bound conformation of bradykinin, 
13C/
15N 
uniformly labeled bradykinin variants were incubated with the purified B2R. This 
receptor-ligand complex was then transferred to 4-mm MAS rotor, flash frozen
 and 
subjected to NMR analysis. It was possible to detect signals of 
13C/
15N labeled peptide 
(roughly 25 µg) bound to just 1 mg of receptor. However, to get good signal/noise ratio, 
the experiments had to be carried out for long durations (9-10 days). Therefore, in order 
to increase the signal/noise, the amount of purified receptor was increased (this will 
increase the amount of bound 
13C/
15N labeled bradykinin). Unfortunately, it was not 
possible as the volume of MAS rotor is only 50 µl and the purified receptor has a   161
tendency to aggregate at higher concentrations. Therefore, an alternative approach (i.e. 
measurements at low temperature) was used to shorten the measurement time. At 180 K, 
it became feasible to get sufficiently good signal /noise ratio within one day (compared to 
3-5 days at 210 K). Interestingly, significant changes in the chemical shifts of receptor 
bound bradykinin were observed as compared to the lyophilized bradykinin or bradykinin 
in detergent micelles. Bradykinin has two arginines (R
1and R
9), three prolines (P
2, P
3 and 
P
7) and two phenylalanines (F
5 and F
8). The next step is to use selectively labeled 
bradykinin in order to assign the signals to individual amino acids. The information 
derived from these measurements will finally be used to generate a three-dimensional 
model of receptor bound bradykinin. It is expected that the receptor bound conformation 
of bradykinin will pave the way to design more specific and potent drugs acting on B2R. 
 
8.7 Coexpression of B2R and AT1aR 
 
As mentioned before, GPCRs have a small polar surface area that can make crystal 
contacts. Therefore, a heterodimer complex of a given GPCR with another GPCR can be 
a more suitable object for crystallization. Human B2R forms a stable heterodimer with 
human AT1aR (Abdalla et al., 2000) and this heterodimerization increases the activation 
of Gαq and Gαi proteins, the two major signalling G-proteins triggered by AT1aR. 
Therefore, the coexpression of these two receptors was performed in order to isolate the 
heterodimer complex. Interestingly, it was found that the coexpression of B2R with 
AT1aR leads to cell surface translocation of B2R. 
 
8.7.1 Heterodimerization with AT1aR promotes surface localization of B2R 
 
Several members of  class I GPCRs, such as α1D-AR (McCune et al., 2000, Chalothorn et 
al., 2002 and Hague et al., 2004), α2C-AR (Von Zastrow et al., 1993), adenosine 2b 
receptor (Sitaraman et al., 2002)), and bitter-taste receptor (Chandrasekhar et al., 2000)
 
are known to be largely intracellular when expressed in heterologous system. Similarly, 
human B2R, when overexpressed in BHK cells, was predominantly retained intracellulary 
with only a minor fraction reaching the plasma membrane (section 3.3.6.2). Effects of   162
homodimerization and heterodimerization on surface localization of GPCRs have been 
observed in some cases. It has been suggested that homo or heterodimerization may be a 
pre-requisite
 for certain GPCRs to be exported to the plasma membrane. In most cases, 
heterodimerization of two members of the same subfamily i.e. different subtypes has 
been shown to drive this phenomenon. The only published example where surface 
localization of a GPCR is driven by a distantly related GPCR is heterodimerization of 
mouse olfactory receptor with β2-adrenergic receptor (Hague et al., 2005). It is 
interesting that several other membrane proteins
 also need oligomerization for their cell 
surface targeting. These include shaker
 potassium channels (Gu et al., 2003), the AMPA 
receptor (Dubel et al., 2004), the transforming growth factor β receptor
 (De Crescenzo et 
al., 2004), and the insulin receptor (Wu et al., 2004). Similarly, coexpression of B2R and 
AT1aR in BHK cells resulted in cell surface localization of B2R as revealed by confocal 
microscopy and ligand binding assay. Interestingly, coexpression of angiotensin II type 2 
receptor (AT2R) did not affect the surface expression of B2R, revealing a specific 
interaction between AT1aR and B2R. Cointernalization of B2R and AT1aR after selective 
agonist stimulation was also observed which indicates that these two receptors remain 
associated during the endocytosis pathway. Additionally, colocalization of B2R and 
AT1aR in human foreskin fibroblast cells, which express both the receptors, was also 
observed. It supports the possibility that heterodimerization of these two receptors may 
result in surface localization of B2R in native tissues as well. Infact, heterodimerization of 
these receptors has been shown to occur in platelets and omental vessels from 
preeclamptic women (Abdalla et al., 2002). AT1aR reversibly aggregates due to oxidative 
stress in normotensive pregnant women and signalling is blocked. However, AT1aR-B2R 
heterodimerization confers the AT1aR resistance to inactivation by oxidative stress and 
maintains angiotensin II signalling in preeclampsia. This demonstrates a regulatory role 
of B2R-AT1aR heterodimerization under physiological condition. Although the 
mechanistic
 basis of GPCR dimerization is not well
 understood, recent studies suggest 
that the oligomerization
  of proteins may increase the avidity
  for dimeric molecular 
chaperones such as those of the 14-3-3
 family. These chaperones mediate the release of 
maturating proteins from
 the ER (Yuan et al., 2003). Surface translocation of B2R as a 
result of heterodimerization, supports the hypothesis that for some GPCRs (such as   163
olfactory receptors and B2R), interaction with other specific receptors is required for cell 
surface localization.  
8.7.2 Isolation of B2R-AT1aR heterodimer complex 
By employing a two-step affinity purification, it was possible to isolate the heterodimer 
complex of B2R-AT1aR (as shown by SDS-PAGE, analytical gel filtration and ligand 
binding analysis, see result section 6.5). Unfortunately, this heterodimer complex tends to 
dissociate over time when stored at 4°C. One of the problems associated with purification 
of membrane proteins is  delipidation. Previous reports have shown that increased 
delipidation of the cytochrome bc1 complex leads to a gradual decrease in activity up to 
complete loss of function and destabilization of this multisubunit complex (Yu et al., 
1980). Therefore, one can imagine that significant loss of some particular lipids, which 
are necessary to maintain the heterodimer complex, during purification steps, may lead to 
its dissociation over time. Additionally, choice of detergent is also crucial for long-term 
stability of membrane protein complexes. Therefore, addition of certain lipids during 
purification and screening a range of detergents for purification may be of particular 
importance for the long-term stability of this complex. 
8.8 Production and isolation of AT1aR 
Human AT1aR is one of the most studied GPCRs for its functional properties. However, 
there is no published report attempting heterologous production of this receptor for large-
scale isolation. Although, several small molecule antagonist drugs acting on this receptor 
are already available (e.g. Losartan, Valsartan, Irbesartan and Candesartan), structural 
studies are mandatory in order to understand the ligand binding and receptor activation 
mechanism in detail. Therefore, this receptor was heterologously produced using Pichia 
pastoris, baculovirus system and SFV system. Expression level of AT1aR in Pichia 
pastoris was high (3-4 mg/liter culture). A positive effect of biotinylation domain on 
receptor expression was observed (see section 7.1.4). Similar effect of biotinylation 
domain on GPCR expression in Pichia has already been found (Helmut Reiländer, 
personal communication and Grünewald et al., 1996). Large-scale cultures in shake   164
flasks yielded milligram quantities of this receptor in membranes. The recombinant 
receptor showed similar ligand biding affinity to angiotensin II as the AT1aR in native 
tissues. More importantly, the recombinant receptor was successfully isolated in 
homogenous form and it was stable at 4°C for at least two weeks (gel filtration analysis). 
Therefore, it was used for 3-D crystallization attempts. In order to stabilize the 
recombinant AT1aR, angiotensin II was added during solubilization and purification. As 
discussed before, addition of colored ligands during receptor purification provides a 
useful tool to identify crystals in the crystallization drops. Use of fluorescein labeled 
angiotensin revealed that the ligand (angiotensin II) remains bound to the purified 
receptor. As fluorescent angiotensin II is inexpensive and easily available, it can also be 
used during large-scale purification of the recombinant receptor.  
It should be possible to produce large amounts of recombinant receptor in Pichia 
by using fermentors. It has already been done successfully for the β-2 adrenergic receptor 
(Christoph Reinhart, PhD thesis) and the endothelin-b receptor (Schiller et al., 2002). 
Angiotensin II is a small peptide with no repeated amino acids in its sequence. Therefore, 
it is a good candidate for solid-state NMR studies. In this case, a single uniformly labeled 
(
13C/
15N angiotensin II) peptide (as compared to three different variants of bradykinin) 
should provide sufficient information that is required to generate a model of the receptor 
bound conformation of angiotensin II. 
 Although  AT1aR could be successfully expressed and isolated from Pichia, 
for reasons of comparison, it was also produced in BHK cells and Sf9 cells. Moderate 
expression levels for recombinant AT1aR were obtained in BHK cells and Sf9 cells. The 
binding affinity of the recombinant receptor in these cells was also comparable to that in 
native tissues. Interestingly, out of the three GPCRs produced in BHK cells during this 
study, only this receptor was glycosylated and was localized to the cell surface. Similar to 
Pichia, the recombinant receptor was successfully isolated from BHK and Sf9 cells. 
However, the purified receptor from BHK cells showed proteolytic degradation when 
stored at 4°C. It may be due to copurification of some protease, which leads to the 
receptor degradation over time. However, this problem was not addressed in detail as   165
large amounts of recombinant receptor could successfully be purified from Pichia. The 
stability of recombinant receptor from Sf9 cells has not been tested.  
8.9 Production, characterization and isolation of NmU2R 
Two GPCR subtypes for neuromedin U in human were recently discovered (Raddatz et 
al., 2000). Due to several physiological roles of neuromedin U (e.g. smooth muscle 
contraction, blood pressure control, stress response, feeding and energy homeostasis), 
these receptors are considered to be important drug targets. The two subtypes of this 
receptor share approximately 45-50% sequence homology. During this study, human 
NmU2R was produced in Pichia pastoris and BHK cells. In both systems, moderate 
expression levels of this receptor were achieved. However, during its production in the 
SFV system, only BHK cells were tested so far. It would be interesting to compare its 
expression level in other cell lines such as HEK-293, CHO-K1 or COS-7. The 
recombinant NmU2R produced in Pichia and BHK cells showed a similar ligand binding 
affinity to that of native tissues. Like recombinant B2R, this receptor was also 
glycosylated in Pichia but not in BHK cells. It was possible to purify the recombinant 
receptor using affinity chromatography. Purified receptor from BHK cells revealed 
mainly homogenous population on gel filtration analysis. However, as mentioned before, 
the SFV system is not suited for large-scale production of the receptor (especially for 
those receptors, which have low expression levels) on a routine basis.  
Expression of this receptor in baculovirus system was not tested. It has been 
found that the expression level of NmU1R in insect cells is low (Hongyang Xia, personal 
communication). As mentioned before, NmU1R and NmU2R share high sequence 
similarity and bind to the ligand (NmU) with almost the same affinity. Therefore, in my 
opinion expression of NmU2R may be similar to NmU1R in insect cells. Therefore, 
further attempts to improve the expression and purification of this receptor from Pichia 
should be made. 
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8.10 Effect of DMSO on functional expression of recombinant receptors 
Positive effect of DMSO on functional expression of recombinant GPCRs in Pichia has 
been reported earlier (Alexandra Ivanovic, PhD thesis). During this study also, positive 
effect of DMSO on expression level of three different recombinant GPCRs in Pichia was 
observed. Interestingly, expression of recombinant receptors in BHK cells was also 
increased by the addition of DMSO in the culture medium. However, no such effect was 
observed in Sf9 cells. The exact reason for this DMSO effect is not known yet. However, 
a previous study in S. cerevisiae showed that in response to DMSO, phospholipid 
biosynthesis was significantly increased via up-regulation of INO1
  and OPI3 genes 
(Murata et al., 2003). It was also observed that DMSO treatment leads to membrane 
proliferation and affects membrane integrity. Therefore, increased membrane 
permeability and altered protein-lipid interactions may be responsible for the effect of 
DMSO on the expression of recombinant receptors. 
8.11 Future perspectives 
 
During the course of this study, successful production and isolation strategies for 
recombinant B2R have been established. The next steps should include long-term 
stabilization of the receptor, reconstituting the complex of B2R with its interacting 
partner(s) to increase the polar surface area and to fix the receptor in one conformation. 
In this context, copurification of recombinant B2R and endogenous SHP-2 from insect 
cells provides a unique opportunity. In comparison to overexpressed B2R, the 
endogenous pool of SHP-2 in insect cells may be limited. Therefore, coexpression of 
recombinant B2R and recombinant SHP-2 should be tested. By using two different tags 
on B2R and SHP-2 respectively, it should be possible to isolate the complex of 
recombinant B2R and recombinant SHP-2. Additionally, further attempts to stabilize the 
B2R-AT1aR heterodimer complex and B2R-beta arrestin complex should be made. These 
complexes represent a physiologically relevant signalling state of B2R and structural 
information on these complexes should lead to a better understanding of GPCR signalling 
mechanism. Interestingly, coexpression of AT1aR with B2R drives the later to the cell 
surface. When expressed individually, B2R recycles back to the cell surface after agonist   167
induced endocytosis while the AT1aR undergoes ubiquitination and degradation. It will be 
interesting to see how the ubiquitination machinery responds to this heterodimer complex. 
Also, the problem of proteolytic cleavage of B2R in insect cells should be addressed 
further. The possibilities to overcome this problem include testing different protease 
inhibitors in the culture medium and to identify the cleavage site and to remove it by site-
directed mutagenesis. Another problem associated with the baculovirus system is 
incomplete biotinylation of the biotinylation domain. To circumvent this problem, one 
can try to use constructs with strep II tag. It will also be interesting to coexpress B2R in 
Pichia with G proteins, molecular chaperones or AT1aR, in order to increase functional 
production level. Coexpression of G proteins with neurokinin receptor has already been 
tested in Schizosaccharomyces pombe (Arkinstall  et al., 1995).  In order to get the 
receptor bound conformation of bradykinin, further solid-state NMR studies have to be 
done. This information may provide some new insight into the binding of endogenous 
ligand bradykinin to its cognate receptor. The receptor bound conformation of bradykinin 
can be used to design more potent and specific bradykinin analogs acting as therapeutic 
molecules on B2R.  
The recombinant AT1aR was produced at high levels in Pichia pastoris and could 
be successfully purified. One of the future goals should be to use a fermentor for large-
scale production of this receptor. It should be possible to get milligram quantities of the 
purified receptor and it can be used for crystallization trials and solid-state NMR studies. 
A previous report indicates a strong interaction of β-arrestin with AT1aR (Wei et al., 
2004). Therefore, in vitro reconstitution of receptor-β-arrestin complex should also be 
tested.  
Although the recombinant NmU2R was expressed at moderate levels in Pichia 
and BHK cells, it could be easily purified. Therefore, a major focus should be on 
increasing the expression level of this receptor. As the endogenous peptide ligand (NmU-
8) of NmU2R binds the receptor with high affinity, it represents a potential candidate for 
solid-state NMR analysis. NmU2R was identified only recently (Raddatz et al., 2000) and 
only little is known about its interaction with other proteins (such as its homo and 
heterodimerization). It will be interesting to identify its interaction partners and to study 
the roles of these interactions in NmU2R regulated signalling mechanisms.    167
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Zusammenfassung 
 
Die G-Protein-gekoppelten Rezeptoren (GPCRs) stellen die größte Familie der 
Zelloberflächenrezeptoren dar. 1-5% des Wirbeltiergenoms kodiert für diese 
Rezeptorfamilie. Im Humangenom sind etwa 800-1000 Gene vertreten, die für 
GPCRs kodieren. Trotz der großen Unterschiede in ihrer Sequenz und Aktivierung 
haben alle GPCRs zwei Gemeinsamkeiten: (1) Ihre Architektur wird durch sieben 
Transmembranhelices beschrieben. (2) Ihre Funktion in der Signaltransduktion üben 
alle durch Aktivierung der heterotrimeren Guanylnukleotid-Bindeproteine (G-
Proteine) aus. 
Die GPCRs sind an der Regulierung einer Vielzahl von physiologischen 
Prozessen beteiligt und stellen daher wichtige Ziele für die 
Medikamentenentwicklung dar. Bisher gibt es kaum Möglichkeiten zur 
strukturbasierenden Medikamentenentwicklung, da, bis auf das Rinder-Rhodopsin, 
nur sehr wenige Informationen zur dreidimensionalen Struktur von GPCRs verfügbar 
sind. Das Rinder-Rhodopsin nimmt allerdings unter den GPCRs eine Sonderstellung 
ein. Im Gegensatz zu allen übrigen GPCRs bindet es seinen Liganden, 11-cis Retinal, 
kovalent und liegt dann in der nicht-aktivierten Form vor. Zudem kann Rhodopsin in 
großen Mengen aus Rinderretina isoliert werden, wohingegen die übrigen GPCRs nur 
in geringen Mengen in ihren natürlichen Geweben vorkommen. 
Die vorliegende Arbeit verfolgt drei Ziele: Erstens sollen GPCRs durch 
heterologe Expression in hohen Ausbeuten hergestellt und biochemisch charakterisiert 
werden. Die Etablierung eines Solubilisierungs- und Aufreinigungsprotokolls stellt 
das zweite Ziel dar. Drittens soll die Interaktion von Ligand und Rezeptor mittels 
verschiedener Techniken untersucht werden.    192
Grund für die erste Zielsetzung ist die geringe Verfügbarkeit reinen, 
homogenen und stabilen Proteins im Milligramm-Maßstab, welches die größte Hürde 
für strukturelle Untersuchungen von GPCRs darstellt. Hier wurden verschiedene 
Expressionssysteme zur heterologen Produktion von Membranproteinen etabliert. Die 
Wahl des Expressionssystems ist hierbei entscheidend, um posttranslationale 
Modifikationen wie Glykosylierung sowie die korrekte Faltung des Rezeptors zu 
gewährleisten. Neben E. coli haben sich hierbei vor allem eukaryotische 
Expressionssystems wie Pichia pastoris bewährt. 
In der vorliegenden Arbeit wurden drei GPCRs hergestellt und analysiert: der 
humane Bradykinin Rezeptor Typ 2 (B2R), der humane Angiotensin II Rezeptor Typ 
1 (AT1aR) und der humane Neuromedin U Rezeptor Typ 2 (NmU2R). Diese drei 
Rezeptoren wurden in drei Expressionsystemen (Pichia pastoris, Insektenzellen und 
Säugerzellen) heterolog produziert und biochemisch charakterisiert. Für jedes der drei 
Proteine wurden Solubilisierungs- und Aufreinigungsprotokolle etabliert. Die 
aufgereinigten Proteine wurden anschließend für Kristallisationsexperimente, für 
Festkörper NMR Untersuchungen und weitere Experimente eingesetzt.  
Der erste untersuchte Rezeptor, B2R, kann vor allem in Endothelzellen, 
vaskulären glatten Muskelzellen und Kardiomyozyten nachgewiesen werden. Seine 
Aktivierung spielt bei der Entstehung von Entzündungen, Schmerz, 
Gewebsverletzung sowie herzschützenden Mechanismen eine Rolle. Im Rahmen der 
Doktorarbeit wurde B2R in der Hefe Pichia pastoris (3,5 pmol/mg), in BHK-Zellen 
(10 pmol/mg) und in Sf9-Zellen (60 pmol/mg) erfolgreich rekombinant produziert. 
Zur Charakterisierung wurde die Bindung des Liganden [
3H] Bradykinin, die G-
Protein-Kopplung, zelluläre Lokalisierung sowie die Glykosylierung des Rezeptors 
untersucht. Der heterolog produzierte Rezeptor konnte in hoher Reinheit isoliert   193
werden. Homogenität und Stabilität des aufgereinigten Proteins wurden mittels 
Gelfiltration analysiert. Aus BHK und Sf9 Zellen konnten Milligramm-Mengen 
reinen und stabilen Rezeptors isoliert werden, die zu Kristallisationsexperimenten 
verwendet wurden. Hier zeigten sich kristallartige Strukturen, die zur Zeit weiter 
charakterisiert werden. 
Der zweite untersuchte Rezeptor, AT1aR, kann in glatten Muskelzellen, Leber, 
Nieren, Herz, Lunge und Hoden nachgewiesen werden. Die Aktivierung dieses 
Rezeptors spielt eine Rolle bei der Regulation des Blutdrucks und bei 
cardiovaskulären Erkrankungen. Rekombinanter AT1aR konnte mit hoher Ausbeute 
(167 pmol/mg) in Pichia pastoris hergestellt werden. Die Ausbeute bei Produktion in 
Insektenzellen (29 pmol/mg) und Säugerzellen (32 pmol/mg) lag im mittleren 
Bereich. Der rekombinante Rezeptor wurde hinsichtlich der Bindung von [
3H] 
Angiotensin II, der zellulären Lokalisierung und Glykosylierung charakterisiert. Im 
Anschluss wurde er erfolgreich mittels Affinitätschromatographie gereinigt. 
Homogenität und Stabilität des gereinigten AT1aR wurden mittels Gelfiltration 
analysiert. Aus Pichia pastoris konnte das Protein im Milligramm-Maßstab isoliert 
werden, so dass Kristallisationsexperimente möglich waren.  
Dem dritten Rezeptor, NmU2R, konnte erst kürzlich sein Ligand, Neuromedin 
U, zugeordnet werden. Der Rezeptor ist im zentralen Nervensystem, und hier 
insbesondere in der Medulla oblongata, dem Rückenmark und dem Thalamus 
lokalisiert. Aufgrund dieser Verteilung wird angenommen, dass er eine Rolle in der 
Regulation der Weiterleitung sensorischer Nervenimpulse sowie deren Modulation 
spielt. Während meiner Arbeit konnte ich bei der heterologen Produktion des 
Rezeptors Ausbeuten von 6 pmol/mg in Pichia pastoris und 9 pmol/mg in BHK 
Zellen erzielen. Der rekombinante Rezeptor wurde mittels  Bindung eines   194
Radioliganden ([
125I] NmU) charakterisiert. Weiterhin wurde die zellulärer 
Lokalisierung und Glykosylierung des GPCRs untersucht. Obwohl der rekombinante 
NmU2R erfolgreich isoliert werden konnte, sind auf Grund der geringen 
Produktionsmengen zur Zeit keine Struktur untersuchungen möglich. 
Zur Analyse der pharmakologisch wichtigen Ligand-Rezeptor-
Wechselwirkung wurde Festkörper NMR Spektroskopie eingesetzt. Durch die 
Verwendung von selektiv mit 
13C und 
15N markierten Peptiden können 
Konformationsänderung des Peptidliganden beim Binden des Rezeptors untersucht 
werden. Die Bestimmung der genauen Konformation des gebunden Liganden ist für 
die Medikamentenentwicklung von Bedeutung. In der vorliegenden Arbeit wurde 
mittels der Festkörper NMR Spektroskopie die Konformation des rezeptorgebunden 
Liganden, Bradykinin, untersucht. Die ersten Ergebnisse weisen auf signifikante 
Strukturänderungen Bradykinins hin, sobald es an den B2R bindet.  
Untersuchungen bezüglich Wechselwirkung von GPCRs mit anderen Protein 
sind auch für die Kristallisation relevant. Eine der Herausforderungen in der 
Kristallisation von GPCRs ist die kleine hydrophile Oberfläche, die zur Bildung von 
Kristallkontakten im Kristallgitter oft nicht ausreichend ist. Eine Möglichkeit, dieses 
Problem zu lösen, ist die Bildung eines stabilen Komplexes aus dem Rezeptor und 
einem interagierenden Protein. Zusätzlich kann der Rezeptor durch die Interaktion in 
eine weniger flexible Form überführt werden, was die Kristallisation und die spätere 
Strukturbestimmung erleichtern kann.  
Basierend auf diesem Ansatz wurden B2R und AT1aR, die einen stabilen 
heterodimeren Komplex bilden, in BHK Zellen ko-exprimiert. Bemerkenswert war 
hierbei dass B2R im Komplex mit AT1aR in der Plasmamembran vorzufinden war, 
während B2R alleine hauptsachlich in intrazellulären Membranen exprimiert wurde.   195
Weiterhin führte die Koexpression der beiden Rezeptoren zu einem vierfachen 
Anstieg der [
3H] Bradykinin Bindungsstellen auf der Zelloberfläche. Es konnte 
ebenfalls nachgewiesen werden, dass nach der Stimulation mit nur einem der beiden 
rezeptorspezifischen Liganden beide GPCRs zusammen internalisiert wurden. Dieses 
Phänomen wurde auch in menschlichen Vorhaut- fibroblasten nachgewiesen, in denen 
beide Rezeptoren vorkommen. Die erhaltenen Ergebnisse deuten darauf hin, dass 
auch in nativen Geweben die Anwesenheit des AT1aR für die Expression und den 
Transfer des B2R zur Plasmamembran nötig ist. Diese Daten unterstützen die 
Hypothese, dass Heterodimerisierung eine Voraussetzung für die 
Zelloberflächenlokalisierung bestimmter GPCRs ist. 
Der Ko-Komplex aus B2R und AT1aR konnte mittels dualer 
Affinitätschromatographie isoliert, wie durch SDS-PAGE Analyse, analytische 
Gelfiltration und Bindung von Radioliganden gezeigt werden konnte. „Pull-down“ 
Experimente, die drei Tage nach der Reinigung durchgeführt wurden, wiesen darauf 
hin, dass der Ko-Komplex nicht stabil war und zerfiel. Bei der Reinigung von 
Membranproteinen verursacht der Verlust von Lipiden während des 
Isolationsprozeßes oft eine Beeinträchtigung der Stabilität des Proteins. Auch das 
verwendete Detergenz beeinflusst die Stabilität von Membranproteinen. Experimente 
zur Verbesserung der Langzeitstabilität des Komplexes durch Zugabe von Lipiden 
und anderen Detergenzien sind in Vorbereitung.  
Die Bildung von Ko-Komplexen wurde zusätzlich mit Beta-Arrestin, einem 
Inhibitor der Kopplung von G-Proteinen und ihren Rezeptoren untersucht. Beta-
Arrestin ist ein zytosolisches Protein, dass an der Desensibilisierung der Agonist-
stimulierten GPCRs beteiligt ist. Versuche, eine Ko-Komplexbildung aus gereinigtem 
B2R und gereinigtem Beta-Arrestin in vitro zu erzielen, schlugen fehl. In „Pull-Down“   196
Experimenten konnte keine Interaktion nachweisen werden. Wurde anstatt des nativen 
B2R eine C-terminale Mutante, bei welcher der C-Terminus des B2R gegen den des 
Vasopressinrezeptors ausgetauscht worden war, verwendet, konnte in vitro Ko-
Komplexbildung mit Beta-Arrestin festgestellt werden. Mit Experimenten zur 
Bestimmung der Langzeitstabilität des Ko-Komplexes sowie zur Ko-Kristallisations 
wurde begonnen. 
Im Rahmen der vorliegenden Arbeit wurde die Produktion, Charakterisierung 
und Aufreinigung von drei rekombinanten humanen GPCRs etabliert. Die 
rekombinanten Rezeptoren wurden im Milligramm-Maßstab produziert. Damit ist die 
erste, wesentliche Hürde zur Strukturanalyse genommen. Der B2R-β-Arrestin 
Komplex kann sich als vorteilhaft für die Kristallisation herausstellen. Zusätzlich 
konnte zum ersten Mal gezeigt werden, dass der Transfer eines GPCRs an die 
Zelloberfläche von der Heterodimerisierung mit einem anderen nicht-verwandten 
GPCR abhängig sein kann.   197
Abbreviations 
 
AP         alkaline  phosphatase   
ATP         adenosine-triphosphate   
cAMP       cyclic  adenosine-monophosphate   
cDNA         complementary deoxyribonucleic acid  
BHK          baby hamster kidney  
BSA          bovine serum albumin  
CAP         capsid  protein   
CHO          chinese hamster ovary  
Cpm       counts  per  minute   
DMSO       dimethylsulfoxide   
DNA         deoxyribonucleic  acid   
DTT         dithiothreitol   
EDTA         ethylenediaminetetraacetic  acid   
FCS          fetal calf serum  
GDP         guanine  diphosphate   
GPCR         G protein-coupled receptor  
GTP         guanine  triphosphate   
HEK       human  embryonic  kidney 
HF-15       human  foreskin  fibroblasts 
H5       high  five  cells 
IgG          immunoglobulin G  
LB         luria  bertani   
OD         optical  density   
PAGE         polyacrylamide gel electrophoresis  
PBS          phosphate buffered saline  
PEG         polyethylene  glycol   
PMSF         phenylmethylsulfonylfluoride   
RNA         ribonucleic  acid   
RT         room  temperature     198
SDS          sodium dodecyl sulphate  
S f 9        Spodotera frugiperda cells 
2-D         two-dimensional   
3-D         three-dimensional   
TBS         Tris-buffered  saline   
TCA         trichloroacetic  acid   
TMH          transmembrane helix  
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Appendix 
 
Amino-acid sequences of affinity tags used in this work  
 
Flag-tag   DYKDDDDK  
His10-tag   HHHHHHHHHH  
Strep II-tag    AWSHPQFEK  
Bio-tag 
GGTGGAPAPAAGGAGAGKAGEGEIPAPLAGTVSKILVKEGDTVKAGQTVLV 
LEAMKMETEINAPTDGKVEKVLVKERDAVQGGQGLIKIG 
 
Amino acid sequence of receptors 
B2R 
MLNVTLQGPTLNGTFAQSKCPQVEWLGWLNTIQPPFLWVLFVLATLENIFVLSVF
CLHKSSCTVAEIYLGNLAAADLILACGLPFWAITISNNFDWLFGETLCRVVNAIIM
NLYSSICFLMLVSIDRYLALVKTMSMGRMRGVRWAKLYSLVIWGCTLLSSSPML
VFRTMKEYSDEGHNVTACVISYPSLIWEVFTNMLLNVVGFLLPLSVITFCTMQIM
QVLRNNEMQKFKEIQTERRATVLVLVVLLLFIICWLPFQISTFLDTLHRLGILSSCQ
DERIIDVITQIASFMAYSNSCLNPLVYVIVGKRFRKKSWEVYQGVCQKGGCRSEPI
QMENSMGTLRTSISVERQIHKLQDWAGSRQ. 
NmU2R 
MSGMEKLQNASWIYQQKLEDPFQKHLNSTEEYLAFLCGPRRSHFFLPVSVVYVPI
FVVGVIGNVLVCLVILQHQAMKTPTNYYLFSLAVSDLLVLLLGMPLEVYEMWR
NYPFLFGPVGCYFKTALFETVCFASILSITTVSVERYVAILHPFRAKLQSTRRRALR
ILGIVWGFSVLFSLPNTSIHGIKFHYFPNGSLVPGSATFTVIKPMWIYNFIIQVTSFL
FYLLPMTVISVLYYLMALRLKKDKSLEADEGNANIQRPCRKSVNKMLFVLVLVF
AICWAPFHIDRLFFSFVEEWSESLAAVFNLVHVVSGVFFYLSSAVNPIIYNLLSRR
FQAAFQNVISSFHKQWHSQHDPQLPPAQRNIFLTECHFVELTEDIGPQFPCQSSMH
NSHLPTALSSEQMSRTNYQSFHFNKT.   200
AT1aR 
MILNSSTEDGIKRIQDDCPKAGRHNYIFVMIPTLYSIIFVVGIFGNSLVVIVIYFYKL
KTVASVFLLNLALADLCFLLTLPLWAVYTAMEYRWPFGNYLCKIASASVSFNLY
ASVFLLTCLSIDRYLAIVHPMKSRLRRTMLVAKVTCIIIWLLAGLASLPAIIHRNVF
FIENTNITVCAFHYESQNSTLPIGLGLTKNILGFLFPFLIILTSYTLIWKALKKAYEIQ
KNKPRNDDIFKIIMAIVLFFFFSWIPHQIFTFLDVLIQLGIIRDCRIADIVDTAMPITIC
IAYFNNCLNPLFYGFLGKKFKRYFLQLLKYIPPKAKSHSNLSTKMSTLSYRPSDVS
SSTKKPAPCFEVE. 
 
Previously reported Kd values of B2R, AT1aR in native cells and NmU2R (COS cells)  
 
GPCR    Kd(nM) Reference 
B2R  Human lung fibroblasts 
Human decidual cells 
2.5 
0.85 
Baenziger et al., 1992 
Rehbock et al., 1997 
AT1aR  Human skin fibroblasts  1.0 +/- 0.7  Nickenig et al., 1997 
NmU2R COS-7  cells  0.83  Raddatz  et al., 2000 
 
Sequences of peptide ligands 
Bradykinin   RPPGFSPFR 
Angiotensin II   DRVYIHPF 
Neuromedin U-25  FKVDEEFQGPIVSQNRRYFLFRPRN 
Neuromedin U-8  YFLFRPRN 
 
 
 #1 mmb 12 3 4 5 6 78 9 1 0 1 1 1 2
Formiate Citrate MES MOPS Tricine Borate Formiate Citrate MES MOPS Tricine Borate
pH pH pH pH pH pH pH pH pH pH pH pH
4 5 6 789 4 5 6 789
A 50% PEG 400 10% 4M Malonate 0,8 M A
B 15% 1,6 M B
C 22% 2,4 M C
D 33% 3,2 M D
E 50% PEG 4000 3% 3M K/Na-Pi 0,6 M E
F 6% pH 4; 5; 6; 7; 8; 9 1,2 M F
G 12% 2,1 M G
H 18% 3 M H
ddH2O ddH2O
#2 mmb 12 3 4 5 6 78 9 1 0 1 1 1 2
Formiate Citrate MES MOPS Tricine Borate Formiate Citrate MES MOPS Tricine Borate
pH pH pH pH pH pH pH pH pH pH pH pH
4 5 6 789 4 5 6 789
A 50% PEG 2000 MME 6% 4M (NH4)2SO4 0,8 M A
B 12% 1,6 M B
C 18% 2,4 M C
D 24% 3,2 M D
E 4M 0,8 M 2M Citrate 0,4 M E
F 1,6 M 0,8 M F
G 2,4 M 1,2 M G
H 3,2 M 1,6 M H
ddH2O ddH2O
3-D crystallization screening scheme
200 200 200 600 200
0,5 M 0,5 M
0,1 M 0,1 M
360 600
600
300 200 500 400 200 400
200 200
660 200 140 800 200 -
440 200
200 680
60 200 740 200 - 800
600
240 200 560 700 - 300
400 - 120
360 200 440 1000 - -
0,5 M 0,5 M
0,1 M 0,1 M
120 200 680 600
240 200 560 400 200 400
600
200 200
200 200
480 200 320 800 200 -
360 200 440
400 400
Formiate 200 200 600 200 200 600
200 400
600 200 200 600 200 200
400 200
200 - 800 200 - 800  202
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